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Aims: The general aim of this research is to advance knowledge of effects of whole-body 
vibration on exercise tolerance and functional performance of the lower limbs of people with 
chronic obstructive pulmonary disease in a community setting.  Achieving the general aim of 
this research would determine efficacy of a whole-body vibration intervention to: (1) avoid 
exacerbations of chronic obstructive pulmonary disease that add to physical inactivity and, (2) 
improve performance of activities of daily living of people with chronic obstructive 
pulmonary disease.  To meet the general aim of this research, specific aims were to: (1) 
establish validity of a WBV platform, (2) determine safety of a single session of whole-body 
vibration for people with chronic obstructive pulmonary disease by quantifying rating of 
perceived dyspnoea and selected physiological responses to physical activity, (3) describe 
transmission of whole-body vibration about the knee of people with chronic obstructive 
pulmonary disease, (4) establish reliability of the test procedure for the major intervention 
study, and (5) determine efficacy of a six week whole-body vibration intervention on rating of 
perceived dyspnoea, selected physiological responses to physical activity, and functional 
performance of the lower limbs of people with chronic obstructive pulmonary disease 
compared with a six week placebo intervention. 
Scope: Chronic obstructive pulmonary disease can be treated with an ongoing pulmonary 
rehabilitation program.  The beneficial effects of components of pulmonary rehabilitation 
programs incorporating aerobic conditioning and resistance training have been confirmed for 
improving exercise tolerance and functional performance of the lower limbs.  However, 
effects of whole-body vibration as a mode of physical activity are yet to be explored in a 
community setting for people with chronic obstructive pulmonary disease even though whole-
body vibration has been beneficial as a mode of physical activity for other sub-optimal health 
population sub-groups.  This research therefore, is designed as a non-randomised placebo 
cross-over efficacy trial conducted in the home of participants affected with chronic 
obstructive pulmonary disease. Dependent variables of exercise tolerance and functional 
performance were tested across a 14 week intervention period.  Participants first completed a 
six week whole-body vibration intervention, then after a 2 week washout period, completed a 
six week placebo intervention.  Sixteen community-dwelling adults with stable chronic 
obstructive pulmonary disease provided voluntary informed consent to participate in this 14 
week research (mean ± SD age = 72 ± 7 years, stature = 1.7 ± 0.1 metres, body mass = 85.7 ± 
20.4 kilograms). 
Conclusions: The general aim of this research was met, thus supporting the efficacy of whole 
body vibration as a safe mode of physical activity for people with chronic obstructive 
pulmonary disease.  Results showed that whole-body vibration did not exacerbate symptoms 
of the disease associated with physical inactivity.  Furthermore, the whole-body vibration 
intervention improved tests to mimic activities of daily living such as rising from a chair, 
turning, and walking gait with greater effect than a placebo intervention.  As such, if a 
placebo effect was systemic to a whole-body vibration intervention, the effect was negligible.  
In conclusion, whole-body vibration was a safe mode of physical activity for people with 
stable chronic obstructive pulmonary disease that did not negatively effect exercise tolerance 
or exacerbate the disease, while concurrently improving functional performance of the lower 
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GLOSSARY OF ABBRAVIATIONS & DEFINITION OF TERMS 
Acute data:    Data collected within two minutes of the final bout of a WBV 
    or PLACEBO session. 
ADLs:    Activities of daily living such as non assisted walking and  
    independent living. 
Aerobic conditioning:  A purposeful component of pulmonary rehabilitation with the 
    aim of  improving cardiovascular fitness. 
Amplitude:   The maximum distance from the equilibrium position of pure 
    sinusoidal vibration. 
ANZCTR:    Australian New Zealand Clinical Trials Registry. 
Borg CR-10:   A visual analogue scale to quantify prating of perceived  
    breathlessness (i.e., dyspnoea). 
Community dwelling:  A potential participant had to be living in a fully-independent 
    residence, and needed to have the capacity to complete  
    ADLs (i.e., functional independence). 
COPD:   Chronic Obstructive Pulmonary Disease. 
Dyspnoea:   A clinical term of breathlessness 
Exercise:   Structured and purposeful physical activity. 
Exercise tolerance:  The ability to participant in exercise (i.e., exercise intolerance). 
FEV1:    The forced expiratory volume after one second during a  
    spirometry test. 
FVC:    The forced vital capacity of a spirometry test. 
Frequency:   The quantification of motion of pure sinusoidal vibration 
     measured by the number of cycles of motion per second  
    (Hertz; Hz). 
Functional performance:  The ability of the lower limbs to assist with performance of 
    ADLs and walking gait. 
Gait:    The manner in which participants with COPD walked over a 
    straight, flat and even surface as a self-selected comfortable 
    speed. 
GOLD:   Global Initiative for Chronic Obstructive Lung Disease. 
Gravitational force:  A quantification of WBV intensity (i.e., g force). 
HR:    Heart rate. Quantified also with the heart rate reserve (HRR) 
    and the percentage of heart rate reserve (%HRR). 
Hypoxemia:   A > 4% drop in saturation of haemoglobin to resting levels. 
xiv 
 
Instantaneous data:   Data collected during the final bout (after 30 sec) of a WBV or 
    PLACEBO session. 
ISO:    International Organisation for Standardisation. 
Isometric stance posture: Maintaining a static knee flexion angle during a WBV or  
    PLACEBO bout (i.e., isotonic skeletal muscle contractions). 
Isotonic stance posture: Performing both eccentric and concentric skeletal muscle  
    contractions during a WBV bout. 
Kinematics:   Spatiotemporal variables of gait. 
Long-term data:   Data collected at least 48 hours after a WBV or PLACEBO 
    bout. 
Mid-test:   A level of the ‘test occasion’ independent variable. Data  
    collected at week 3 and week 11. 
Muscular deconditioning: A loss of skeletal muscle strength and power. 
NHMCR Australia:  National Health and Medical Research Council Australia. 
Peak-to-peak displacement: The peak movement in one direction to the peak movement in 
    the opposite direction of pure sinusoidal vibration. 
Peripheral muscle training: Strengthening the upper and lower limbs to improve exercise 
    tolerance and functional performance. 
Physical activity:  Any mode of activity that can increase the resting metabolic 
    rate. 
Post-test:   A level of the ‘test occasion’ independent variable. Data  
    collected at week 6 and week 14. 
Pre-test:   A level of the ‘test occasion’ independent variable. Data  
    collected at week 1 (i.e., baseline) and week 9. 
PLACEBO:   A six week intervention consisting of 12 bouts of a PLACEBO 
    vibration intervention where the amplitude of the vibration  
    platform was ~0.0 mm.  
Pulmonary rehabilitation: The comprehensive management of COPD. 
Reliability:   The test-retest-retest test procedure used to calculate the intra-
    class correlation coefficient (ICC), standard error of  
    measurement (SEM) and coefficient of variation (CV) of the 
    dependent variables of this research. 
Resistance training:  A component of pulmonary rehabilitation with the aim of  
    improving skeletal muscle strength and power. 
SpO2:    Saturation of haemoglobin. 
Side alternating:  A vibration platform that creates pure sinusoidal vibration. The 
    amplitude is changed by changing stance width about the axis 
    of rotation. 
xv 
 
Skidding:   A method to validate the intensity of WBV (i.e., Hz and peak-
    to-peak displacement). 
Stride length:   The line of progression between two consecutive footprints of 
    the same foot.  
Stride time:   Stride time was the time taken in seconds between the first  
    contacts of two consecutive footballs of the same foot. 
Stride velocity:   The ratio of stride length to stride time and quantified as metres 
    per second (m.sec-1). 
Spirometry:    A mode of clinical diagnosis of COPD to quantify airflow  
    limitation. 
Sub-optimal health   Any sample population with pathology.   
 population:    
The 5-Chair Stands Test:  A dependent variable of functional performance.  A valid  
    measure of performance ADLs. 
The Timed Up and   A dependent variable of functional performance.  A  
 Go Test:   valid measure of performance ADLs.     
Transmission of WBV: The measurement of attenuation of WBV about various  
    bony landmarks of the body. 
Vibration:   Shock that is ISO regulated for industrial exposure to vibration 
    that can be detrimental to health with both acute and chronic 
    exposure. 
Washout:    A duration of two weeks within the WBV and PLACEBO  
    interventions where the participants were instructed not to  
    commence any form of physical activity.  
WBV:    Whole-body vibration. A six week intervention consisting of 12 
    bouts of WBV intervention where the amplitude of the vibration 
    platform was ~1.0 mm. 
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CHAPTER 1. GENERAL INTRODUCTION 
 
1.1 Statement of the Problem 
The World Health Organisation’s (WHO) current definition of chronic obstructive pulmonary 
disease (COPD) is a lung ailment fundamentally characterised by “persistent blockage of 
airflow from the lungs” (WHO, 2008a, p. 1).  In 2004 the WHO estimated 64 million global 
cases of COPD and later predicted COPD would become the third leading cause of death by 
2030 (WHO, 2008b).  In Australia, COPD was the third leading cause of burden of disease 
and injury behind ischaemic heart disease and stroke (ABS 1301.0, 2001).  Although not 
always the case, tobacco smoke is the leading risk factor for COPD (WHO, 2011).  Somewhat 
understandably, tobacco usage was listed with physical inactivity as the two leading risk 
factors eliciting burden of disease in Australia (ABS 1301.0, 2001).  While the cost of COPD 
in Australia has not been directly estimated, respiratory disease alone accounted for AU$3.31 
billon (6.3%) of the total allocated health expenditure in Australia (ABS 1301.0, 2010).    
 
Given that COPD diminishes the ability of the lungs to supply the body with oxygen, most 
activities of functional independence lead to breathlessness if the disease is progressed.  
Perceived breathlessness, or dyspnoea, leads to physical inactivity and consequently 
compounds the risk of burden of disease to those individuals.  The combined effect of tobacco 
smoke and physical inactivity was responsible for 17% of the total burden of disease in 
Australia (ABS 1301.0, 2001).  As a treatment strategy, physical activity is routinely 




Habitual physical activity practices among people with COPD have not been reported by 
leading health authorities and as such, the effect of COPD on physical activity in adults was 
limited (Vorrink, Kort, Troosters & Lammers, 2011).  However, physical inactivity among 
older adults, regardless of health status, was a concern for health professionals (e.g., the 
‘Swap It’ campaign recently introduced by the Federal Australian Government, 
www.swapit.gov.au).  In Australia, no more than 65% of people over the age of 40 years 
engaged in physical activity (ABS 4156.0.55.001, 2011).  Among adults aged 65 years or 
older, fewer than one in two adults were participating in physical activity (ABS 
4156.0.55.001, 2011). 
 
Based on recommendations from the WHO, the American Thoracic Society, the European 
Respiratory Society and the Thoracic Society of Australia and New Zealand, and other 
professional bodies, physical activity is now integral to pulmonary rehabilitation programs in 
public heath settings to assist individuals affected by COPD (GOLD 2007).  A goal of 
physical activity within pulmonary rehabilitation is to improve or maintain exercise tolerance 
and functional independence of people with COPD.  Improvement of exercise tolerance and 
functional independence can increase the ability to complete activities of daily living (ADLs).   
 
Maintenance and improvement of ADLs was central for functional independence (GOLD, 
2007; O’Shea, Taylor & Paratz, 2009).  Muscular strength, muscular power and gait ability 
are integral to the functional independence needed to complete ADLs.   Specifically, activities 
requiring strong and powerful muscular contraction are fundamental and include rising from a 
chair, climbing stairs, turning and adjusting posture, and stumbling to avoid a fall (i.e., 
functional performance).  People with COPD have less strength and power than healthy age 
matched controls (Hamilton, Killian, Summers & Jones, 1995).  Subsequently, people with 
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COPD may have poorer exercise tolerance due to muscular weakness (Gosselink, Troosters & 
Decramer, 1996; Cooper 2009), a reduction of saturation of haemoglobin, and dyspnoea 
(GOLD, 2011).  A diagnosis of COPD therefore, is synonymous with muscular 
deconditioning/dysfunction leading to poor performance of ADLs and poor exercise tolerance 
that is commonly addressed with pulmonary rehabilitation (GOLD, 2007).   
 
Primary objectives of pulmonary rehabilitation are to combat poor exercise tolerance and poor 
functional performance.  The components of pulmonary rehabilitation to beneficially effect 
exercise tolerance and functional performance can vary, but include exercise training (both 
aerobic conditioning and resistance training), healthy lifestyle education, and nutritional 
counselling (GOLD, 2011).  Initially, pulmonary rehabilitation can be implemented at an 
outpatient setting, usually followed by a home based intervention that relies mostly on the 
compliance of the patient.  The efficacy of both outpatient pulmonary rehabilitation (Donner 
& Muir, 1997; Dhein, Münks-Lederer & Worth, 2003; Fromer, Barnes, Garvey, Ortiz, Saver 
& Yawn, 2010) and home based pulmonary rehabilitation (Cigna & Turner-Cinga, 2005; 
Bartoli, Zanaboni, Maselle & Ursini, 2009; Vieira, Maltais & Bourbeau, 2010) is supported 
by systematic reviews.   
 
During pulmonary rehabilitation, aerobic conditioning improved exercise tolerance at 
intensities over 50% of peak oxygen consumption ( O2peak) (Mahler, 1998; GOLD, 2011).  
Although resistance training improved muscular strength (Shaw, Shaw & Brown, 2009), 
muscular power (Sayers & Gibson, 2010), and variables of gait (Fahlman, McNevin, 
Boardley, Morgan & Topp, 2011), dedicated strategies for resistance training of the lower 
limbs to improve functional performance lack thorough recommendations for people with 
COPD.  A recent literature review reported efficacy of resistance training of the lower limbs 
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for people with COPD to elicit appreciable gains in muscular strength that may carry over to 
performance of some ADLs (O’Shea, Taylor & Paratz, 2009).  However, resistance training 
was conducted in conjunction with other modes of training such as variants of aerobic 
conditioning.  The independent effect of resistance training therefore, could not be 
established.   
 
The need for safe and valid exercise interventions specifically for people with COPD is 
salient, and would add to the scientific evidence essential for public health initiatives to 
promote physical activity and reduce burden of the disease.  Two common modes of physical 
activity; aerobic conditioning and resistance training, exacerbate dyspnoea for people with 
COPD and may lead to reduced physical activity because of fear of breathlessness (e.g., 
Normandin, McCusker, Connors, Vale, Gerardi & ZuWallack, 2002).  The clinical and social 
merit of modes of physical activity that can minimise dyspnoea may add to the benefit of 
pulmonary rehabilitation interventions for people with COPD.  Whole-body vibration (WBV) 
may be such a mode of physical activity.  
 
Whole-body vibration is a mode of physical activity during which an individual stands on a 
vibration platform.  The device can create acceleration predominantly in the vertical (Fz) 
direction (Figure 1.1).  The acceleration forces are transmitted to the body and postulated to 
elicit physiological responses comparable to other modes of physical activity such as aerobic 
conditioning and resistance training (Pollock, Martin & Newham, 2012; von Stengel, 
Kemmler, Engelke & Kalender, 2012).  Recent recommendations of nomenclature by the 
International Society of Musculoskeletal and Neuronal Interactions stipulate that vibration 
platforms are either; synchronous or side alternating (Rauch, Sievanen, Boonen, Cardinale, 














Figure 1.1. A person with COPD stands on a side alternating vibration platform. 
Assistance/support to an individual may be supplied. 
 
Independent of type of vibration platform, WBV increased leg muscular strength and 
muscular power (Bosco, Iacovelli, Tsarpela, Cardianle, Bonifazi, Tihanyi et al., 2000; Furness 
& Maschette, 2009), oxygen consumption (Rittweger, Schiessl & Felsenberg, 2001; 
Rittweger, Ehring, Just, Mutschelknauss, Kirsch & Felsenberg, 2002), growth hormone, and 
testosterone levels (Bosco et al., 2000; Roelants, Delecluse, Goris & Verschueren, 2004) 
among a variety of healthy young and older adult sample groups.  Furthermore, WBV may be 
a safe and effective mode to improve muscular strength, body balance and mechanical 





Sievänen, Järvinen, Pasanen, Kontulainen et al., 2002; Yue & Mester, 2002).  A growing 
body of literature has reported benefit of WBV for sub-optimal health populations such as 
people suffering with cystic fibrosis (Rietschel, van Koningsbruggen, Fricke, Semler & 
Schoenau, 2008), multiple sclerosis (Jackson, Merriman, Vanderburgh & Brahler, 2008) and 
stroke (van Nes, Latour, Schils, Meijer, Kuijik & Geurts, 2006).  To date, trials into efficacy 
of WBV in patients with COPD are scarce in the literature. 
 
Since the completion of the data collection period of this research, one paper has been 
published investigating efficacy of WBV to improve muscular strength and muscular power 
of people with COPD.  In conjunction with a three week pulmonary rehabilitation 
intervention, WBV “may” have enhanced exercise tolerance of a multidisciplinary 
rehabilitation program (Gloeckl, Heinzelmann, Baeuerle, Damm, Schwedhelm, Diril et al., 
2012, p. 79).  These authors suggested that long-term studies are needed to determine optimal 
intensity and duration of WBV for people with COPD, though WBV seemed to be a 
“promising new exercise mode” (Gloeckl et al., 2012, p. 76).   
 
1.2 General Aim of this Research 
The general aim of this research is to advance knowledge of effects of WBV on exercise 
tolerance and functional performance of the lower limbs of people with COPD in a 
community setting.  Achieving the general aim of this research would determine efficacy of a 
WBV intervention to: (1) effect exercise tolerance while avoiding exacerbations of COPD 





Specific Aims of this Research 
The specific aims of this research were to: 
 Establish validity of a WBV platform, 
 Determine safety of a single session of WBV for people with COPD by quantifying 
rating of perceived dyspnoea and selected physiological responses to exercise, 
 Describe transmission of WBV about the knee of people with COPD, 
 Establish reliability of the test procedure for the major intervention study, and, 
 Determine efficacy of a six week WBV intervention on rating of perceived dyspnoea, 
selected physiological responses to exercise, and functional performance of the lower 
limbs of people with COPD compared with a six week PLACEBO intervention. 
 
Limitations 
Given the nature of COPD and potential exacerbations expected of people affected with it, 
this research is an efficacy trial and as such is not conducted as a randomised controlled trial. 
Rather than randomise the order of treatment intervention (i.e., WBV and PLACEBO 
interventions), it was thought necessary to first conduct the WBV intervention, and then the 
PLACEBO intervention.  The main reason for that decision was to maximise participant 
numbers in the WBV group, with anticipated drop-out over the 14 weeks of this research.  
Other factors, considered beyond the scope of this research may have limited the results of 
this research. As such, this research design did not examine: 
 The nutrition, exercise history, motivation and other environmental support 
mechanisms of community dwelling older adults, 
 Current levels of physical activity,  
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 Current or past pharmacological treatment for COPD other than bronchodilator or 
corticosteroid treatment,  
 Assessment and monitoring of the disease, 
 Risk factors associated with the disease, and, 
 Exacerbations of the disease earlier than six months prior to recruitment to the study. 
 
Delimiters 
Considering limitations, this research was delimited to a study of: 
 People with well managed and stable COPD whom were independent living in 
metropolitan Melbourne and the Mornington Peninsula.   
 Exercise associated dyspnoea and functional performance of the lower limbs for 
people with stable COPD, 
 People with stable COPD whom were not engaged in pulmonary rehabilitation 
associated with usual outpatient hospital care, but were community dwelling and 
physically active in their independent living, 
 Community based (field) tests of functional performance of the lower limbs designed 
to show improvement of muscular strength, muscular power, and ADLs, 
 Selected linear kinematic variables of gait quantifiable by a portable electronic 
walkway, 
 A six week WBV intervention and a six week PLACEBO intervention (interspersed 
with a two week washout period) with a session frequency of two sessions per week, 
and, 
 Portable vibration platforms, able to be transported among the homes of the 
community dwelling participants.   
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CHAPTER 2. LITERATURE REVIEW 
 
In the first section of this literature review COPD is defined and the mandate developed by 
the Global Initiative for Chronic Obstructive Lung Disease (GOLD) is selected to describe 
COPD and the methods of COPD assessment and management.  Then a narrative review of 
literature describing pulmonary rehabilitation of people with COPD is presented.  The more 
general narrative review is followed by a systematic review of literature specifically relating 
to peripheral muscle training (i.e., the legs) of people with COPD.  It was conducted in an 
effort to more objectively understand contemporary knowledge and recommendations for 
improving exercise tolerance and functional performance of the lower limbs of people with 
COPD.   
 
In the second section of this literature review, WBV is defined, and then literature describing 
WBV as a mode of exercise is reviewed.  Also, theoretical perspectives of effects of WBV are 
reviewed in order to describe the physiological responses elicited by WBV.  Further, 
published research recruiting sub-optimal health sample groups is reviewed.  Concurrently, 
research involving healthy sample groups is included due to limited publications of sub-
optimal health sample groups.  Intervention methods of WBV are appraised in order to clarify 
the current understanding of WBV recommendations.  Published literature targeting children, 
adolescents, and WBV during sitting, prone, and supine body positions are excluded because 





2.1 Chronic Obstructive Pulmonary Disease 
A disease of the lungs, chronic obstructive pulmonary disease (COPD) is a leading cause of 
mortality worldwide (Casanova, Cote, Marin, Pinto-Plata, de Torres, Aguirre-Jaíme et al., 
2008).  The disease diminishes functional capacity of the pulmonary system, the goal of 
which is gaseous exchange (Celli, MacNee, Agusti, Anzueto, Berg, Bulst et al., 2004).  Data 
of the Australian Bureau of Statistics report COPD to be more common than most cancers, 
road traffic accidents, coronary artery disease and diabetes (ABS 3303.0, 2007).  An 
estimated 2.1 million Australians are affected with COPD, with predictions escalating that 
total to 4.5 million by 2050 (ABS 3303.0, 2007; Access Economics, 2008).  Considering the 
known effect of COPD on mortality and a projected increase of incidence of COPD, research 
about assessment, prevention, management, and treatment of the disease is salient.  
 
The disease is characterised by breathlessness (dyspnoea), excessive sputum production, 
chronic cough, bronchitis, and emphysema (Foy, Wickley, Adair, Lang, Miller, Rejeski et al., 
2006).  Chronic lung disease is typically not amenable to cure (Bemt, Schermer, Smeele, 
Bischoff, Jacobs, Grol et al., 2008).  Functionally, exercise tolerance is negatively affected by 
COPD, resulting in for example, difficulty in performing ADLs (O’Shea, Taylor & Paratz, 
2004), due partly to dyspnoea (Foy et al., 2006), and skeletal muscle dysfunction (Debigaré, 
Côté & Maltais, 2001).  Major risk factors include tobacco smoke, occupational dust and 
chemicals as well as indoor and outdoor pollution (GOLD, 2007).  For those reasons, COPD 





A unified approach was taken by the World Health Organisation and the United States 
National Heart, Lung, and Blood Institute to combat COPD resulting in the creation of the 
Global Initiative for Chronic Obstructive Lung Disease (GOLD) in 1998. The GOLD 
mandate has four specific considerations for COPD: (1) assess and monitor the disease, (2) 
reduce risk factors, (3) manage stable COPD, and (4) manage exacerbations.  
 
2.1.1 Assess and Monitor the Disease 
A clinical diagnosis of COPD must include measurement of airflow limitation with 
spirometry the recommended method (GOLD, 2007).  A spirometer is a device for measuring 
flow and volume of inspired and expired air (Miller, Hankinson, Brusasco, Burgos, Casaburi, 
Coats et al., 2005).  Given that COPD is a progressive deterioration of lung function, the 




















Stage I: Mild FEV1.FVC
-1
 < 0.70 
FEV1 ≥ 80% predicted 
Possible chronic cough 
and sputum production 
 
Stage II: Moderate FEV1.FVC
-1
 < 0.70 
FEV1 < 80% predicted 
Shortness of breath, likely 
chronic cough and sputum 
 
Stage III: Severe FEV1.FVC
-1
 < 0.70 
FEV1 < 50% predicted 
Reduced exercise capacity 
and fatigue  
 
Stage IV: Very severe FEV1.FVC
-1
 < 0.70 
FEV1 < 30% predicted 
Respiratory failure, low 
quality of life 
Note: FEV1: forced expired volume of oxygen in the first second. FVC: forced vital capacity 
of the lungs. Predicted FEV1 can be calculated based on age, sex, height, and race (GOLD, 
2007). 
 
The key indices of spirometry for diagnosing COPD include forced vital capacity (FVC) and 
forced expiratory volume after one second (FEV1) (Miller et al., 2005).  The severity of 
COPD can be determined by comparing spirometry indices to predicted normal values 
because people with COPD present both a reduced FVC and FEV1.  However, universally 
applicable reference values are not available due to alterations to predicted estimates by age, 
sex, height, and race (GOLD, 2007).  Predicted FEV1 after one second of a 65 year old, 165 
cm Caucasian female can vary between 2.41 L and 2.83 L (e.g., Cherniack & Raber, 1972; 
Crapo, Morris & Gardner, 1981; Roberts, MacRae, Winning, Adams & Seed, 1991; Enright, 
Kronmal, Higgins, Schenker & Haponik, 1993).  Greater disparity exists among ethnic 
groups.  For example, a 65 year old African American female with a stature of 165 cm would 
have a predicted FEV1 of 1.97 L (Stinson, McPherson, Hicks, Scott, Sykes, Cobbs et al., 
1981).  Multiple prediction equations can lead to difficulty when comparing among COPD 
sample groups.   
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A more precise definition of the lower limits of normal for spirometry values were recently 
established for Caucasians (Stanojevic, Wade, Stocks, Hankinson, Coats, Pan et al., 2008).  
Stanojevic et al. (2008) drew data from over 3500 Caucasian participants by modelling from 
previous research including the third National Health and Nutrition Examination Survey 
(NHANES III) and results from Hankinson, Odencrantz and Fedan (1999).    
 
Accurate assessment and ongoing monitoring of COPD enables appropriate modification of 
therapy and identification of exacerbations (van den Bemt, Schermer, Smeele, Bischoff, 
Jacobs, Groll et al., 2008).  From a research perspective, accurate assessment of COPD is 
necessary to add validity and reliability of treatment interventions.  The trend of published 
literature however, was not to rigidly abide the GOLD spirometry classification of COPD 
severity.  Some published works clustered participants with large (30%) variance in predicted 
FEV1 (Clark, Cochrane, Mackay & Paton, 2000; Bjørnshave & Korsgard, 2005; Vagra, 
Porszasz, Boda, Casaburi & Somfay, 2007; Casanova et al., 2008).  By using the GOLD 
classification method, such variance covered Stage II, Stage III and Stage IV COPD.  The 
severity of COPD affects symptoms (table 2.1) and should therefore be considered when 
planning research interventions.  
 
Other studies have disregarded the GOLD method.  One study reported FEV1 values ranging 
between 23-68% of predicted, yet assigned those participants, with a large range in airway 
function, to the same cycle ergometer protocol (van Helvoort, van de Pol, Heijdra & 
Dekhuijzen, 2005).  Another study recruited Stage III and Stage IV COPD participants to the 
same aerobic conditioning intervention group (Dreher, Walterspacher, Sonntag, Prettin, 
Kabitz & Windisch, 2008).  Therefore, internal and external validity issues prevail in studies 
that recruited people with COPD for exercise interventions. 
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Accurate reporting of severity of COPD is required for exercise interventions because severity 
can determine intensity and duration of physical activity.  Significant differences in ADLs as 
well as recreational physical activity were found among groups of COPD severity within 
~2400 participants classified according to the GOLD method (Garcia-Aymerich, Lange, 
Benet, Schnohr & Antó, 2006).  Subsequently, problems arise when interpreting results from 
populations with significant differences in their functional performance due to COPD 
severity.    
 
In contrast, low variances in FEV1 prediction values have also been reported.  One study 
recruited 24 Stage III COPD participants with a 4% variance in the predicted FEV1 (Mador, 
Bozkanat, Aggarwal, Shaffer & Kufel, 2004).  The variance was 3% for another study of 
Stage III COPD participants although the number of participants with COPD was six 
(Radom-Aizik, Kaminski, Hayek, Halkin, Cooper & Ben-Dov, 2007).  The FEV1 values 
reported in those two studies are externally valid because a clear, specific population was 
identified, rather than a broad sample of people with COPD.  For studies to be reliable and 
externally valid, recommendations, such as that of the GOLD committee should be followed. 
 
2.1.2 Reduce Risk Factors 
Smoking cessation is the most effective method to reduce COPD risk (GOLD, 2007).  World 
Health Organisation data show over one billion tobacco smokers globally, with 10 nations 
accounting for almost two thirds of global use (WHO, 2008b) (figure 2.1).  Over 80% of 
smokers live in third world and developing nations, while tobacco use is declining in 
developed nations (WHO, 2008b).  The daily smoking rate in Australia, for example, has 
reduced from ~50% of the population in the 1940s (Scollo & Winstanley, 2008) to ~20% of 
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the population, with a further 4% of the population occasionally smoking (Australian Institute 
of Health and Welfare, 2009).   
 
 
Figure 2.1. Global tobacco rates among the top 10 most prolific nations (WHO, 2008b).  
 
Passive smoking and occupational exposure to indoor and outdoor air pollution are other risk 
factors for COPD.  The WHO reported that over 50% of the world’s children are affected by 
poor air quality (WHO, 2008a).  Given that COPD is a progressive disease, predominantly 
affecting those over 40 years of age, a case for early intervention strategies to reduce risk 
factors is strong.  Reducing risk factors of COPD however, can be compounded by other 
factors related to aging such as sarcopenia, arthritis and accessibility to health related 































2.1.3 Manage Stable COPD 
Although COPD is an irreversible disease, stable COPD can prevail but it is dependent upon 
the severity of the disease and clinical status of the patient (GOLD, 2007).  Clinical and 
perceived measures of stability such as saturation of haemoglobin and dyspnoea can facilitate 
a diagnosis of stability.  Alternatively, people with COPD were only included to an aerobic 
conditioning and resistance training intervention when free from respiratory infections and 
exacerbations two months prior (Marrara, Marino, de Held, de Oliveria Jn, Jamami & Di 
Lorenzo, 2008).  Management strategies of stable COPD have focussed on both non-
pharmacological and pharmacological treatments with the goal to prevent disease progression, 
relieve symptoms and improve quality of life (GOLD, 2007).   
 
Aetiology of Poor Exercise Tolerance and Functional Performance of the Lower Limbs  
A recently published review provided evidence that airflow obstruction did not impair 
peripheral muscle (i.e, arms and legs) structure and function for people with COPD (Wüst & 
Degens, 2007).  That evidence may be attributed to the net effect of gaseous exchange 
meeting demand because exercise capacity improved after various cardiovascular training 
interventions among people with COPD (Bernard, Whittom, LeBlanc, Jobin, Belleau, Bérubé 
et al., 1999; Berry Rejeski, Adair & Zaccaro, 1999; Arnardóttir, Sörensen, Ringqvist & 






Although airflow limitation may not directly affect peripheral muscle structure and function, 
perceived breathlessness (i.e., dyspnoea) negatively impacts physical activity (Préfaut, Varray 
& Vallet, 1995; figure 2.2).  The so called ‘dyspnoea spiral’ is a useful model to visualise 
effects of lung function impairment (i.e., airflow limitation).  
 
 
Figure 2.2. The dyspnoea spiral showing how reduced lung function leads to reduced physical 
activity, and deconditioning (Préfaut, Varray & Vallet, 1995). 
 
Shown in figure 2.2, a sedentary lifestyle leads to deconditioning.  For people with COPD, 
deconditioning of peripheral muscle may result in a loss of muscular strength, power and 
endurance, muscle cross sectional area, and muscle fibre Type distribution (Gosker, Wouters, 
van der Vusse & Schols, 2000; Storer, 2001; Degens & Always, 2006).  Specifically, the age-
related atrophy of Type II muscle fibres of the quadriceps femoris was exacerbated in the 




The underlying physiological mechanism for augmented atrophy may include systemic 
inflammation, nutritional depletion, reduced saturation of haemoglobin, hypoxemia, and 
hypercapnia (Serres, Hayot, Préfaut & Mercier, 1998; Debigaré, Côté & Maltais, 2001; 
Augusti, Norguera, Sauleda, Sala, Pons & Busquets, 2003; GOLD, 2007; Wüst & Degens, 
2007).  Given that the major roles of Type II skeletal muscle fibres is to contract with great 
speed and power (Saltin, Henriksson, Nygaard & Anderson, 1977; ACSM, 1998a; Mahoney, 
& Tarnopolsky, 2005), modes of training to modify effects of underlying physiological 
mechanisms, or at least reduce the rate of atrophy through peripheral muscle training are 
justified (Chodzko-Zajko et al., 2009).   
 
Fast and powerful muscular contractions are used for ADLs such as standing from a chair and 
climbing stairs.  Understandably therefore, the deconditioning of Type II skeletal muscle 
fibres may lead to sedentary behaviours.  However, functional measures of performance 
specific to speed and power have rarely been reported in the COPD literature, and therefore 
forms part of the rationale of this research. 
 
Non-Pharmacologic Treatment 
The third component of the GOLD mandate, to manage stable COPD, can be partly addressed 
by improving or maintaining exercise tolerance with non-pharmacologic methods.  Following 
a review of literature, GOLD reported that all people with COPD benefit from structured 
physical activity programs in relation to exercise tolerance (GOLD, 2007).  The dependent 
variables of exercise tolerance were; maximal exercise capacity during walking, cycling 
(O’Shea, Taylor & Paratz, 2004) and stair climbing (Foy et al., 2006; Dreher et al., 2008), 
lower limb cross sectional area, muscular strength and power (Bernard, LeBlanc, Whittom, 
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Jobin, Belleau & Maltais et al., 1998; Storer, 2001), and six-minute-walk-test distance 
(Dreher et al., 2008).  Of the variables frequently listed to test exercise tolerance, stair 
climbing and the six-minute-walk-test distance should be considered to mimic ADLs.  
Furthermore measurement equipment and skill requirement for stair climbing and walking are 
low compared with for example, maximal capacity testing using a cycle ergometer.    
 
To date, research into improvement in exercise tolerance and functional performance has been 
mainly directed at individuals with Stage III COPD.  People with severe COPD almost always 
have a reduced quality of life and subsequently have a high need for medical attention 
(GOLD, 2007).  It is therefore understandable that people with no greater than a Stage III 
COPD diagnosis are the most accessible for research.  Generally, COPD is diagnosed at Stage 
II.  At Stage II, not Stage I, individuals begin to seek advice for management of their 
condition (GOLD, 2007).  Despite the GOLD spirometry classification system of COPD 
severity, limited literature is available on exercise interventions among people with Stage I 
and Stage II COPD.  The relative lack of management advice in the early onset of the disease 
may be due to the classification description of COPD because individuals in the less severe 
Stages are generally not aware of abnormal lung function (GOLD, 2007) (i.e., table 2.1). 
 
Non-pharmacologic treatments for all people with stable COPD were shown to reduce 
dyspnoea, and improve exercise tolerance (Nici, Donner, Wouters, Zuwallack, Ambrosino, 
Bourbeau et al., 2006).  The treatment is evidence-based, multidisciplinary, and 





Pulmonary Rehabilitation  
Pulmonary rehabilitation methods for treatment of stable COPD involve patient assessment, 
exercise training, education, nutritional intervention and psychological support (Nici et al., 
2006).  Case specific, the rehabilitation method may also incorporate supplemental oxygen 
therapy or surgical intervention (e.g., lung transplant) (GOLD, 2007).    
 
The content of a multidisciplinary and comprehensive pulmonary rehabilitation program 
should consist of more than breathing and relaxation exercises (e.g., Strijbos, Postma, van 
Altena, Gimeno & Koëter, 1996), or respiratory machines and upper arm strengthening 
exercises (e.g., Martinez, Vogel, Dupont, Stanopoulos, Gray & Beamis, 1993).  Recently, a 
collective effort of the American Thoracic Society, the European Respiratory Society and 
GOLD, agreed on a more thorough understanding of appropriate and effective pulmonary 
rehabilitation.  Pulmonary rehabilitation is now viewed as the cornerstone of comprehensive 
management of patients with COPD (Nici et al., 2006). 
 
Although clinical evidence of the benefits of pulmonary rehabilitation have wide acceptance, 
replication based on the methods of published literature can be difficult.  One study for 
example, beneficially affected people with COPD after a comprehensive multidisciplinary 
pulmonary rehabilitation intervention including formal education sessions (Normandin et al., 






A comprehensive pulmonary rehabilitation program must incorporate strength training of 
skeletal muscle.  Strengthening the upper and lower limbs is known as peripheral muscle 
training (O’Shea, Taylor & Paratz, 2004).  The training methods to improve exercise 
tolerance and functional performance of the lower limbs of people with COPD are 
systematically reviewed later in this chapter (2.1.5 Systematic Review of Peripheral Muscle 
Training – Resistance Training).  The following section, however, describes some peripheral 
muscle training modes.   
 
Peripheral Muscle Training  
People with COPD have lower muscle mass than healthy counterparts (Hamilton et al., 1995; 
Gosselink, Troosters & Decramer, 1996).  As a consequence, skeletal muscular strength of the 
leg has been described as less than age and sex matched controls (Hamilton et al., 1995), 
although the exact cause (i.e., atrophy) remains speculative (Decramer, Lacquet, Fagard & 
Rogiers, 1994).  Subsequent purpose designed peripheral muscle training interventions to 
improve muscular strength of the legs among people with COPD have concurrently improved 
various kinematic variables of gait (Panton, Golden, Broeder, Browder, Cestaro-Seifer & 
Seifer, 2004; Alexander, Phillips & Wagner, 2008).  Strength of skeletal muscle is a required 
fitness component for maintenance of ADLs among people with COPD (GOLD, 2011) and 
can be correlated with improved gait performance of people with COPD (Alexander, Phillips 
& Wagner, 2008).  Maintenance or improvement of gait can describe functional independence 





Resistance training is a primary peripheral muscel training mode to beneficially alter skeletal 
muscle (GOLD, 2007).  The independent variables germane to resistance training and the 
American College of Sports Medicine (ACSM) recommendations are listed in table 2.2.  
Articulate and detailed disclosure of the training method needs to be reported in literature to 
enable replication.  Recently, resistance training with an emphasis on strength surrounding the 
knee was incorporated into a training regime in an attempt to improve maximal leg strength of 
a sample with COPD (Skumlien et al., 2008).  The authors did not however, report rest 
intervals.  Lack of disclosure, or justification of resistance training protocols is not uncommon 
among COPD studies (e.g., Clark et al., 2000; Ortega, Toral, Cejudo, Villagomez, Sánchez, 
Castillo et al., 2002; Rooyackers, Berkeljon & Folgering, 2003; Mador et al., 2004).  Again, 
such non-disclosure makes precise replication, comparisons and meta-analyses challenging.    
 
Table 2.2 
Independent variables of resistance training for a skeletal muscle or skeletal muscle groups 
Variable Definition Position stand 
(minimum recommendation 
for healthy adults) 
Repetition A single lift 8-12 
Set Number of repetitions 
completed without rest 
1 
Sessions Number of sets per workout 8-10 
Frequency Sessions per week 2-3 
Load Resistance 8-12 Repetition Maximum 
Rest Interval Time in seconds between sets 60-180 seconds 
Length of Intervention Weeks of intervention Ongoing 
Overload Increment in load over time 2-10% 
Note: Sources: American College of Sports Medicine (1998b) and American College of 





Peripheral muscle training interventions have also incorporated aerobic conditioning for 
people with COPD.   Various methods were used at different intensities.  Intensity on cycle 
ergometers ranged from at least 50% of predicted peak work (Ortega et al., 2002; Mador et 
al., 2004; van Helvoort et al., 2005) to 80% of peak work (Radom-Aizik et al., 2007).  
Treadmill walking at 60% of the average speed of the six-minute-walk-test (Spruit, Gosselink, 
Troosters, De Paepe & Decramer, 2002), and 70% VO2max were also used (Puente-Maestu, 
Sánz, Sánz, Cubillo, Mayoi & Casaburi, 2000).  Only one study, (Ortega et al., 2002) reported 
participant drop-out due to COPD exacerbations (n = 4) and lack of motivation (n = 3).  
Nevertheless, the six-minute-walk-test was probably the most representative of ADLs. 
 
The limited available evidence about peripheral muscle training independent of other modes 
of pulmonary rehabilitation allowed three subjective conclusions: (1) moderate intensity 
peripheral muscle training exercises appear tolerable to people with COPD, (2) moderate 
intensity peripheral muscle training exercises were beneficial to people with COPD, and (3) 
functional measures of performance were not commonly assessed after moderate intensity 
peripheral muscle training exercises in people with COPD. 
 
Contraindications to Exercise Participation and Recruitment for Research 
Chronic obstructive pulmonary disease is not a contraindication to exercise.  Some 
medications however, are contraindicated for exercising in people with COPD.  Generally, 
medications that suppress respiratory drive or alleviate mucus are contraindicated for exercise 




By definition, the effect of COPD on airway obstruction is irreversible (GOLD, 2007).  
Subsequently, people with COPD were excluded from exercise interventions if their 
expiratory airflow limitation was reversible after bronchodilator inhalation and/or they had a 
long-term history of oral steroid therapy (Berry, Rejeski, Adair & Zaccaro, 1999; Clark et al., 
2000).  Prospective participants have also been excluded if self-reported breathing difficulty 
(i.e., dyspnoea) was present after performing ADLs such as: walking a city block, grocery 
shopping, completing household chores, lifting objects, walking up stairs, and rising from a 
chair (Berry et al., 1999).  
 
Oversights of the GOLD statements (2007 & 2011) include the absence of detailed discussion 
around exercise training heart rate, subjective measures of perceived exertion to determine 
maximum intensity exercise, and subsequent suitability to certain exercise protocols.  
Although to establish exercise guidelines are beyond the scope of this research, the oversight 
obscures the management of stable COPD using resistance training and aerobic conditioning 
because the importance of peripheral muscle training had already been established.  
 
Pharmacologic Treatment 
A full review of pharmacological treatment is beyond the scope of this research.  In this 
section, some common pharmacologic treatments are described due to their possible impact 
on the variables to be measured in this research.  Participant screening protocols should 
include current pharmacologic treatment because the effect of some medications is to improve 
exercise capacity.  Thorough screening allows replication for future research and removes the 




Usual pharmacologic treatment of COPD focuses on pulmonary function.  The goal of 
pharmacologic treatment is to treat or prevent exacerbations (GOLD, 2007).  Typical 
exacerbations are characterised by changes in a patient’s baseline dyspnoea, cough or sputum 
beyond normal daily variation (GOLD, 2007).  
 
In the past, nitric oxide was prescribed for disease management because it assisted pulmonary 
vasodilatation.  More recently, nitric oxide was shown to worsen gaseous exchange (Barberá, 
Roger, Roca, Rovira, Higenbottom & Rodriguez-Roisin, 1996; Jones & Evans, 1997).  
Corticosteroids are frequently prescribed to reduce exacerbations and increase exercise 
capacity for individuals with COPD (Gartlehner, Hansen, Carson & Lohr, 2006).  However, 
the long-term use of corticosteroids is not recommended (GOLD, 2007) because habitual and 
substantial dosage may alter bone metabolism and bone health (Richy, Bousquet, Ehrlich, 
Meunier, Israel, Morii et al., 2003).    
 
Contemporary pharmacologic treatments use bronchodilators to prevent and control 
symptoms, reduce exacerbations, and improve exercise tolerance for individuals with COPD 
(GOLD, 2007).  Bronchodilators also increase exercise capacity for people with COPD (Man, 
Mustfa, Nikoletou, Kaul, Hart, Rafferty et al., 2004) and are subsequently viewed as 
performance enhancing.  Salbutamol, a short-acting β2-adrenergic receptor agonist is 
commonly used to assess airflow limitation reversibility (Johannessen, Lehmann, Omenaas, 
Eide, Bakkle & Gulsvik, 2006).  Salbutamol can be used in the recruitment of participants 
with COPD for research to assess airflow limitation (Berry et al., 1999; Clark et al., 2000; 




2.1.4 Manage Exacerbations 
As mentioned, exacerbations of COPD change ‘baseline’ dyspnoea, cough or sputum beyond 
normal day to day variation (Rodrigues-Roisin, 2000; Burge & Wedzicha, 2003).  Generally, 
respiratory infection and poor air quality cause exacerbations (GOLD, 2007).  Exacerbations 
can be successfully treated with pharmacologic treatment and pulmonary rehabilitation 
(Puhan, Scharplatz, Troosters, Walters & Steurer, 2009).   
 
Exercise can also change baseline dyspnoea for people with COPD.  Dyspnoea was perceived 
as ‘somewhat severe’ to ‘severe’ for some patients with COPD during supervised cycling 
(Oliveira, Carrascosa, Borghi-Silva, Berton, Queiroga Jn, Ferreira et al., 2010) and walking 
(Breyer, Breyer-Kohansal, Funk, Dornhofer, Spruit, Wouters et al., 2010).  It was 
recommended that exercise should be terminated if saturation of haemoglobin reduced to ≤ 
85% (Poulain, Durand, Palomba, Ceugniet, Desplan, Varray et al., 2003; Jenkins, Hill & 
Cecins, 2010).  However, despite perceived breathing discomfort and a risk of reduced 
saturation of haemoglobin for people with COPD during exercise, peripheral muscle training 
remains integral to pulmonary rehabilitation. 
 
2.1.5 Systematic Review of Peripheral Muscle Training – Resistance Training 
The objective of this section is to identify and review published literature of peripheral muscle 
training (i.e., resistance training) of people with COPD.  The aim is to systematically quantify 
evidence levels for effective peripheral muscle training interventions using National Health 
and Medical Research Council (NHMRC Australia), GOLD evidence level, and CONSORT 
guidelines (table 2.3).  A level of evidence V category is also added to incorporate position 
statements of professional bodies, associations and societies.  Interventions of combined 
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aerobic and resistance training are excluded unless the research design allowed the 
independent effect of resistance training to be known.  Literature of aerobic conditioning is 
excluded due to the ‘power continuum’.  The continuum describes the divide among 
metabolic power and mechanical power for anaerobic (e.g., resistance training) and aerobic 
energy pathways (Knuttgen, 2007).  Interventions of less than six week duration are excluded 




NHMRC Australia and GOLD levels of evidence 
Level Intervention Diagnostic accuracy 
I A systematic review / 
meta-analysis of level II 
studies 
A systematic review of level II studies 
II A randomised controlled 
trial 
A study of test accuracy with: an independent, 
blinded comparison with a valid reference 
standard, among consecutive persons with a 
defined clinical presentation 
III-1 A pseudo-randomised 
controlled trial 
A study of test accuracy with: an independent, 
blinded comparison with a valid reference 
standard, among non-consecutive persons with a 
defined clinical presentation 
III-2 A comparative study with 
concurrent controls 
A comparison with reference standard that does 
not meet the criteria required for:  
Level II and III-1 evidence 
III-3 A comparative study 
without concurrent 
controls 
Diagnostic case-controlled study 
IV Case series with either 
post-test or pre-test/post-
test outcomes 
Study of diagnostic yield 
V* Panel Consensus 
Judgement 
Based on clinical experience or knowledge 




Evidence Level I 
To meet the aim and specially answer the question “what resistance training protocols are 
beneficial for people with COPD?”,   the search terms and MeSH headings for COPD were 
established a priori, and are listed in table 2.4.  The abstract for each paper was screened for 
content and accepted/rejected for review (table 2.5).  An accepted paper had to show clear 




Search strategy of Medline and Cochrane for evidence level I (to March 2012)  
Search Terms Results 
  Medline Cochrane Library 
1 "COPD" or "chronic obstructive pulmonary 
disease" or "obstructive lung disease" or 
"chronic obstructive lung disease" or 
"chronic obstructive airway disease" or 
"chronic airways limitation" or "chronic 
airways obstruction" or "chronic bronchitis" 
or "pulmonary emphysema" or "chronic 
airflow obstruction" or "obstructive lung 
disease". mp. [mp=title, original title, 
abstract, name of substance word, subject 







"strength training" or "strength exercise" or 
" weight training" or "weight lifting" or 
"resistance exercise" or "resistance training" 
or "progressive resistance exercise" or 
"progressive resistance training". mp. 
[mp=title, original title, abstract, name of 












Reviews of COPD and peripheral muscle training 









Evidence level: II, 
III-1, III-2 




Overall N = 202,  
δ = 0.90 favours 
treatment to ↑ 
knee extensor 
strength 
Note: * The authors did not use NHMRC evidence level guidelines nor CONSORT 
guidelines. # Inclusion criteria based on NHRMC evidence level guidelines used in this 
reserach. 
 
O’Shea et al. (2004) conducted meta-analysis based on findings of five papers of varying 
NHMRC evidence.  Review of the methods of those studies revealed that effective resistance 
training occurred in outpatient clinics when the participants used machine weights.  However, 
because of inconsistent study descriptions and an oversight of CONSORT guidelines, a 
knowledge gap remained.  Furthermore, the authors did not nominate an effective resistance 
training protocol for people with COPD.  Given that the most recent review was published in 
2004, it was considered necessary to revisit the literature to seek any additional knowledge in 
resistance training interventions.  The search strategy of table 2.4 was used.  The CONSORT 
checklist was used as a method of quality control for NHMRC Level II evidence.    
 
Evidence Level II 
At this level of evidence, only randomised controlled trials (NHMRC evidence level II) were 
considered for review since they can establish superior efficacy of a health care intervention 
and minimise potential bias, confounders, and group contaminant (Schulz, Altman, Moher, & 
the CONSORT Group, 2010).  The literature search was limited to publications in the English 
language.  For the purpose of this review, a randomised controlled trial is determined as a 
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study “in which the subjects were randomly allocated to a new treatment, to a control group or 
to an existing treatment group” (Peat, Mellis, Williams & Xuan, 2001, p. 22).  The inclusion 
criteria for randomised controlled trials are shown in table 2.6. 
 
Table 2.6 
Criteria for a randomised controlled trial acceptable for this review  
Type Cohort Cohort with condition (i.e., COPD) 
RCT 1 Control 
Experimental 
 
RCT 2  Existing treatment (control) 
Experimental 
Experimental + Existing treatment 
Note: Cohort: a group randomly gathered not currently receiving a condition such as 
resistance training.  Cohort with condition: the condition may be an existing treatment, e.g., 
resistance training or pharmacologic treatment. 
 
The exclusion criteria stated that the following methods and designs were unacceptable: (1) 
parallel design, (2) control or intervention group drawn from a different cohort, and, (3) 
participants were not randomly recruited (Peat et al., 2001; Schulz et al., 2010).  Specific to 
this research, the exclusion criteria extended to: combined aerobic and resistance training 
groups and/or resistance training of the upper limbs only.     
 
Applying the exclusion criteria resulted in a total of four acceptable papers (table 2.7).  Of 
those papers however, three were susceptible to the Hawthorne Effect (changed behaviour via 
the process of being recruited to a study, independent of true experimental effect) and the 
remaining paper (i.e., Kongsgaard, Backer, Jørgensen, Kjaer, & Beyer et al., 2004) did not 
report the administered control procedure (e.g., non-activity, pamphlet or information 
session).  One paper did not report control data (i.e., Ortega et al., 2002).  Criteria for meta-
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analysis were not met because dependent variables were not common among studies.  
Statement of allocation concealment was absent among all studies.  Of the four papers in table 
2.7, the method of one study was to assess FEV1 after bronchodilator (i.e., Ortega et al., 
2002).  Therefore, of the other three studies the participant’s “COPD” may be reversible (i.e., 
airflow limitation), and thus, is not considered COPD to the GOLD classification method. 
 
Unjustified sample sizes and resistance training protocols (i.e., reliability and validity), were 
evident in existing randomised controlled trials using resistance training in populations with 
COPD.  Specifically, the number and intensity of repetitions was not justified or consistent, 
and the number of sets and rest intervals lacked clarity.  The resistance training methods 
appeared perfunctory rather than systematic.  Despite this, two strong trends emerged: (1) 
muscular strength improved for people with COPD after at least eight weeks of resistance 
training, and (2) resistance training interventions were well tolerated by people with COPD.  
While measures of muscular strength and power such as one repetition maximum (1RM) and 
work rate (J) are commonly reported, they do not necessarily transfer to functional 
performance of ADLs.  Given the employed search strategy was unable to reveal any 
NHMRC evidence level II studies for effects of resistance training on functional performance 








Groups Intervention Findings Adverse effects 
Simpson et al. (1992) 
3 sessions/week 
8 weeks 
28 Stage III  
(FEV1 SD = 
20%) 
G1: Resistance training 
G2: No-activity control 
§
 
3 sets, 10 reps,  
50-85% 1RM (overload) 
Hip flexors &  
leg extensors   
‡
 
G1: 1 RM ↑ for all 
muscle groups  
G2: no change 
n = 0 
Clark et al. (2000) 
2 sessions/week 
12 weeks 
43 Stage II 
(FEV1 SD = 
23%)* 
G1: Resistance training 
G2: No-activity control 
§
 
3 sets, 10 reps,  
70% 1RM 
Hip flexors & extensors, 
leg extensors   
‡ 
G1: Work (J) ↑ for all 
muscle groups 
G2: no change 
Not reported 
Ortega et al. (2002) 
3 sessions/week 
12 weeks 
35 Stage III 
(FEV1 SD = 
14%)*† 




4 sets, 6-8 reps 
70-85% 1RM 
Leg flexors & extensors   
‡ 
G1: 1 RM ↑ for all 
muscle groups 
G2: data not reported  
n = 1 due to 
exacerbations 
Kongsgaard et al. (2004) 
2 sessions/week 
12 weeks 
13 Stage III 
(FEV1 SD = 
4%)* 
G1: Resistance training 
G2: Control 
 
4 sets, 8 reps 
80% 1RM 
Hip flexors,  
leg flexors & extensors   
‡ 
G1: 5 RM ↑ for all 
muscle groups 
G2: no change 
n = 5 unrelated 
to the study 
Note: *: Did not report prediction equation used. †: post-bronchodilator. 
§
: Susceptible to Hawthorne Effect. ‡: Protocol was not justified with 




Systematic Review of Resistance Training and Functional Performance of People with 
COPD 
Functional independence is of considerable importance to people with COPD and of equal 
concern is the maintenance of ability to complete ADLs (GOLD, 2007).  Measurement tools 
to quantify such have been used in a variety of settings through published research.  This 
section therefore, focuses on published research in which the primary outcomes were 
measures of functional performance specific to ADLs.  The included studies were listed in 
table 2.8.  The search terms; “functional performance" or "health status" or "mobility" or 
"function" or "functional fitness” or “functional independence”, were combined with search 
terms from table 2.4.   
 
The additional search produced 38 papers.  Two papers, shown in table 2.8, were acceptable 
according to the criteria that the following methods and designs were excluded: (1) Evidence 
Level V, (2) combined aerobic and resistance training groups and resistance training of the 
upper limbs only, and (3) dependent variables of a primarily aerobic nature. 
 
Of the functional performance tests identified, validity and reliability had been previously 
established for the sit-to-stand repetitions in 30 seconds test (Rikli & Jones, 2001), but not for 
the sit-to-stand repititions in 60 seconds test.  Both studies of table 2.8 did not establish 
reliability or validity of the dependent variables.  Furthermore, one study combined data of 
people with Stage II and Stage III COPD severity (Normandin et al., 2002).  Although later, 
COPD severity was shown to affect functional performance (Garcia-Aymerich et al., 2006).  










Groups Intervention Findings Adverse effects 
Normandin et el. (2002) 
2 sessions/week 
8 weeks 
(Evidence Level III-1) 
 
40 Stage II 
and Stage III 
(FEV1 s.d = 
18%)*+ 
G1: Resistance training 
G2: Aerobic training 
G3: Pulmonary rehabilitation 
 
Sets unknown, 8-10 reps 
Resistance unknown 
Hip & leg flexors & 
extensors   
Chair stand 
repetition ↑ from 16 
to 18.8 per minute 
n = 14 due to 
exacerbations 
Kongsgaard et al. (2004) 
2 sessions/week 
12 weeks 
(Evidence Level II) 
13 Stage III 
(FEV1 s.d = 
4%)* 
G1: Resistance training 
G2: Control 
 
4 sets, 8 reps 
80% 1RM 
Hip flexors,  
leg flexors & extensors   
‡ 
Stair climbing ↓ 
from 4.7 sec to 3.9 
sec 
Chair stand 
repetition ↑ from 
17.0 to 18.3 per 
minute 
n = 5 unrelated 
to the study 
Note: *: Did not report prediction equation used. ‡: Protocol was not justified with known evidence of efficacy. +: Did not separate groups 




Evidence Level V 
A rationale for the use of peripheral muscle training to improve skeletal muscle function in 
people with COPD has been addressed by GOLD, the American Thoracic Society, the 
European Respiratory Society, the Thoracic Society of Australia and New Zealand, the 
Australian Lung Foundation, the International Federation of Sports Medicine, and the 
American Department of Veterans Affairs.  Authoritative health bodies supported the 
importance of aerobic conditioning and resistance training, yet specific practical guidelines 
for the implementation of resistance training were not described.  Specifically, the joint 
American Thoracic Society/European Respiratory Society statement (Nici et al., 2006) 
recommended more research to identify appropriate resistance training intensities for people 
with COPD.  Such research could aid the creation of universal guidelines that may be 
followed by health professional in an effort to improve the third consideration of the GOLD 
mandate (i.e., to manage stable COPD), with an overarching goal to improve or maintain 
exercise tolerance and functional performance.   
 
Summary of Systematic Review 
A component of pulmonary rehabilitation, peripheral muscle training of the lower limbs 
improved exercise tolerance of people with COPD (tables 2.7 and 2.8).  In particular, 
resistance training improved muscular strength and power, and performance of ADLs with, at 
most, evidence level II (table 2.9).  Despite evidence, variation exists among resistance 
training interventions and exercise guidelines have not been established.  Calls for guidelines 
from professional bodies at the forefront of clinical practice remain without a united response.  
Specifically, after a systematic review of literature, an optimal resistance training method has 





Statements of effectiveness of resistance training and associated evidence level after a 
systematic review of resistance training and functional performance  
Statement Level of Evidence 
Resistance combined aerobic training beneficially effect exercise 
tolerance and health status for people with COPD 
Level I 
Resistance training beneficially effects exercise tolerance and 
health status for people with COPD 
Level II 
Resistance training is well tolerated for people with COPD Level II 
Resistance training was most effective when set at between 50-
85% 1RM 
Level II 
Resistance training was most beneficial when conducted at least 
two sessions per week 
Level II 
Resistance training beneficially effects measures of functional 
performance of activities of daily living 
 
Level II & Level III-I 
Guidelines of resistance training for people with COPD None 
 
 
2.1.6 General Summary 
Creation of the Global Initiative for Chronic Obstructive Lung Disease, backed by the most 
internationally respected health organisation (i.e., the WHO) has allowed narrative and 
systematic analyses of the COPD literature.  These analyses established four mandates for the 
consideration of COPD: (1) assess and monitor the disease, (2) reduce risk factors, (3) 
manage stable COPD, and (4) manage exacerbations.  The third mandate; to manage stable 
COPD, can be addressed partly by improving or maintaining exercise tolerance and functional 






Resistance training has been routinely incorporated to pulmonary rehabilitation interventions 
(table 2.4).  However, study protocols could not allow the independent benefit of resistance 
training to be identified.  As such, the independent benefit of resistance training has been 
limited to very few studies (table 2.7).  Furthermore, effects of resistance training on 
functional performance of ADLs appear almost to have been ignored by researchers working 
with people affected with COPD (table 2.8).  The independent effect of resistance training is 
only known for stair climbing and chair standing repetitions (i.e., Normandin et el., 2002; 
Kongsgaard et al., 2004).  Other field tests, such as the timed-up-and-go test (TUG test) and 
the 5-chair stands test (5-chair test), and/or kinematic variables of gait with known reliability 
and validity could be used to describe effects of resistance training on exercise tolerance and 
functional performance of the lower limbs of people with COPD.   
 
Further research is required to thoroughly establish effective interventions to beneficially 
improve or maintain exercise tolerance and functional performance of the lower limbs of 
people with COPD.  Ideally, interventions should be randomised controlled trials and may 
focus on functional effects of resistance training related to ADLs.    
 
2.2 Whole-Body Vibration 
Vibration may occur in most environments.  Workers are exposed to vibration when they use 
jack hammers and drive trucks.  The vibrations are generated by the machinery.  Athletes are 
exposed to vibration when they run or ride a horse.  Vibrations in this case are generated by 
the contact of the foot upon the running surface and the movements of the horse.  In everyday 





Typically, vibration affects the whole-body and henceforth is referred to as whole-body 
vibration (WBV).  Further, WBV may be moving in alternate directions simultaneously 
(Griffin, 1994).  More specifically, vibration may be evident in the frontal, sagittal and 
transverse planes (Hamill & Knutzen, 2003; Marieb, 2004).  The International Organisation 
for Standardisation (ISO) devised guidelines within which WBV magnitude must adhere.  
These limits are to ensure that deleterious conditions such as gastrointestinal upsets (Ishitake, 
Ando, Miyazaki & Matoba, 1998; Ishitake, Mitazaki, Noguchi, Ando & Matoba, 2002) and 
biological structural damage are avoided (Necking, Dahlin, Fridén, Lundborg, Lundström & 
Thornell, 1992).    
 
While ISO guidelines are established for occupational environments, such guidelines do not 
exist for athletic, social exercise, exercise training, and exercise rehabilitation environments, 
despite a theory that WBV may cause structural damage to bones (Kiiski, Heinonen, Järvinen, 
Kannus & Sievänen, 2008).  Furthermore, because WBV research in exercise training 
environments is relatively recent, scientific knowledge of effects of WBV on all body systems 
are not thoroughly understood.  Unsurprisingly, and possibly due to the variability of 
physiological demands across sport and exercise environments, ISO standards and scientific 
guidelines for safe and effective WBV have not been established.   
 
Despite the known deleterious effects of occupational WBV (ISO 2631-1, 1997), as an 
exercise training mode, WBV has been created by vibration platforms and used for both 
healthy young adult and older adult populations.  Moreover, within the commercial health and 
fitness industries, WBV represents an exercise mode in which an individual stands on a 
functioning vibration platform and may improve a variety of physiological components such 




Furthermore, WBV has been advertised and marketed as an essential tool with multiple 
capabilities such as eliminating cellulite and fat and improving the users’ golf swing.  
However, claims from the commercial health and fitness industry are based almost 
exclusively upon anecdotal opinion and lack scientific evidence.   
 
 
Figure 2.3. Whole-body vibration can be used as a mode of physical activity in the 
commercial health and fitness industries. 
 
Vibration platforms may deliver side alternating vibration or synchronous vibration to an 
individual (figure 2.4).  Primarily, side alternating WBV occurs when one places the feet 
equidistant about the axis of rotation.  Synchronous WBV occurs when one places the feet at 







Figure 2.4. Side alternating WBV (left) and synchronous WBV (right).  Adopted from 
Cardinale & Wakeling (2005). 
 
2.2.1 Whole-Body Vibration as a Mode of Physical Activity 
During interventions, WBV is used when a participant stands upon a vibrating platform.  
Exercise protocols have varied among several sets of 30 second bouts, to bouts as long as four 
minutes (Torvinen, Kannus, Sievänen, Järvinen, Pasanen, Kontulainen et al., 2003; Bogaerts, 
Verschueren, Delecluse, Claessens & Boonen, 2007; Rees, Murphy & Watsford, 2008).    
  
Whole body vibration has been reported to increase/improve; jump height (Bosco, Cardinale, 
Tsarpela, Colli, Tihanyi, von Duvillard et al., 1998; Roelants, Delecluse, Goris & 
Verschueren, 2004; Rønnestad, 2004), knee extensor strength (Delecluse, Roelants & 
Verschueren, 2003; Roelants, Delecluse & Verschueren, 2004), explosive lower limb strength 
(Russo, Lauretani, Bandinelli, Bartali, Cavazzini, Guralnik et al., 2003), neuromuscular 
activation as measured by surface electromyography (Abercromby, Amonette, Layne, 
McFarlin, Hinman & Paloski, 2007a), oxygen uptake (Rittweger et al., 2002), postural control 
(Cheung, Mok, Qin, Sze, Lee & Leung, 2007; Rees, Murphy & Watsford, 2008), and 
hormonal responses such as testosterone and growth hormone (Bosco et al., 2000) among 




human body however, have been contradicted by other research.  Whole body vibration failed 
to improve; jump height (Cochrane, Legg & Hooker, 2004; Delecluse, Roelants, Diels, 
Koninckx & Verschueren, 2005), lower limb muscular strength and power (de Ruiter, van 
Raak, Schilperoort, Hollander & de Haan 2003; Bautmans, Van Hees, Lemper & Mets, 2005) 
and hormonal responses such as testosterone and growth hormone (Cardianle, Leiper, 
Erskine, Milroy & Bell, 2006) among various young and old adult populations. 
 
Different findings among studies may be due to variation of study methods.  Participant 
number, gender, age and health status, WBV intervention type (i.e., frequency, intensity, type 
and time; FITT), dependent variables, measurement instruments, statistical analyses, and 
study location (i.e., laboratory or community based) varied among published literature.  The 
quantification of WBV as a mode of exercise is in need of further understanding and 
standardisation.  Accurate reporting of vibration platform descriptors and disclosure of WBV 
interventions methods will allow replication among future studies.  
 
Quantifying WBV / Vibration Platform Descriptors 
Theoretically, vibration platforms generate pure sinusoidal WBV (figure 2.5).  Such WBV 
allows investigation and application of a single frequency of motion rather several alternate 
and simultaneous frequencies (Griffin, 1994; Cardinale & Bosco, 2003).  The frequency of 
motion is measured by the number of cycles of motion per second (Hertz) (Griffin, 1994).  





Figure 2.5. Pure sinusoidal WBV. 
 
Alternate and simultaneous frequency can occur in any environment; occupational or 
recreational.  Alternate WBV frequency refers to shock WBV; whist simultaneous refers to 
numerous alternate vibrations acting in conjunction (Griffin, 1994).  Figure 2.6 shows other 
forms of vibration that occur in all environments.  Most notably, the frequency of the motion 
is inconsistent.  Further, not shown in figure 2.6, the motion frequencies may be occurring 





Figure 2.6. Multiple vibration frequency types.  Whole-body vibration as a mode of physical 
activity is described as ‘sinusoidal’. Taken from Griffin (1994). 
 
As mentioned, vibration may be evident in the frontal, sagittal and transverse planes in 
conjunction.  With reference to vibration platforms and WBV however, the vibration moves 





The magnitude of pure sinusoidal motion is measured by the displacement of the vibration 
(Griffin, 1994).  Within literature, however, inconsistency exists because several nouns are 
used (Lorenzen, Maschette, Koh & Wilson, 2009).  Amplitude, displacement, peak-to-peak 
amplitude and peak-to-peak displacement have been used, and at times, used synonymously 
(e.g., Delecluse, Roelants & Verschueren, 2003).  Those authors initially referred to 
amplitude, only later to refer to peak-to-peak displacement of the same magnitude.  
 
Griffin (1994) suggested displacement is defined by the peak movement in one direction to 
the peak movement in the opposite direction (i.e., peak-to-peak displacement) (figure 2.7).  
The definition would find support from Knight (2000) who suggested amplitude was the 
maximum distance from the equilibrium position, whilst Mester, Spitzempfeil and Yue (2002) 
defined magnitude of the motion as amplitude (mm) of a half wave form.  Figure 2.8 shows 




Figure 2.7. Peak-to-peak displacement and amplitude of pure sinusoidal vibration. The peak-








Using the frequency (Hz) and amplitude (mm) of a vibration platform, it is possible to 
quantify WBV at the surface of the platform.  Equation 1 shows the calculation of gravity (g), 
which can be reported within WBV literature along with frequency and amplitude (Rittweger, 
Schiessl & Felsenberg, 2001).  
 
    equation 1 
 
Where ‘A’ is the amplitude (m), ‘f’ is the frequency (Hz), ‘(2πf)
2
’ is the maximum 
acceleration of the platform, and 9.81 is the acceleration of gravity.  If for example, peak-to-
peak displacement was 2.0 mm and frequency was 25 Hz, gravity (g) was 2.52 g, because A 
was 0.001 m.  
 
It seems that WBV has been quantified and, at times, reported in such a way to allow 
comparison among study methods.  Comparison however, is limited because only frequency 
is the most commonly reported variable in the frequency range of 26 to 50 Hz (Bosco, Colli, 
Introini, Cardinale, Tsarpela, Madella et al., 1999; Cardinale & Lim, 2003; Delecluse, 
Roelants & Verschueren, 2003; Erskine, Smillie, Leiper, Ball & Cardinale, 2007).    
 
Given that g is affected by A, the inconsistent definition of A limits g calculation.  Of the 
recent literature, Erskine et al. (2007) reported frequency 30 Hz, peak-to-peak displacement 
4.0 mm and gravity 3.5 g.  Using equation 1, gravity is 7.24 g.  The authors did not disclose 







to-peak amplitude (Rees, Murphy & Watsford, 2008).  As a consequence, incomplete and 
incorrectly reported information limits comparison and accurate replication.   
 
Practical Application of WBV 
Independent of the quantification method of WBV and the subsequent effects found within 
the literature, WBV has been sparsely recommended for most population sub groups (table 
2.10).  That is, no strong evidence based statement exist to advocate the use of WBV as an 
exercise mode.  Whole-body vibration studies incorporating healthy children, healthy young 
adults, healthy young athletes, community dwelling older adults, institutionalised older adults 
and samples of adults recovering from illness, or injury and coping with disease have been 
published mostly without useful and specific practical application of WBV.  Table 2.10 list 
the only published recommendations of WBV as a mode of exercise. 
 
The studies listed in table 2.10 were selected to represent some detailed information as to the 
practical application of WBV.  Such information may be used by the clinician, coach, 
personal trainer, and individual.  Those studies, however, comprised a small proportion of the 
total WBV literature base.  More research is required with the aim to: (1) identify and 
describe physiological mechanisms that elicit performance improvement after WBV, (2) 
identify appropriate vibration platform descriptors and WBV protocols to elicit performance 
improvement, and (3) increase participant numbers and extend WBV interventions to examine 
long-term effects.  Despite the recognised directions for future research, the capacity to 







Recommendations and practical applications of WBV as a mode of physical activity for 
various population sub-groups 
Cohort Condition Authors Year Recommendations of WBV 
Child athletes Mahieu et al. 2006 strength training tool 
Young athletes Issurin & 
Tenenbaum 
 





identify “hidden reserves” (p. 181) 
 
 
improve lower limb muscular power 
Young adults Cormie et al.      
van den Tillaar         
 
Rønnestad 
Da Silva et al. 
 
 
Da Silva et al. 
Garatachea et al. 
 












warm up tool 
 
 




to stimulate weight loss 
 
 
prevent delayed onset of muscle 




Russo et al. 
Roelants et al. 
 
Verschueren et al.  






prevention of bone and muscle 
strength loss  
 
enhance balance ability 
Institutionalised 
older adults 
Bautmans et al. 2005 improve balance and mobility 
Those recovering 
from injury or 
illness or living 
with chronic 
disease 
van Nes et al. 
 
 
Turbanski et al. 
 
 
Ahlborg et al. 
 
 











proprioceptive control in stroke 
patients  
 
part of an intervention for Parkinson’s 
disease 
 
increase gross motor performance in 
adults with cerebral palsy  
 
increase neuromuscular performance 







2.2.2 Aetiology of Performance Improvement after WBV 
Recent systematic reviews concluded that WBV activated the stretch reflex due to muscle 
spindle excitation (Norlund & Thorstensson, 2007) and may trigger hormone responses such 
as testosterone and growth hormone (Rehn, Lidström, Skoglund & Lindström, 2007).  Whole-
body vibration has also been shown to effect other mechanisms of the autonomic nervous 
system in single intervention studies.  Various intensities of WBV increased peripheral 
circulation of the lower limbs when measured with Doppler ultrasound among healthy young 
adults (Kerschan-Schindl, Grampp, Henk, Resch, Preisinger, Fialka-Moser et al., 2001; 
Lythgo, Eser, de Groot & Galea, 2009).   
 
Mechanistic explanations are hypothesised to lie in theoretical perspectives such as the 
Hoffmann-reflex (H-reflex) and stochastic resonance (SR).  Interestingly, because many 
WBV interventions in the sport science field were aimed at affecting skeletal muscle, a 
neuromuscular explanation was sought in an attempt to identify the physiological mechanisms 
underpinning WBV.  Neuromuscular activity, for example, has been determined indirectly by 
surface electromyography (EMG).  Specifically, EMG results indicated enhanced motor unit 
recruitment associated with improvement in neuromuscular performance (Rittweger, 
Mutschelknauss & Felsenberg, 2003).  As such, it was postulated that the stretch reflex was 
activated to elicit improvement during WBV (Rittweger, Mutschelknauss & Felsenberg, 
2003).   
 
Motoneuron excitability may also be quantified in an effort to describe WBV effects, yet 
investigations of a neurophysiologic nature remain incomplete.  In attempts to quantify effects 




(TMS) (Mileva, Botwell & Kossev, 2009), resistance training, and direct measurement of 
neuromuscular activity with intramuscular electrodes (Kidgell, Sale & Semmler, 2006) and 
stimulation of the H-reflex (Hamada, Sale, MacDougall & Tarnopolsky, 2000; Palmieri, 
Hoffman & Ingersoll, 2002; Hoffman, Palmieri & Ingersoll, 2003). 
 
Transcranial magnetic stimulation of the motor cortex activated spinal motoneurons of the 
lower limbs (Brouwer & Ashby, 1992; Chen, Tam, Bütefisch, Corwell, Ziemann, Rothwell et 
al., 1998).  Such a method provided access to descriptions of motor-evoked potentials in 
healthy men after WBV (Mileva, Botwell & Kossev, 2009).  During a bout of WBV, a static 
squat posture increased tibialis anterior muscle activity above static squatting alone, 
suggesting that WBV increased motoneuron excitability for that sample of healthy men.  
Whole-body vibration however, did not potentiate the stretch reflex of healthy young adults 
(Hopkins, Fredericks, Guyon, Parker, Gage, Feland et al., 2009).  The stretch reflex is a 
somatic spinal reflex and is an involuntary action because the higher centre is located in the 
grey matter of the spinal cord (Jenkins, Kemnitz & Tortora, 2007; Tortoda & Derrickson, 
2009).  As such, for healthy young adults, WBV may have activated the stretch reflex during 
WBV (due to increased motoneuron excitability observed with TMS), but it did not potentiate 
the reflex once a WBV bout was completed (Hopkins et al., 2009).   
 
Current knowledge of the physiological mechanisms affected by WBV remains imperfect.  
Therefore, it was necessary to further explore the major theories of WBV mechanistic 
responses from a broader area.  The following sections described the: (1) motor cortex, (2) 





The Motor Cortex 
The motor cortex, a component of the cerebral cortex of the brain, is responsible for 
perceiving and interpreting sensory information, making conscious decisions and controlling 
voluntary movements (Latash, 1998).  Standing in a squat position, for example, requires 
voluntary movement, affected by gamma (γ) -motoneurons (figure 2.8).  The γ-motoneurons 




Figure 2.8. The motor cortex showing how γ-motoneurons regulate sensitivity of a muscle 
spindle (modified from Latash, 1998, p. 84). 
 
The process of such voluntary activity depends on γ activity (Latash, 1998).  As such, an 
increase in γ activity represents a lengthening of muscle.  Such activity may then lead to α-






The Stretch Reflex 
Maintenance of body posture is dependent on the ability of skeletal muscle to maintain 
muscle tone.  Skeletal muscles maintain a slightly toned state in preparation for quick 
contraction required to attenuate changes in body position (Luttgens & Hamilton, 1997). 
When skeletal muscles experience a brief, unexpected increase in length, the reflex response 
is to shorten the muscle to avoid adverse events including injury or unstable body posture.  
For example, when the patella tendon is tapped with a patella reflex hammer, a seemingly 
instant and involuntary contraction of the quadriceps muscle group occurs resulting in knee 
extension.  
 
The process of initial stimulation to reaction is theorised to occur in less than 40 milliseconds 
(Abernethy, Kippers, Mackinnon, Neal & Hanrahan, 1996; Martini, 1998).   As such, the role 
of the stretch reflex is to detect and respond to changes in skeletal muscle length (Luttgens & 
Hamilton, 1997).  The usual response is a concentric contraction of the stretched muscle.  As 
such, both sensory and motor mechanisms must react within the stretch reflex (figure 2.9).   
 





Skeletal muscle comprises both intrafusal and extrafusal fibres.  Intrafusal fibres of the stretch 
reflex have a sensory function, whilst extrafusal fibres are responsible for muscular 
contraction (Punkt, 2002; Martini, 2006).  Of intrafusal fibres, muscle spindles convert 
changes in muscle length and tension to nerve impulses that enter the spinal cord (Hamill & 
Knutzen, 1995).   
 
Muscle spindle afferent neurons, Type Ia or Type II, synapse in the dorsal root of the spinal 
cord with an interneuron.  At the spinal cord, the afferent α-motoneuron synapses with the 
interneuron resulting in stimulation of a motor unit (Shumway-Cook & Woollacott, 2001; 
Enoka, 2002; McBride, Porcari & Scheunke, 2004; Jordan, Norris, Smith & Herzog, 2005).  
The fibres also play an inhibitory role because they stimulate the antagonist muscle to relax, 
thus allowing the agonist to be the prime mover (Shumway-Cook & Woollacott, 2001); a 
function known as reciprocal inhibition (Marieb, 1995). 
 
Thus, γ-motoneurons regulate sensitivity of the muscle spindles for afferent α-motoneurons 
during voluntary movement (Felton & Józefowicz, 2004).  Subsequently, α-motoneurons 
regulate contraction of skeletal muscle to produce movement if the muscle spindle is 





Figure 2.10. The motor cortex and spinal region for γ-motoneuron and α-motoneurons activity 
(modified from Latash, 1998, p. 84).  The γ-motoneurons regulate sensitivity of the muscle 
spindles.  The α-motoneurons regulate contraction of skeletal muscle. 
 
 
As shown in figure 2.10, both γ- and α-motoneurons may be activated during a voluntary 
isometric contraction if some stimulus lengthens the muscle.  Researchers concluded that 
WBV was such a stimulus (Norlund & Thorstensson, 2007).  Direct measurement of motor 
unit activity however, has only recently been established with WBV using TMS (Mileva, 
Botwell & Kossev, 2009).  That result is in contrast to previous research reporting that the 
TMS did not stimulate muscle spindle activity (Armstrong, Nestle, Grinnell, Cole, Van 
Gilder, Warren et al., 2008).       
 
The effect of WBV on physiological mechanisms of the stretch reflex requires further 
research to advance the understanding of the effect of WBV.  If adding WBV during an 
isometric squat activates muscle spindles and, for example, Type Ia afferent neurons, then 
 




what is the role of the antagonist muscles, the hamstrings?  Within the context of reciprocal 
inhibition, should EMG activity of the antagonist be affected by WBV?  More research is 
required.  Are both the agonist and antagonist simultaneously activated to the same extent 
during WBV?  If so, then is reciprocal inhibition constrained?  Speculation about 
physiological mechanisms of WBV may have led to statements such as the following: WBV 
can be used to identify the “hidden reserves” of an athlete to allow performance improvement 
(Issurin & Tenenbaum, 1999, p. 181). 
 
The Tonic Vibration Reflex 
The neural response to vibration of high frequency and low amplitude applied directly to 
muscle is the activation of the tonic vibration reflex (TVR) (Griffin, 1994; Latash, 1998).  The 
TVR indicates increased muscular activity through a large number of motor units, compared 
with voluntary contraction (Latash, 1998).  The TVR was activated with 30 Hz vibration 
frequency (Seidel, 1988), though it was suggested about 100 Hz was required (Latash, 1998).  
Later EMG activation was significantly enhanced after 30 Hz vibration of the biceps brachii, 
yet the authors did not confirm that the TVR was the attributing factor (Bosco, Cardinale & 
Tsarpela, 1999). 
 
The neural pathway of the TVR resembles that of the stretch reflex. Since the TVR refers only 
to vibration applied to the muscle belly or tendon, by definition, it cannot be a contributing 
factor of WBV effects.  Possibly for that reason, the stretch reflex was used to describe WBV 






The Hoffmann Reflex 
The Hoffmann reflex (H-reflex) can be quantified in EMG waves, usually of the triceps surae 
(Griffin, 1994; Latash, 1998). The H-reflex is analogous with the stretch reflex, yet is 
activated by electrical stimulation of, for example, the posterior tibial nerve (Latash, 1998, 
Scaglioni, Narici, Maffiuletti, Pensini & Martin, 2003; Voerman, Gregorič & Hermens, 
2005).  Therefore, activation of the H-reflex bypasses the muscle spindle (Armstrong et al., 
2008).  
 
The H-reflex may be a contributor to WBV effects since it represents motoneuron excitability 
(Hamada et al., 2000; Palmieri, Hoffman & Ingersoll, 2002; Hoffman, Palmieri & Ingersoll, 
2003).  Recently WBV was shown to affected the H-reflex (Armstrong et al., 2008).  Links of 
WBV to the H-reflex should be expected because, as previously mentioned, TMS elicited 
greater activity of tibialis anterior during WBV (Mileva, Botwell & Kossev, 2009).  However, 
because the H-reflex is electrically stimulated rather that mechanically stimulated (i.e., 
WBV), the role of the H-reflex and WBV remains unclear.  Furthermore, the general 
mechanistic effect of WBV on the human body remains speculative although exposure to 
WBV is linked to greater muscular activity (Cardinale & Lim, 2003; Abercromby et al., 
2007a).  Intuitively, three reflexes, that share a similar neural pathway, may be activated 
during WBV.  However, only the H-reflex has been directly quantified, despite not activating 








Stochastic Resonance  
Another theoretical perspective of vibration effects is stochastic resonance (SR).  While 
barely discussed in WBV literature, SR may be causal to WBV effects.  Theoretically, it is a 
“phenomenon whereby a nonlinear system can detect an otherwise undetectable stimulus with 
the addition of a random stimulus to the input” (Fallon & Morgan, 2005, p. 928).  The 
‘nonlinear system’ in this case is the human body and the ‘random stimulus’ is the WBV.  
 
It was thought that ‘noise’ could interfere with the ability to process relevant information 
about a signal (Ward, Doesburg, Kitajo, MacLean & Roggeveen, 2006).  However, if the 
noise generated a resonance in tune with the nonlinear system, then SR would elicit for 
example, an osteogenic response to low-amplitude broad frequency (0 to 50 Hz) vibration 
(Tanaka, Alam & Turner, 2003). 
 
Stochastic resonance (SR) therefore, may enhance the human body response to WBV.  
Previous studies had established SR in the sensory system of humans, and only recently SR 
was identified in the motor system as well (Martinez, Pérez, Mirasso & Manjarrez, 2007).  
Interestingly, vibration platform frequency for maximal EMG activity of the vastus lateralis 
during WBV was different for individual young adults (Di Giminiani, Tihanyi, Safar & 
Scrimaglia, 2009).  The frequency range was 20 to 55 Hz.  Despite the absence of mechanistic 
discussion, it is possible that WBV elicited a SR for the vastus lateralis muscle that was 






Musculoskeletal pain after resistance training of healthy young adults reduced after 
‘stochastic resonance whole-body vibration’ (Elfering, Thomann, Schade & Radlinger, 2011).  
A trend towards improved functional performance of the lower limbs among healthy older 
adults was also reported (Rogan, Radlinger, Schmid, Herren, Hilfiker & de Bruin, 2012; 
Roga, Hilfiker, Schmid & Radlinger, 2012) when WBV frequency was set at 5 Hz.  No 
explanations were presented for possible mechanisms of reduced pain or the trend towards 
improved functional performance, nor to the potential that the ‘random stimulus’ that may 
have been too low.   
 
2.2.3 Whole-Body Vibration Guidelines 
Whole-body vibration interventions vary within existing literature.  However, no published 
guidelines for safe and effective WBV exist.  Nevertheless, the absence of guidelines has not 
diminished proliferation of development and use of vibration platforms in community settings 
such as health and fitness clubs. 
 
The benefit of safe and effective WBV guidelines are salient, yet such knowledge remains 
poorly understood from a scientific perspective.  Establishing guidelines may be difficult 
because of a multitude of variables than can be manipulated to affect the intensity/effect of 
WBV upon the body (table 2.11).  Whole-body vibration interventions within the existing 
literature have used multiple manipulations of variables that may be broadly categorised as: 







Components of WBV that can effect dependent variables regardless of population sub-group 
Category Variable Intensity / Effect 
Individual Transmission 
Stance posture: Static and Dynamic 
Additional load 











Gravitational force (g) 
Intervention Time per bout (sec) 
Bouts per session 
Session per week 
Weeks of intervention 




Generally, access to WBV is only possible in health and fitness clubs.  This may be due to 
several reasons, but most probably, that vibration platforms are beyond the financial capacity 
of individuals for home based use.  It may also be that WBV is seen as a gimmick, as a review 
of advertising strategies might suggest.  Regardless, it seems logical that before such time that 
vibration platforms become more readily available to the general community, guidelines for 
safety and effective methods should be established. 
 
The creation of guidelines is a large task, and is envisaged to comprise knowledge of vast 
numbers of variables across many population sub-groups (i.e., table 2.11).  However, the 
scope of this research was to identify a safe and effective method of WBV for people with 






The stance posture adopted during WBV can alter the transmission and location of WBV 
about the body.  Changing body posture (particularly the angle of knee flexion) can alter the 
transmission of WBV through various bony landmarks (Harazin & Grzesik, 1998).  Typically, 
transmission is the ratio of vertical acceleration at the surface of the vibration platform to 
vertical acceleration at a specific landmark of the body.  Wobbling mass refers to all non-rigid 
parts of the body, namely; muscles, soft tissues, fluids, and organs (Yue & Mester, 2002).  
Generally, a transmission value does not discriminate among wobbling mass and rigid bodies 
(Yue & Mester, 2002).  However, the value can usefully quantify the rate of vibration 
attenuation among various landmarks and across populations.  
 
Transmission of WBV in the sitting posture has been thoroughly researched, yet literature 
describing transmission in the standing posture is lacking.  Perhaps another explanation for 
the imperfect knowledge of physiological mechanisms activated by stance alterations during 
WBV may be in part due to lack of knowledge of transmission of WBV through the standing 
body.  The exact degree of transmission remained uncertain following one WBV intervention, 
despite claims the intervention caused high-frequency loading of the skeleton (Verschueren, 
Roelants, Delecluse, Swinnen, Vandershcueren & Boonen, 2004).   
 
Transmission 
The International Organisation for Standardisation devised a vibration exposure threshold 
based upon occupational environments (ISO-2631-1, 1997).  When WBV was in the sitting 
position and about the spine and head, the threshold considered frequency, magnitude, 




Vibration exposure below a value of 17.0 was considered safe.  The ISO recommendation has 
subsequently been used for a WBV intervention and the estimated vibration dose was above 
17.0 (Abercromby, Amonette, Layne, McFalin, Hinman, & Paloski, 2007b).  The healthy 
young adults stood on a vibration platform and were exposed to a gravitational force of 7.24 
g.  
 
The intervention of Abercromby et al. (2007b) violated ISO defined safe daily exposure to 
WBV.  Given that interventions of many studies have used similar and larger gravitational 
forces and durations, it is probable that the ISO recommendation has been ignored or 
unknown.  Conversely, the safety of long-term WBV interventions above an estimated 
vibration dose value of 17.0 can also be questioned because occupational vibration was shown 
to negatively affect normal bodily functions in healthy adults (Ishitake et al., 1998; Ishitake, et 
al., 2002).  Abercromby et al. (2007b) suggested that since participants in their study stood 
with knee flexion between 10 and 35º, transmission attenuation occurred and thus, the posture 
may have reduced deleterious effects of WBV about the spine and head.       
 
Other computation methods have been used to determine a transmission value.  The ‘cross-
spectral density function method’ (Paddan & Griffin, 1993), the ‘transmission factor’ (Mester, 
Spitzenfell, Schwarzer & Seifriz, 1999), and the ‘transmissibility transfer function’ (Rubin, 
Pope, Fritton, Magnusson, Hansson & McLeod, 2003).  Independent of the computation 
method used, the collective data demonstrate differences among the use of vibration platform 






Few studies have described transmission of WBV when the participant stood on a vibration 
platform.  Transmission of synchronous WBV was described after participants stood with 45 
and 70º knee flexion (Harazin & Grzesik, 1998).  Another design incorporated participants 
standing with the knees bent so that they were vertically aligned to the toes (Matsumoto & 
Griffin, 1998).  It should be noted that Matsumoto and Griffin (1998) did not measure 
proximal nor distal limb lengths to screen for difference among participants.  At 
approximately 20 Hz, both studies reported vertical transmissibility (VT) about the knee of ~ 
1.0 for each stance postures.  Essentially, the vertical acceleration of the vibration platform 
was the same as the vertical acceleration about the knee.   
 
The results of those two studies can lead to some practical considerations.  First, WBV with 
an intensity of approximately 20 Hz, independent of stance posture, was not attenuated before 
the knee.  The magnitude of the vibration therefore, must be attenuated at some other 
locations above the knee.  Second, because peak-to-peak displacement was different among 
the two studies (Harazin & Grzesik = 1.40 mm; Matsumoto & Griffin = 0.45 mm), the 
resultant acceleration of the vibration platform would have been 11.05 m.s
-2
 (1.13 g) 
compared with 3.55 m.s
-2
 (0.36 g).  Thus, despite the large differences in magnitude, 
transmission of WBV was not affected. 
 
At 31.5 Hz however, VT was larger when participants increased knee flexion to 45º (Harazin 
& Grzesik, 1998).  The VT was < 1.0 at that frequency.  Subsequently, vertical acceleration 
was attenuated about the knee.  Furthermore, VT about the knee was greater as flexion 
increased.  At that frequency however, the peak-to-peak displacement of the vibration 
platform was 0.40 mm.  Thus, vertical acceleration was estimated to be 7.83 m.s
-2




It is difficult to draw conclusions from existing literature due to the inconsistent methods 
within the Harazin and Grzesik (1998) study and among studies.  Furthermore, the validity of 
the vibration platforms was not reported.  It seems that vibration platform frequency above 20 
Hz attenuates VT about the knee.  It is possible that a subsequent increase in vertical 
acceleration would explain such an occurrence, yet at 31.5 Hz, vertical acceleration was less 
than at 20 Hz due to the different peak-to-peak displacements among the studies.    
 
A negative VT value represents a higher vertical transmission about a body location than at 
the surface of the vibration platform.  Such occurrences have not been reported suggesting 
that attenuation of WBV occurred throughout the body.  It was reported that the attenuation of 
WBV can partially be understood by observations of wobbling mass and rigid bodies (Yue & 
Mester, 2002).  Researchers have used varying mathematical models to describe impact forces 
on wobbling mass (Gruber, Ruder, Denoth & Schneider, 1998; Yue, Kleinöder & Mester, 
2001; Gittoes, Brewin & Kerwin, 2006).  However, to date, mathematical modelling has not 
been applied to WBV. 
 
Transmission of WBV in the standing posture has been measured directly (Rubin, et al., 
2003).  Pins with accelerometers were surgically inserted in the spinous process of L4 and the 
greater trochanter of the left femur of six participants.  The method was time consuming and 
invasive and limited by a possibly understandable low number of participants.  Nevertheless, 
transmission of WBV to the spine and hip was greatly attenuated below the hip when the 





Less invasive estimates of transmission research also exist in the WBV literature.  Three 
studies indirectly identified transmission of WBV with accelerometers at the knee in the 
frequency range of 20 to 30 Hz.  Two studies incorporated synchronous WBV (Harazin & 
Grzesnik, 1998; Kiiski et al., 2008) while another incorporated side alternating WBV 
(Crewther, Cronin & Keogh, 2004).  Comparison of attenuation with the Rubin et al. (2003) 
study was lacking, though the bone insertion method was thought to be the most accurate 
method of transmission quantification (Kiiski et al., 2008). 
 
Of published work, one study examined gravitational forces of synchronous WBV when 
participants stood in 60º knee flexion and 3-5º knee flexion at 20 and 30 Hz (Crewther, 
Cronin & Keogh, 2004).  Given that a transmission value was not computed, interpretation of 
the results was limited.  While gravitational force about the knees was 3.91 g, it was not 
possible to determine the vibration platform frequency, peak-to-peak displacement and 
subsequent gravitational force.  Furthermore, the stance posture adopted by the healthy young 
adults was not reported.  Therefore, it is difficult to comment further on the findings of that 
paper, or compare side alternating WBV with synchronous WBV, suffice to suggest that 
further research is required to gain knowledge about transmission with side alternating WBV.  
 
Stance Posture 
Stance posture can be sub-classed as static and dynamic.  For example, a static stance posture 
occurs when an individual stands with the knees fixed at 70º knee flexion during WBV.  An 
example of dynamic posture occurs when an individual bends the knees through a specified 
range of motion during WBV resulting in the knee both flexing and extending.  The major 




static stance posture demands an isometric contraction of skeletal muscle, while the dynamic 
stance posture demands isotonic skeletal muscle contractions; both eccentric and concentric 
contraction of the flexors and extensors.   
 
Without WBV, the EMG activity of the vastus lateralis during unloaded squatting was 
observed to increase between 21 and 63% of maximal voluntary contraction (MVC) (Isear, 
Erickson & Worrell, 1997).  Both isometric and isokinetic (concentric/eccentric) resistance 
training affected performance of a self-paced 40-step stair climbing speed to the same degree 
in 30 older adults (mean age = 73 years) (Symons, Vandervoort, Rice, Overend & Marsh, 
2005).  Regarding repetition maximum (RM), 10 RM training on a dynamometer was 
effective independent of skeletal muscle contraction type (Symons et al., 2005) even though 
dynamic stance demanded more oxygen than static stance (Rittweger, Schiessl & Felsenberg, 
2001).  Whole-body vibration should not be compared with RM training due to the 
fundamental differences of the two exercise modes, yet interestingly, an isometric squat (55º 
knee flexion) during WBV increased EMG activity of vastus lateralis from between 53.0 and 
58.8% of MVC in healthy young adults (Roelants, Verschueren, Delecluse, Levin & Stijnen, 
2006).  Higher EMG activity of the vastus lateralis was also observed during static stance 
with WBV compared with non-WBV (Cardinale & Lim, 2003) although MVC data were not 
recorded.  Though EMG activity of the lower limbs increases with WBV, a paucity of 
publications limits conclusions, practical applications, and external validity. 
 
Accordingly, eight weeks of static and dynamic squats during WBV (maximal gravitational 
force = 10.88 g) did not improve the knee flexor and extensor strength of older adults (Rees, 
Murphy & Watsford, 2008).  No significant improvement was found in ankle dorsiflexor 




activity during static and dynamic squatting (Abercromby et al., 2007a).  Increased EMG 
activity of the lower limbs had been attributed to muscle length and/or vibration platform 
frequency in earlier research (Cardinale & Lim, 2003).  Later though, muscle length (i.e., 
stance posture) and vibration platform frequency failed to alter maximal knee joint extension 
moments (Savelberg, Keizer, & Meijer, 2007).     
 
Additional loads have been used to theoretically increase the intensity of WBV via dynamic 
stance posture although results varied among studies.  Additional load of between 35 and 40% 
of body weight placed about the hips of healthy young adults elicited greater oxygen uptake 
during WBV (Rittweger, Schiessl & Felsenberg, 2001).  Yet functionally, additional load of 6 
to 10 RM during WBV did not improve the counter movement jump among a similar sample 
population (Rønnestad, 2004). 
 
Essentially, dependent variables of WBV can be affected by the individual via manipulating 
the stance posture and the load placed on the individual.  Such manipulation will change the 
transmission of WBV through the body, with the theory that attenuation of WBV occurs with 
the knees flexed to 20º.  Such attenuation was thought to involve muscular activity measured 
by EMG, yet in both WBV and non-WBV conditions, muscle contraction type did not affect 
strength, even though EMG activity and oxygen uptake increased.  Despite a recent increase 
in the volume of WBV literature, the effects of WBV on functional performance remains 
limited to counter movement jump performance and maximal strength after WBV.  As such, 
the effects of WBV with static and dynamic stance postures on functional performance of 






Vibration Platform Frequency (Hertz) 
Vibration platform frequency can be manipulated in a WBV intervention with many methods: 
(1) the frequency (Hz) is increased as the intervention progresses, (2) the frequency (Hz) is 
maintained at the same frequency for the duration of the intervention, (3) the frequency (Hz) 
is reduced as the intervention progresses, (4) the frequency (Hz) is both increased and 
decreased across the duration of the intervention, and (5) the frequency (Hz) is randomly 
assigned for each WBV session/bout across the duration of the intervention. 
 
Methods one and two were most common in the literature.  Typically, vibration platform 
frequency increased from 15 Hz to 40 Hz across the duration of interventions for healthy 
young and old adults (Torvinen et al., 2002; Roelants et al., 2004; Rietschel et al., 2008; Roth, 
Wust, Rawer, Schnabel, Armbrecht, Beller et al., 2008; Furness & Maschette 2009).  
Vibration platform frequency range was also similar, but inconsistent across studies that 
maintained frequency for healthy sample groups (Lamont, Cramer, Bemben, Shehab, 
Anderson & Bemben, 2008; Edge, Műndel, Weir & Cochrane, 2009; Jacobs & Burns, 2009; 
Stewart, Cochrane & Morton, 2009). 
 
Evidence was equivocal for methods one and two, and may explain why WBV guidelines 
remain unknown.  Reporting a justification of each method used would assit future research.  
It seems the ‘overload principle’ was used in WBV interventions.  Such theory however, has 
never been justified with previous WBV literature.  Progressive overload theory seems logical 
since the perceived general consensuses is that lower increasing to higher frequency will 




Precision identifying ‘lower’ and ‘higher’ vibration platform frequency however, remains 
equivocal. 
  
The potential effects of methods three (the frequency is reduced as the intervention 
progresses), four (the frequency is both increased and decreased across the duration of the 
intervention), and five (the frequency is randomly assigned for each WBV session/bout across 
the duration of the intervention) have not been investigated.  It seems an oversight within the 
literature that all methods to manipulate vibration platform frequency have not been 
investigated.  While such an investigation is necessary and should be conducted in the future, 
it was beyond the scope of this research for several reasons: (1) limited availability of 
resources, (2) availability of participants, and their health status, and (3) it is difficult to 
justify such research because limited knowledge of people with COPD and WBV persists.       
 
Recently, optimal vibration platform frequency was determined in a healthy sample group for 
peak counter movement jump height.  Estimated peak power was higher when the vibration 
platform was operating at 50 Hz in conjunction with 6.0 mm peak-to-peak displacement 
(Adams, Edwards, Serviette, Bedient, Huntsman, Jacobs et al., 2009).  Gravitation force at 
those platform dynamics would have been 30.18 g.  However, vibration platform frequency of 
30 Hz in conjunction with 4.0 mm peak-to-peak displacement was as effective for estimated 
peak power (Adams et al., 2009).  Gravitation force at those platform dynamics would have 






It may be that vibration platform frequency of 30 Hz was large enough to elicit physiological 
mechanisms, independent of peak-to-peak displacement.  It should be noted that the methods 
of the study (Adams et al., 2009) were not adequately reported to allow reproduction.  For 
example, the rest interval among each WBV bout was not disclosed.  Also, a residual WBV 
effect cannot be discounted.  In previous work, at least 24 hours was used to ensure adequate 
washout (Cochrane, Legg & Hooker, 2004; Furness & Maschette, 2009).  Also, for the 30.18 
g protocol, estimated peak power increased from 3225.6 W to 3245.6 W, an increase of 20 W 
(0.62%).  The practical benefits of such improvement may have been more valid if, for 
example, jump height was reported.  Therefore, the clinical significance and subsequent 
external validity of the study could be questioned. 
 
Peak-to-Peak Displacement (mm) 
Accurate reporting of peak-to-peak displacement is difficult because it has not always 
precisely described.  Part of the confusion is due to inconsistent nomenclature (Lorenzen, 
Maschette, Koh & Wilson, 2009).  Nouns such as amplitude and peak-to-peak displacement 
have been used interchangeably, yet true definition differs.  Given that the vibration platform 
amplitude is used to calculate gravitational force, inaccurate reporting of amplitude affects 
interpretation.   
 
Both peak-to-peak displacement and amplitude were used to describe the same value (5.0 
mm) (Delecluse, Roelants & Verschueren, 2003).  It is impossible to determine what the 5.0 
mm value represented.  However, the corresponding gravitational force was either 16.10 g or 
32.19 g when vibration platform frequency was 40 Hz.  In contrast, the measured motion of 




to 5.09 g.  It should be noted that the concurrent validity of the accelerometer was not 
reported, nor the method used to incorporate the accelerometer and the vibration platform.  
Hence, precision in reporting forces can be confusing. 
 
It seems that study designs to specifically determine the effect of vibration platform peak-to-
peak displacement are lacking.  As such, researchers have been designing studies omitting 
justification of the peak-to-peak displacement (Lorenzen, Maschette, Koh & Wilson, 2009).  
In context with vibration platform frequency, more research is required to further understand 
WBV effects.   
 
Research designs may be limited by the specifications of the type of vibration platform used.  
Typically, peak-to-peak displacement can be changed by two means.  A button can be pressed 
for synchronous vibration platforms that changes the mechanisms within the vibration 
platform.  Of side alternating vibration platforms, changing the stance width will change the 
peak-to-peak displacement.  A prototype side alternating vibration platform has been designed 
so that peak-to-peak displacement could be manipulated without changing stance width 
(Furness & Maschette, 2009; Maschette, Lorenzen & Furness, 2009) (Appendix N).      
 
Stance Width  
Few studies have examined EMG activity of the lower limbs during different stance widths in 
healthy adults.  Without WBV, electrical activity of the lower limbs was between 12 and 64% 
larger with narrow (10 cm) than wide (32 cm) heel stance (Henry, Fung & Horak, 2000).  As 
such, greater leg muscle activity occurred during the narrow heel stance and may be partly 




Where EMG activity increased during WBV compared with non-WBV conditions 
(Abercromby et al., 2007a; Hazell, Jakobi & Kenno, 2007; Roelants et al., 2006) stance width 
was manipulated with the aim to describe effects of peak-to-peak displacement, not EMG.  As 
such, the effect of stance width and WBV on EMG of the lower limbs remains unknown.  
Knowledge of stance is important because WBV may potentially be more effective at eliciting 
electrical activity of the lower limbs when the heels are 10 cm apart rather than for example, 
21 cm (Abercromby et al., 2007a).  Furthermore, manipulating stance width may introduce 
extraneous variables such as muscular co-activation or different motor unit recruitment 
patterns therefore, potentially changing a training effect of WBV. 
 
Vibration Direction 
Direction of WBV can effect practical considerations.  The only group of researchers to 
compare WBV direction, reported that side alternating and synchronous WBV affect EMG 
activity of the lower limbs differently (Abercromby et al., 2007a).  Furthermore, synchronous 
WBV was potentially more harmful because acceleration about the head was significantly 
greater, mindful of ISO guidelines (Abercromby et al., 2007b).  That is, the transmission of 
WBV to the head was greater with synchronous WBV.  It should be noted that the 
participants of those investigations were very fit young adults (n = 16 astronauts).  More 
research is needed with synchronous and side alternating vibration platforms, with particular 









The variation of past WBV intervention protocols persists in relatively recently published 
studies.  Single bouts of WBV ranged from 30 seconds (Rhea & Kenn, 2009), to six minutes 
(Jacobs & Burns, 2009).  Those investigations were designed to view acute effects of WBV.  
Typically, data collected immediately after, or within 30 minutes of a WBV bout/session were 
considered acute (Cardianle & Lim, 2003; Humphries, Warman, Purton, Doyle & Dugan, 
2004).     
 
Interventions designed to collect long-term WBV data have also varied.  Long-term data are 
recorded after a series of WBV sessions over an extended period (Luo, McNamara & Moran, 
2005).  As such, interventions have varied in length from five weeks to one year (Rønnestad, 
2004; Bogaerts et al., 2007; Lamont et al., 2008; Di Giminiani et al., 2009).  Such variance in 
intervention design does not allow a dose response explanation since outcome variables and 
study designs differ too greatly to draw meaningful conclusions. 
 
For studies examining the long-term effects of WBV, another consideration for data are the 
acute/residual effects of WBV.  A minimum 24 hour rest period was thought prudent to 
overcome residual effects of WBV (Roelants, Delecluse & Verschueren, 2004).  Data 
collected before that time are considered acute.  Recently, data were collected at least 48 
hours after WBV to ensure long-term data responses were profiled (Cochrane, Legg & 






Table 2.12 shows some of the most cited papers of WBV and the methods of each (cited 144 
to 300 times).  Table 2.13 shows subsequent publications.  It seems that WBV interventions 
rarely coincide on time per bout, bouts per session, sessions per week, weeks of intervention, 
and rest intervals. 
 
The range of participant number, age, maximal gravitational force, and maximum exposure 
are shown in table 2.14.  Selected data were of commonly referenced and subsequent 
published WBV interventions (i.e., table 2.12 and table 2.13).  Age range falls into the ‘young 
adulthood’ category (Gallahue & Ozmun, 2006).  There is a large range of both maximum 
gravitational force and maximum WBV exposure time.  Such range may highlight the lack of 





Commonly referenced published studies of WBV  







Protocol Dependent variables 
  Age n Female      
Bosco et al., 
(2000) 




100º knee flexion 
EMG of lower limbs 
and CMJ 
10 bouts in 1 
session 
 
         
Cardinale & 
Lim (2003) 
3 bouts in 1 
session 
 




100º knee flexion 






no 21.8 – 24.4 
years 
19 52.6% side 
alternating 
16.32 g unknown Dynamic squats 





Torvinen et al., 
(2003) 
~ 2.8 sessions 
per week over 
8 months 
yes 19 – 38 
years 




Note: unknown: information regarding was not disclosed. RCT: randomised controlled trial. EMG: electromyography. CMJ: counter movement 
jump. RPE: Borg’s rating of perceived exertion. DEXA: dual-emission X-ray absorptiometry. pQCT: peripheral quantitative computed 







Examples of published studies of WBV    





Protocol Dependent variables 
  Age n Female      








et al., (2009) 
240 bouts over 
8 weeks 
 











no 28.6 years 20 50% side 
alternating 
unknown 6 minutes Isometric stance 




Knee torque  




yes 20 – 30 years 36 0% synchronous 30.18 g 30 sec, 60 
sec rest 
unknown Jumping performance 
Rhea et al., 
(2009) 
1 bout 
no 22.6 years 16 0% unknown 9.86 g 30 sec Dynamic squat Power 





Range of various variables for WBV interventions (tables 2.12 and 2.13)  
Range 
n Age Gravitational force WBV Duration 
14 - 56 19 - 39 8.12 – 50.33 g 30 sec – 6 min 
 
 
2.2.4 Whole-Body Vibration for Sub-Optimal Health Populations and Functional 
Performance 
A sub-optimal health population, for the purpose of this research, is defined as any sample 
population with pathology.  Older age is not considered sub-optimal, but for example, women 
with low bone mineral density or individuals of residential aged care (i.e., non-community 
dwelling) are considered as sub-optimal health sample groups.  The volume of published 
literature of WBV as an exercise/rehabilitation intervention for sub-optimal health 
populations is small.  The dearth is obvious when searching for papers of COPD and WBV, 
since only one published paper could be found.  Possible explanations for the limited research 
include availability of equipment and knowledgeable/skilled staff, inconsistent finding in the 
body of WBV literature for perceived safe and effective protocols, and the absence of WBV 
guidelines for both acute and long-term effects.  
 
The earliest intervention of WBV and a sub-optimal health sample was of chronic lower back 
pain (Rittweger, Just, Kautzsch, Reeg & Felsenberg, 2002).  A more recent intervention used 
WBV as rehabilitation for Parkinson’s disease (Ebersbach, Edler, Kaufhold & Wissel, 2008).  
All other published interventions of WBV and sub-optimal health samples are listed in table 




osteogenesis imperfecta in which WBV was delivered in an inclined position (i.e., the body 
was not perpendicular to the vibration platform) (Semler, Fricke, Vezyroglou, Stark, Stabrey 
& Schoenau, 2008), and a study of stroke patients who received WBV while balancing their 
body weight over one limb (Tihanyi, Horváth, Fazekas, Hortobágyi & Tihanyi, 2007) were 
excluded because the research directions were beyond the scope of this research.   
 
Since 2009 and inclusive of January 2012, an additional 25 papers were published on WBV 
and sub-optimal health sample populations, highlighting the increased trend of WBV research 
of clinical populations.  The majority of papers were of people with spinal cord injury (Ness 
& Field-Fote, 2009; Davis, Sanborn, Nichols, Bazett-Jones & Dugan, 2010; Sayenko, Masani, 
Alizadeh-Meghrazi, Popovic & Craven, 2010; Herrero, Menéndez, Gil, Martín, Martín  
García-López et al., 2011), multiple sclerosis (Schyns, Paul, Finlay, Ferguson & Noble, 2009; 
Broekmans, Roelants, Alders, Feys, Herbert & Eijnde, 2010; Wunderer, Schabrun & 
Chipchase, 2010) and fibromyalgia (Alentorn-Geli, Moras, Padilla, Fernández-Solà, Bennett, 
Lázaro-Haro et al., 2008; Sañudo, de Hoyo, Carrascol, McVeigh, Corral, Cabeza et al., 2010; 
















All published research of WBV and sub-optimal health populations 
Cohort Condition Authors  Year 
Cerebral palsy Ahlborg et al. 
 
2006 
Cystic fibrosis Rietschel et al. 











Schuhfried et al. 









Bruyere et al. 
 
2005 




van Nes et al. 





Women with low 
bone mineral 
density 










Of all literature, adverse or negative effects of WBV are rarely reported.  Crevenna, Fialka-
Moser, Rödler, Keilani, Zöch, Nuhr et al. (2003) considered WBV performed to ‘subjective 
exhaustion’ safe for heart transplant recipients as soon as six months post surgery.  The 
average WBV exposure time was 248 consecutive seconds (4.08 g), while heart rates rose 
from 98 beats.min
-1
 at baseline, to 121 beats.min
-1






One paper, published in 2012, was designed to investigate WBV for people with COPD as a 
mode of exercise to improve muscular strength, muscular power and functional performance 
of the lower limbs.  In conjunction with traditional pulmonary rehabilitation, dynamic squats 
during WBV elicited a “striking” improvement in functional performance quantified with the 
six-minute walk test compared with traditional rehabilitation and dynamic squats without 
WBV (Gloeckl et al., 2012, p 78).  The three week intervention caused six of 42 participants 
(14%) to drop out of the WBV intervention due to acute exacerbations of COPD (n = 5) and 
acute gonarthrosis (n = 1).  Interestingly, WBV was proposed to beneficially affect 
gonarthrosis (Stein, Knoell, Faymonville, Kaulhausen, Siewe, Otto et al., 2010), though 
equivocal evidence of WBV for bone health persisted (Wysocki, Butler, Shamliyan & Kane, 
2011). 
 
Maintenance of ADLs was essential for people with COPD (GOLD, 2011).  Effects of WBV 
on ADLs and functional performance however, remained unknown since the intervention was 
not completed independent to other modes of pulmonary rehabilitation (Gloeckl et al., 2012).  
Furthermore, the effects of a community based WBV intervention on valid and reliable field 
tests of ADLs such as the TUG test and the 5-chair test, or kinematic variables of gait remain 
unknown.   
 
Although the effects of WBV on people with COPD have rarely been investigated, it was 
important to draw reference of previous published work of different sub-optimal health 
populations.  For example, a WBV intervention was well tolerated by participants with cystic 
fibrosis (Roth et al., 2008).  That is, six months of WBV did not cause exacerbations of cystic 
fibrosis, nor as expected, did it alter lung function.  Subsequently, those findings were 




Considering the limited body of literature of WBV and sub-optimal health populations, only 
speculative conclusions could be drawn.  However, given that WBV had not negatively 
altered lung function, it should not be considered a component of pulmonary rehabilitation for 
lung function rehabilitation.  It also seems that WBV is safe because it did not elicit 
exacerbations of pathology, even when exercise is performed to subjective exhaustion for 
heart transplant patients.  It remains unknown however, if a long-term community based 
WBV intervention will cause acute exacerbations in people with COPD or improve/maintain 
exercise tolerance and functional performance of the lower limbs.   
 
2.3 Summary and Significance of this Research Question 
Whole-body vibration is used as a mode of exercise to impact the musculoskeletal, endocrine 
and cardiovascular systems of the human body.  Researchers can choose to use several 
different vibration platform designs to expose participants to WBV.  As a consequence, both 
effective and ineffective results after WBV have been reported.  However, incidences of 
negative effects of WBV have been rarely reported.   
 
Considering the growing WBV literature base, it is an oversight that guidelines for safe and 
effective WBV have not been established, despite increased popularity of vibration platforms 
in the health and fitness industry.  However, it seems that many variables of a WBV 
intervention can be manipulated.  Therefore, comparison among studies and subsequent 
guideline recommendations remains challenging.  Further research is required to thoroughly 





Transmission of WBV through the body for example, needs to be established for different 
vibration platforms, frequencies, peak-to-peak displacements, stance postures and widths, and 
sample groups.  Electrical activity of skeletal muscle of the lower limbs should also be 
examined.  Such information may assist in establishing both acute and long-term WBV 
protocols that primarily affects the wobbling mass of lower limbs rather than, for example, the 
rigid bodies of the spine and head. 
 
Whole-body vibration is becoming increasingly used as an exercise intervention for people 
with sub-optimal health.  Whole-body vibration has to date, limited application as an exercise 
intervention for people with COPD.  As mentioned, further research is required in all sample 
populations.  However, from the existing literature base of sub-optimal health populations, 
WBV rarely caused exacerbations.   
 
A WBV intervention should be associated with safe exercise practices before it can be more 
widely incorporated into the lifestyle regimes of population sub-groups, especially those of 
sub-optimal health.  Encouragingly, WBV did not negatively affect heart transplant recipients 
or people with cystic fibrosis.  Whole-body vibration increased heart rate and oxygen 
consumption but did not affect FEV1 or increase exacerbations.  Current findings can only 
partially justify the use of WBV to improve or maintain exercise tolerance and functional 
performance of the lower limbs of people with COPD.  
 
Despite existing knowledge of WBV, as a standalone mode of exercise, efficacy has not been 
established for improvement or maintenance of exercise tolerance and functional performance 




community based WBV intervention would elicit exacerbations of COPD, such as increased 
dyspnoea or reduced saturation of haemoglobin, or if the WBV intervention will be well 
tolerated and adhered to by community dwelling adults with COPD. 
 
Future research of effects of WBV on exercise tolerance and functional performance of the 
lower limbs should be confirmed with robust research designs such as randomised controlled 
trials of people with COPD.  However, before long-term interventions of effect of WBV on 
exercise tolerance and functional performance of the lower limbs can be conducted, safety 
and efficacy of WBV as a standalone intervention should first be established.  As such, the 
research design of this project was established to first describe safety, and then efficacy of 
WBV for people with COPD.  Since WBV had never been used as a standalone intervention 
in a community setting for people with COPD, this research design incorporated a non-
randomised crossover placebo design to answer the question “Will WBV improve or maintain 
exercise tolerance and functional performance of the lower limbs of people with COPD?”     
 
2.4 Research Hypotheses 
The following research hypotheses were tested to determine and efficacy of WBV on exercise 
tolerance and functional performance of the lower limbs of people with COPD: 
Exercise Tolerance 
HI: For people with COPD, a six week WBV intervention; two sessions per week of 
five 60 second bouts interspersed with 60 seconds passive rest will: (1) acutely 
increase dyspnoea during a WBV bout, (2) not elicit a long-term change of dyspnoea 




and reduce saturation of haemoglobin during a WBV bout, and (4) not elicit a long-
term change of heart rate and saturation of haemoglobin. 
HI: For people with COPD, there will be a difference among a six week WBV 
intervention and a six week PLACEBO intervention (two sessions per week of five 60 
second bouts interspersed with 60 seconds passive rest) for dyspnoea, heart rate and 
saturation of haemoglobin. 
Functional Performance 
HI: For people with COPD, a six week WBV intervention; two sessions per week of 
five 60 second bouts interspersed with 60 seconds passive rest will improve: (1) 
performance of the timed-up-and-go test, (2) performance of the 5-chair stands test, 
and (3) stride time, stride length and stride velocity quantified with a portable 
electronic walkway. 
HI: For people with COPD, a six week WBV intervention will improve functional 
performance compared with a six week PLACEBO intervention (each intervention; 











CHAPTER 3. METHODS 
 
3.1 Overview 
This chapter comprises the selected procedures and protocols relevant to the pilot tests 
targeted for this research.  Following the review of literature, three essential pilot studies were 
conducted to: (1) validate a vibration platform, (2) describe transmission of WBV about the 
knee of healthy young adults, and (3) describe reliability of selected psychological and 
physiological dependent variables of exercise tolerance and functional performance of the 
lower limbs of people with COPD.  The third pilot study (section 3.4) described the shared 
methods of participant selection criteria, selection protocol, instruments and data collection of 
people with COPD used for Chapter 4 and Chapter 5. 
 
Given that effects of WBV on people in a community setting with COPD had never been 
investigated, and in keeping with the ‘first do no harm’ philosophy of research, the first major 
study: safety of WBV for people with COPD was completed and described in Chapter 4.  The 
second major study: to describe efficacy of WBV to improve or maintain exercise tolerance 
and functional performance of the lower limbs of people with COPD was completed and 
described in Chapter 5.  Sample size calculations of major study 2 are described in section 3.5 
of this chapter.  Common statistical procedures of Chapter 4 and Chapter 5 were described in 
the final section of this chapter (section 3.6).  The design of this research is shown in figure 

















Figure 3.1. Overview of the design of this research to describe efficacy of WBV on exercise 








MAJOR STUDY 2 (Chapter 5) 
Efficacy of WBV for people with COPD 
MAJOR STUDY 1 (Chapter 4)  
Safety of WBV for people with COPD 
Efficacy of Whole-Body Vibration on Exercise Tolerance and Functional 
Performance of the Lower Limbs of People with Chronic Obstructive Pulmonary 
Disease 
 
Pilot Testing (Chapter 3) 
 Validity of a vibration platform 
 Transmission of WBV 
 Reliability of dependent variables 




3.2 Pilot Test 1: Validity of a Vibration Platform 
Overview 
This pilot test was completed to validate the frequency (Hz) of the vibration platform to be 
used in the major studies of this research.  This pilot test was presented in 2009 at the 7th 
Australasian Biomechanics Conference (Appendix A), and was based upon a previous project 
conduced by the student researcher to quantify vibration platform frequency (presented at the 
Australian Conference of Science and Medicine in Sport 2009, Appendix B).  The major 
finding of the previous project (Appendix B) was that manufacturer specifications of vibration 
platform frequency could be validated with advanced and precise laboratory based 
biomechanical equipment.  For research therefore, manufacturer specifications of the 
vibration platform should be confirmed in the laboratory to allow accurate description of 
frequency.   
 
Introduction  
Depending on specifications of a vibration platform, frequency (Hz) may be manipulated to 
alter intensity (g force) of WBV.  Frequency needs to be accurately reported in literature to 
strengthen the rigour required to allow replication in laboratory and community settings.  
Measurement of frequency can occur in the laboratory with three-dimensional (3D) motion 
analysis systems, but portable, light weight and inexpensive measurement instruments are 
desired in community settings.  The purpose of this pilot test therefore, is to concurrently 
validate a portable accelerometer with a 3D motion analysis system to: (1) quantify the range 
of frequency of the vibration platform at pre-determined speeds, and (2) determine if an 
accelerometer can be used to establish concurrent validity and potentially allow its use in 





Instruments and Test Procedure 
A side alternating vibration platform was used (Vibro-Trainer, Amazing Super Health, AUS).  
Vertical (Fz) data were concurrently recorded at 500 Hz with: (1) a 3D motion analysis system 
(VICON Oxford Metrics, Oxford UK, six cameras), and (2) a tri-axial accelerometer 
(CXL25GP3, Crossbow Technology, San Jose, USA) (figure 3.2).  The accelerometer was 
placed at the lateral end of the vibration platform surface, ~ 26 cm from the axis of rotation.  
Small (1 cm diameter) reflective ball markers were placed at both lateral ends of the vibration 
platform (figure 3.3).  Data were analysed for five seconds during steady-state operation of 
the vibration platform for three common vibration platform frequencies: 20, 25 and 30 Hz.   
 
Figure 3.2. A tri-axial accelerometer (CXL25GP3, Crossbow Technology, San Jose, USA) 






Figure 3.3. Superior view of a vibration platform showing locations of reflective markers and 
the accelerometer. The reflective markers are identified by the 3D motion analysis system. 
 
Statistical Procedures 
To quantify vibration platform frequency, descriptive statistics of mean and standard 
deviation were computed for 20, 25 and 30 Hz.  Concurrent validity was described with 95% 
limits of agreement and shown with Bland-Altman plots.  Descriptive statistics were 
computed with the Statistical Package for Social Scientists (SPSS) 17.0 for Windows (SPSS 





Axis of rotation 
Reflective marker 
Accelerometer 







Descriptive statistics are shown in table 3.1.  The 95% limits of agreement are shown in figure 
3.4.  The difference in vibration platform frequency was less than 0.50 Hz among a 3D 
motion analysis system and a tri-axial accelerometer.  To the nearest whole number, 
manufacturer determined vibration platform frequency was the same as those quantified with 
a 3D motion analysis system and a tri-axial accelerometer.  The 95% limit of agreement was 
within ± 2.1 Hz for vibration platform frequency.  As such, if the vibration platform was 
operating at 25 Hz, and the peak-to-peak displacement was 2.0 mm, then the gravitational 
force would be between 2.1 g and 3.0 g.    
 
Table 3.1 
Descriptive statistics and 95% limit of agreement among VICON and an accelerometer for 




VICON Accelerometer Mean difference 
(VICON-
Accelerometer) 
95% Limit of 
Agreement 
 
 Mean SD Mean SD   
20 19.9 0.2 19.7 0.5 0.2 Hz -2.1 Hz and 2.1 Hz 
25 24.9 0.4 24.5 1.9 0.4 Hz  









Figure 3.4. Bland-Altman plot showing the 95% limit of agreement among VICON 3D 
motional analysis system (VICON Oxford Metrics, Oxford UK) and a tri-axial accelerometer 
(CXL25GP3, Crossbow Technology, San Jose, USA). 
 
 
Discussion and Summary 
Results of this pilot test show that manufacturer defined vibration platform specifications and 
frequency quantified with laboratory and field based instruments are similar.  Furthermore, 
concurrent validity of a tri-axial accelerometer and a 3D motion analysis system was 
acceptable.  If laboratory conditions can be replicated in a community setting, such concurrent 
validity may allow data collection with a tri-axial accelerometer to quantify vibration platform 
frequency or other components of vibration description such as transmission and acceleration 









































3.3 Pilot Test 2: Transmission of WBV about the Knee of Healthy Young Adults 
Overview 
This phase of pilot testing was a preliminary investigation into transmission of side 
alternating WBV.  Given that the major aim of this research is to describe efficacy of WBV 
for people with COPD (i.e., major study 2, Chapter 5), it was considered crucial to enhance 
the level of understanding of transmission and side alternating WBV.  Results of this phase of 
the pilot testing were presented in 2010 at the 28th International Conference on Biomechanics 
in Sport (Appendix C).   
 
The data reported in this section describe transmission of WBV when the vibration platform 
frequency was 25 Hz and the peak-to-peak displacement of the vibration platform was 2.0 
mm even though the test procedure describes other, more detailed data collection.  The 
vibration platform descriptors (25 Hz and 2.0 mm) were selected to be inclusive of anticipated 
descriptors of major studies 1 and 2 (Chapter 4 and Chapter 5).  The entire data collection 
protocol of the pilot test however, is reported to show the effort afforded to control for 
intervention bias and a potential learning effect.  Specifically, there were three independent 
variables: (1) vibration platform frequency (20, 25 and 30 Hz), (2) stance width (10 and 20 
cm), and (3) knee flexion angle (20, 40 and 60º).  
 
Introduction 
The mechanistic understanding of improved performance following WBV is uncertain.  For 
example, transmission of WBV throughout the body is not thoroughly understood.  Although 
increasingly available in gymnasiums and rehabilitation centres, the evidence base of WBV 




only been investigated for side alternating WBV among healthy young adults (Abercromby et 
al., 2007b; Crewther, Cronin & Keogh, 2004) (Chapter 2, section 2.2.3).  As such, a greater 
understanding of transmission and attenuation of WBV with a side alternating vibration 
platform is required to assist with WBV intervention planning for people with COPD. 
 
Previously, transmission was calculated by placing accelerometers on a vibration platform 
and the knee (Harazin & Grzeski, 1998), head (Abercromby et al., 2007a), tibial shaft and 
thigh (Cook, Mileva, James, Zaidell, Goss, & Botwell, 2011), pelvis and spine (Mansfield & 
Griffin, 2002) or directly into bone (Rubin et al., 2003; Nsiah Edwards, Meardon, & Ward, 
2006).  Some methods were more invasive than others, yet an acknowledged error was 
created when accelerometers were attached to skin.  A data correction method to eliminate 
effects of local tissue-accelerometer resonance from surface measurements of vibration about 
the spine was proposed (Kitazaki & Griffin, 1995), yet since then, the method has not been 
routinely used during research.  
 
Generally, peak-to-peak displacement and vibration platform frequency were manipulated in 
WBV interventions to alter physiological responses, though a consensus of specifications has 
not been attained.  Nevertheless, for side alternating vibration platforms, changing stance 
width about the sagittal axis of rotation can change peak-to-peak displacement.  Currently, no 
published evidence exists of transmission of WBV for different stance width when 
participants are using a side alternating vibration platform, even though stance width altered 





Typically, vibration platform frequency is manipulated in an intervention by either increasing 
the frequency (Hertz) as the intervention progressed (Torvinen et al., 2002; Roth et al., 2008), 
or by maintaining the frequency for the duration of the intervention (Jacobs & Burns, 2009; 
Stewart et al., 2009).  Regardless of method, the vibration platform frequency range to date 
has been 15 to 50 Hz.  Investigations of transmission of WBV therefore, should quantify 
transmission in a similar range.   
 
Two studies have identified transmission of WBV with accelerometers at the knee in the 
frequency range of 20 to 30 Hz with synchronous vibration platforms (Harazin & Grzesik, 
1998; Kiiski et al., 2008).  Accelerometer results showed WBV was attenuated to some extent 
about the knee, though dependent on vibration platform frequency and knee flexion angle.  
Accelerometer assessments using a side alternating vibration platform are yet to be published 
for transmission about the knee.  
 
Knee flexion angle during WBV alters transmission of vibration when standing upon a 
synchronous platform (Harazin & Grzesik, 1998).  Previously, knee flexion angle was 
investigated at for example, 20 (Rubin et al., 2003), 31-35 (Abercromby et al., 2007b) and 70º 
(Harazin & Grzesik, 1998).  Effects of knee flexion angle upon attenuation about the knee 
with a side alternating vibration platform however, are unknown.  
 
Recently, noise of skin-mounted accelerometers was shown to minimally impact acceleration 
quantified during gait compared with bone-mounted accelerometers (Nsiah et al., 2006).  As 
such, skin-mounted accelerometers were considered a good predictor of skeletal impact 




of WBV in order to eliminate error associated with skin-mounted accelerometers (Smith 
Bressel, & Snyder, 2009).  For interventions in a community setting, laboratory procedures 
and access to complex equipment to identify precision are often unsuitable.  Therefore, 
research based in a community setting generally acknowledges the limitation (i.e., noise) of 
skin-mounted accelerometers but persist with their use because of ease of operation, cost, and 
transportability.  
 
The purpose of this pilot test therefore, was to quantify transmission of WBV about the knee 
of healthy young adults to determine the most effective knee flexion angle for vibration 
attenuation.  If the methods used in the pilot test allow quantification of transmission, then the 
methods could be adopted and replicated in a community setting to subsequently quantify 




Fifteen healthy, recreationally active males and females (mean ± SD age = 20 ± 1 years, 
stature = 1.8 ± 0.1 metres, mass = 70.5 ± 10.6 kilograms) (table 3.2) provided informed 
voluntary consent to participate in the pilot test.  Participants were free from lower limb injury 
in the month prior to testing and had no known articular joint injuries.  A convenient sample 
was recruited from the undergraduate degree within the School of Exercise Science, 
Melbourne.  Data were collected in the postgraduate laboratories within the School of 
Exercise Science in 2009.  The project was approved by the Australian Catholic University 






Each participant received six bouts of side alternating WBV delivered by a sinusoidal 
oscillating vibration platform (Vibro-Trainer, Amazing Super Health, AUS).  Each bout lasted 
60 seconds and consisted of a predetermined stance posture (i.e., knee flexion angle) and 
stance width (i.e., peak-to-peak displacement) while vibration platform frequency was 
randomly assigned.  A minimum of 60 seconds of passive rest occurred between bouts.  
Stance posture consisted of 20, 40 and 60º knee flexion, for which 0º knee flexion 
corresponded with full knee extension (figure 3.5).  Stance width was 10 and 20 cm from the 
axis of rotation for each leg as measured to the second toe.  As such, the peak-to-peak 
displacement was 1.0 and 2.0 mm respectively.  Vibration platform frequencies were 20, 25 
and 30 Hz (cognisant of the findings of pilot study 1).  Data were recorded for five seconds at 
each vibration platform frequency after platform steady-state was achieved.  
 
Figure 3.5. Demonstration of 40º knee flexion angle upon the vibration platform. The 





The independent variables were: (1) vibration platform frequency (20, 25, and 30 Hz), (2) 
stance width (10, and 20 cm), and knee flexion angle (20, 40, and 60º).  The dependent 
variable, transmission, was calculated from the ratio of root mean square (RMS) knee 
acceleration (KRMS) to RMS platform (PRMS).  A transmission value of 1.00 represented parity 
among the platform and knee.  A transmission value less than 1.00 represented a larger PRMS 
than KRMS (figure 3.6).  
 
Figure 3.6. An example of transmission, where the maximum acceleration about the knee is 
less than the maximum acceleration of the platform. For this example, the transmission value 
would be < 1.00. Note, data are m.sec
-2
 rather than RMS because negative values are squared 



































Two 25 g tri-axial accelerometers (CXL25GP3, Crossbow Technology, San Jose, USA) 
sampling at 250 Hz were used to quantify: (1) vibration platform vertical acceleration, and (2) 
knee vertical acceleration.  The mass of each accelerometer was 46 gm.  One accelerometer 
was mounted to the vibration platform.  Another accelerometer was firmly taped to the centre 
of the left patella of a participant to reduce skin movement.  That location was determined at 
the intersection of midpoints of the transverse and sagittal planes.  The left leg was used due 
to laboratory room width.  Knee flexion angle was constant for each WBV bout and checked 
manually with a goniometer.  The accelerometer about the knee was checked for vertical 
alignment before and during each WBV bout. 
 
Left leg length was measured with the ‘total true shortening’ method (McRae, 1999).  A tape 
was placed from the left anterior superior iliac spine to the left medial malleolus.  The 
participant lay in the supine position.  The data were recorded because it was thought leg 
length may impact on transmission of WBV given that wobbling mass and rigid bodies affect 
transmission (Yue & Mester, 2002). 
 
Knee flexion angle was filmed with a digital camcorder (NV-GS11, Matsushita Electric 
Industrial Co., Osaka JPN) and digitised with Siliconcoach Pro 7 (Siliconcoach, San 
Francisco, USA).  Small reflective markers (1 cm diameter) were adhered on the skin to the 
right; greater trochanter, lateral condyle, and lateral malleolus.  Data were filmed for each 







Although this pilot test included several independent variables, only knee angle was used for 
inferential analysis.  Descriptive statistics were calculated to quantify sample statistics, root 
mean square acceleration, knee angle, and WBV transmission.  Normality was tested by: (1) 
homogeneity of variance should not be violated, and (2) the data should not exceed ± 2 for 
skewness and kurtosis (Bluman, 1997; Macellari, Giacomozzi & Saggini, 1999; Vincent, 
1999; Portney & Watkins, 2000; Coakes, Steed & Dzidic, 2006).  Independent sample t-tests 
were computed for gender effects.  A one-way ANOVA was computed to describe effects of 
knee angle on transmission at 25Hz with 2.0 mm peak-to-peak displacement.  Data were 
imported to SPSS 17.0 for Windows (SPSS Inc., Chicago, USA).  Significance was accepted 
at p ≤ 0.05.  Some root mean square acceleration data were lost due to technical difficulties.  
For vibration platform frequency 25 Hz and peak-to-peak displacement 2.0 mm, data were 
analysed for no less than 9 participants and no more than 11 participants respectively. 
 
Results 
Descriptive and inferential statistics are shown to describe transmission of WBV about the 
knee of healthy young adults.  Participant anthropometric and selected descriptive statistics 
are shown in table 3.2. Descriptive and inferential statistics of transmission are shown in table 
3.3.  Descriptive statistics of knee angle are shown in table 3.4.  
 
The males and females in this pilot test were different for stature and mass, but not leg length. 
Males were 8.0 cm taller and 12.6 kg heavier than females (p < 0.05).  Left leg length (where 
the accelerometer was placed) was not significantly different (mean difference = 4.5 cm), so 





Anthropometric and descriptive statistics of the healthy young adults  












  mean SD  mean SD  mean SD  
Female 7 1.7 0.1 0.1* 63.8 7.2 12.6* 88.7 4.7 4.5 
Male 8 1.8 0.1  76.4 9.7  93.2 3.9  
Note: * significant difference p ≤ 0.05 
 
Root mean square acceleration was reported as transmission of WBV about the knee to best 
support the description of the effect of knee flexion angle (table 3.3).  There was no effect of 
the three knee flexion angles on root mean square acceleration of WBV about the knee 
(F(2,28) = 1.45, p = 0.25).  Transmission, the ratio of root mean square acceleration about the 
knee to root mean square acceleration at the surface of the vibration platform, was greater 
when the knee was flexed to 60°.  Attenuation of WBV about the knee was least when the 
knee was flexed to 40°. 
 
Table 3.3 
Transmission of WBV about the knee for various vibration platform frequencies, stance 























Mean SD  
20° 20.0 2.2 12.6 27.4 30.0 3.9 0.7 
40° 23.0 6.4 16.9 28.9   0.8 
60° 16.1 5.4 11.9 20.2   0.5 





Table 3.4 shows variability of pre-determined knee flexion angle during each WBV bout. 
Although the 20º knee flexion stance posture was most accurately maintained, variability 
across all stance postures was almost identical.  
 
Table 3.4  
Pre-determined stance postures and knee flexion angles by ‘Siliconcoach’ 
Pre-determined knee flexion angle  
 Mean SD 
20º 22.1º 4.2º 
40º 36.6º 4.1º 




In this pilot test, transmission of WBV was quantified by the ratio of root mean square 
acceleration of the vibration platform and root mean square acceleration about the knee.  
Three major findings emerged: (1) knee flexion angle influences transmission, though the 
differences among each of the knee flexion angles were not significant (2) transmission can 
be quantified with a tri-axial accelerometer, and (3) speculatively, the methods of 
accelerometer based transmission assessment may be used in a community setting to quantify 
transmission of WBV about the knee in other populations such as people living with COPD if 






A shortage of knowledge exists about WBV transmission with side alternating vibration 
platforms.  Although not specific to the vibration platform descriptors of this pilot test, for 
synchronous WBV at 20 Hz, independent of stance posture, WBV was not attenuated about 
the knee (Harazin & Grzesik, 1998; Matsumoto & Griffin, 1998).  The results of this pilot test 
showed attenuation of WBV about the knee when transmission was quantified at 25 Hz.  As 
such, attenuation of WBV, due to wobbling mass and rigid bodies were confirmed by the 
results of this pilot test. 
 
Although males were taller and heavier than females, limb length was not significantly 
different.  As such, wobbling mass of recreationally active, healthy adults may affect 
transmission of WBV.  The same case may be made of rigid bodies (i.e., femur and tibia 
length) although further investigation is required.  Furthermore, the effect of wobbling mass 
and rigid bodies on transmission force attenuation about the hip, spine, and head is relatively 
unknown with side alternating vibration platforms and should be further investigated. 
 
About the head, synchronous WBV created more acceleration than side alternating WBV for 
healthy adults (Abercromby et al., 2007b).  The remainder of the WBV was transmitted about 
other locations of the body (i.e., hip, spine and head).  Given the overall aim of this current 
research was to improve or maintain exercise tolerance and functional performance by 
increasing muscular strength and muscular power of the lower limbs of people with COPD, 
transmission of WBV about the head was not considered.  The quantification of transmission 
of WBV at other locations superior to the knee was beyond the scope of this research, 





Quantification of transmission was assessed in this pilot test, despite the known limitation of 
skin-mounted accelerometers.  The accelerometers as such, were sufficiently sensitive to 
detect attenuation of WBV.  Although in the current research noise of skin mounted 
accelerometer data was not accounted for, the error appeared systematic rather than random 
(i.e., figure 3.6).   
 
Variability of knee angle, vertical acceleration of the vibration platform, and individual 
difference in the ratio of wobbling mass and rigid bodies may have affected statistical results.  
Such variability may imply that stance width and knee flexion angle needs to be considered 
for each individual when quantifying efficacy of WBV training interventions.  The results of 
this pilot test show greater transmission at 60º knee flexion angle.  The sustainability of that 
posture, however, for people with muscular deconditioning (i.e., people with COPD) could be 
questioned even though several authors have reported increased EMG activity of vastus 
lateralis during WBV with an isometric squat of 55º knee flexion compared with more erect 
stance postures (Cardinale & Lim, 2003; Roelants et al., 2006).  Given there was no 
difference for knee flexion angle and transmission in the current pilot test (p = 0.25), people 
with muscular deconditioning could stand with a knee flexion angle between 20 and 60º, thus, 










Transmission of side alternating WBV was quantified in this pilot test.  The results showed 
for healthy young adults, knee flexion angle did not alter transmission of WBV about the knee 
(p = 0.25).  Greater knee flexion angles are likely to be less sustainable for people with poor 
muscular conditioning and should be carefully considered when undertaking a WBV 
intervention.  The accelerometer used in this study allowed quantification of WBV 
transmission and could be used in a community setting to allow similar quantification if the 
laboratory conditions could be reproduced.  
 
Limitations to the Planned Research 
A pilot test to quantify transmission of WBV with skin-mounted accelerometers about the 
knee of people with COPD in a community setting was undertaken with approval from the 
Australian Catholic University Human Research Ethics Committee (Appendix E).  
Participants were recruited through community based COPD support groups.  The design of 
the current pilot test was to be replicated, in which the independent variables were: (1) 
vibration platform frequency (20, 25 and 30 Hz), (2) stance width (10 and 20 cm), and (3) 
knee flexion angles (20, 40 and 60º).  The aim was to identify the combination of variables 
that created the largest attenuation of vibration about the knee.   
 
The pilot test was abandoned because the specific laboratory procedures could not be 
replicated in the 11 homes of the participants.  Specifically, several unexpected and 
uncontrollable extraneous variables led to the abandonment: (1) mounting the accelerometer 
to the skin of the participants to reduce noise caused subcutaneous bleeding at the knee when 




disruption of the normal arrangements of the home (i.e., movement of furniture), (2) limited 
space in the home of each participant to establish an adequate field of view to capture knee 
angle with the camcorder, (3) a lack of funding to transport participants to the laboratory at 
Australian Catholic University and general inconvenience of such travel to the participant, 
and (4) only the student researcher was given ethical permission to enter the house of each 
participant to conduct the pilot test in the community setting (i.e., knee angle could not be 
manually checked during a WBV bout) resulting in a largely expanded data collection time 

















3.4 Pilot Test 3: Reliability of Selected Dependent Variables of Major Study 1 and 
Major Study 2 
Overview 
This pilot test was completed to establish inter-day reliability of dependent variables of 
exercise tolerance and functional performance in a community setting.  The dependent 
variables of exercise tolerance collected at rest were: (1) rating of perceived dyspnoea (Borg 
CR-10 visual analogue scale), (2) heart rate, and (3) saturation of haemoglobin.  The 
dependent variables of functional performance were:  (1) the 5-chair test, (2) the TUG test, (3) 
stride length, (4) stride time, and (5) stride velocity.  Data were collected across a test-retest-
retest design to allow a comprehensive assessment of reliability (Weir, 2005) interspersed 




Participants were recruited from the Department of Respiratory and Sleep Medicine, Monash 
Medical Centre.  The Department patient database was accessed by the Clinical Trials 
Manager.  The Clinical Trials Coordinator sent an information letter to potential participants 
whom were then invited to record their interest in the pilot test by contacting the student 
researcher (Appendix F).  Medical consent was complicit within the approval of this research 
by the Department Head (Professor Philip Bardin).  The Australian Catholic University 
Human Research Ethics Committee (Appendix G) and the Southern Health Human Research 
Ethics Committee A (Monash Medical Centre) (Appendix H) approved the procedures.  A 




voluntary informed consent to participate (mean ± SD age = 72 ± 7 years, stature = 1.7 ± 0.1 
metres, mass = 85.7 ± 20.4 kilograms).  Data were collected in the home of each participant. 
 
Selection Criteria, Selection Protocol and Instruments 
Suitability for inclusion to the project was twofold: (1) the potential participant was affected 
with COPD, and, (2) the potential participant was community dwelling.  To satisfy the first 
criterion spirometry testing was conducted to confirm COPD and determine disease severity 
(table 3.5).  
 
Table 3.5 
Spirometry classification of COPD severity (GOLD, 2007)  
Stage FEV1/FVC Spirometry classification 
Stage I: Mild FEV1/FVC < 0.70 
FEV1 ≥ 80% predicted 
Stage II: Moderate FEV1/FVC < 0.70 
FEV1 < 80% predicted 
Stage III: Severe FEV1/FVC < 0.70 
FEV1 < 50% predicted 
Stage IV: Very severe FEV1/FVC < 0.70 
FEV1 < 30% predicted 
Note: Predicted FEV1 is calculated based on height, age, gender, and ethnicity.  
 
A SpiroPro PC connected spirometer (MicroMedical Ltd., Kent, UK) was used to conduct at 
least three FVC (FEV1) lung function tests.  The SpiroPro is concurrently validated with other 
laboratory and office based spirometers to detect COPD (Liistro, Vanwelde, Vincken, 
Vandevoorde, Verleden & Buffels, 2006).  The protocol for an acceptable spirometry test is 




table 3.6.  Spida 5 PC Software (Version 2.7; MicroMedical Ltd., Kent, UK) was used to 
automatically determine predicted FEV1 using the third National Health and Nutrition 
Examination Survey (NHANES III) (Hankinson, Odencrantz & Fedan, 1999). 
 
To be considered community dwelling, a potential participant had to be living in a fully-
independent residence, and needed to have the capacity to complete ADLs such as non-
assisted walking (Furness & Maschette, 2009).  Selected tests of cognition and visual acuity 
were then used assist with determination of the status of ‘community dwelling’ (Appendix I).  
The tests were: (1) the Mini-Mental State Examination (MMSE), (2) the Romberg test, (3) the 
Snellen Eye Chart (six metres), and (4) the Melbourne Edge test.  The tests were always 
conducted in the same order for every participant and data recorded to a results sheet.  
Participants unable to ‘pass’ all tests were not invited to participate further in the project.  The 
selection criteria had been previously used to screen for healthy community dwelling older 













Procedure for recording forced vital capacity     
Description Descriptions/Instructions 
1. Check the spirometer calibration  
 
3L syringe 
2. Explain the test 
 
 
3. Prepare the participant 
 
Measure mass and stature 
4. Wash hands 
 
 
5. Instruct and demonstrate the test 
to the participant 
 
Correct posture with head slightly elevated. 
Inhale rapidly and completely. 
Exhale with maximal force. 
 
6. Perform manoeuvre 
 
Have participant perform the correct posture. 
Attach nose clip, place mouthpiece in mouth     
and close lips around mouthpiece. 
Inhale completely and rapidly with a pause of 
<1 s at total lung capacity. 
Exhale maximally until no more air can be 
expired while maintaining an upright posture. 
Repeat instructions as necessary, coaching 
vigorously. 
Repeat for a minimum of three manoeuvres.   
Note: Adopted from Miller et al. (2005).  The correct posture for a participant was to ensure 
each was person sitting erect in an armless chair.  Following the joint guidelines of the 
American Thoracic Society and the European Respiratory Society, FEV1/FEV data were 
recorded prior to, and 15 minutes after Salbutamol (0.3 mg in spray form) inhalation from a 
spacer (Celli et al., 2004).  The prediction equations of the third National Health and Nutrition 
Examination Survey (NHANES III) were used to classify COPD severity.  
 
 
Tests of Cognition, Motor Function and Visual Acuity 
The Mini-Mental State Examination 
The MMSE was used to assess mental status.  The reliability of the test was previously 
reported as ‘good’ to detect dementia (ICC ≥ 0.80) (Magni, Binetti, Bianchetti, Rozzini & 




attention and calculation, recall and language, and is commonly used as a screeding tool 
among community dwelling older adult groups (Kurlowicz & Wallace, 1999).  A score of 23 
out of 30 iss considered a pass (Dite, & Temple, 2002; Hill & Schwarz, 2004; Melzer, 
Benjuya & Kaplanski, 2004).  The MMSE was conducted with the ‘paper and pen’ method 
described in previous investigations (Kurlowicz & Wallace, 1999; Dite, & Temple, 2002; Hill 
& Schwarz, 2004; Melzer, Benjuya & Kaplanski, 2004).  
 
The Romberg Test 
The Romberg test was used to identify distorted proprioception (Khasnis & Gokula, 2003).  
The test is a good predictor of normal postural sway (Black, Wall, Rockette & Kitch, 1982).  
Each participant stood with their feet together and eyes closed for 30 seconds.  The student 
researcher was close at hand in case the participant began to sway or fall, at which time the 
test was ended.  A successful test was at least 30 seconds in duration, as recorded by a stop 
watch.   
 
The Snellen Eye Chart  
The Snellen Eye Chart was used to establish how well each eye saw printed letters (Gerdhem, 
Ringsberg, Åkesson & Obrant, 2005).  The chart provides a useful test for visual acuity in a 
community setting to assist with participant screening (Schwiegerling, 2004), although for 
ophthalmic diagnosis the test is limited (McGraw, Winn & Whitaker, 1995).  Each participant 
was asked to read letters of the chart at six metres distance.  The participant sat in a chair and 
read, one eye at a time, the chart as accurately as possible (prescription glasses optional).  To 
pass the test the participant had to score at least 0.2 on the chart for the set distance.  The chart 




chart from an identical chair.  A tape measure was fixed to a point on the floor (directly below 
the chart) and drawn six metres from the chart.  The centre of the participant’s seat was placed 
at that point.  
 
The Melbourne Edge Test 
The Melbourne Edge test was used to examine the contrast vision sensitivity of each 
participant (Hill & Schwarz, 2004) because poor performance of the test is linked to increased 
risk of a fall (Lord & Dayhew, 2001).  The reliability of the test was previously reported as 
‘good’ to detect contrast vision sensitivity (ICC = 0.880) (Haymers, & Chen, 2004).  The 
participant was asked to use both eyes (prescription glasses optional) to detect the varying 
contrast among two colours.  A score of at least 11 on the test represents a pass.  The 
Melbourne Edge test was placed on a table directly in front of the participant.  The participant 
sat on the same chair used for the Snellen Eye Chart assessment.   
 
Data Collection 
Data of the dependent variables of major study 1 and major study 2: rating of perceived 
dyspnoea, heart rate, saturation of haemoglobin, 5-chair test, TUG test, and kinematic 
variables of gait; stride length, stride time, and stride velocity were collected over a test-
retest-retest procedure.  Data were collected interspersed with at least 48 hours to allow inter-







Exercise Tolerance: The Borg CR-10 Visual Analogue Scale 
The Borg CR-10 visual analogue scale (Appendix J) was used to quantify the rating of 
perceived level of breathing limitation so that dyspnoea could be anchored.  Reliability of the 
visual analogue scale (VAS) for dyspnoea was previously established (Mahler, 1992; Mahler, 
Mejia-Alfaro, Ward & Baird, 2001; Borg, Borg, Larsson, Letzter & Sundblad, 2010).  
Population specific reliability of the VAS was considered ‘acceptable’ if the ICC was ≥ 0.700 
(George & Mallery, 2003).  Resting rating of perceived dyspnoea was collected after the 
participant had been sitting quietly in a chair for five minutes.   
 
Exercise Tolerance: Heart Rate and Saturation of Haemoglobin 
Heart rate (HR) and saturation of haemoglobin (SpO2) were both quantified with the 
CARESCOPE™ V100 Vital Sign Monitor (GE Health Care, Milwaukee, USA).  At rest, data 
were collected after the participant had been sitting quietly in a chair for five minutes.  
Population specific reliability of the device was ‘acceptable’ if the ICC was ≥ 0.700 (George 
& Mallery, 2003).  An increase of resting heart rate is synonymous with physical activity 
(ACSM, 1998b), while a reduction of SpO2 has been linked to poor diffusing capacity partly 
due to emphysematous change consistent with a diagnosis of COPD (West, 2008).  
 
Functional Performance: The 5-Chair Stands Test 
The 5-chair stands test (5-chair test) was most commonly used in community settings to 
quantify muscular power (Moreland, Richardson, Goldsmith & Clase, 2004) because chair 
rising power was fundamental to functional performance of older adults (Runge, Rittweger, 
Russo, Schiessl & Felsenberg, 2004).  The reliability of the tests was ‘excellent’ for 




Maschette, 2009).  Each participant was asked to sit in a standard height (46 cm, including 
back rest) chair with their arms folded across their chest.  The participant was then asked to 
stand and sit five times (Brill, Cornman, Davis, Lane, Mustafa, Sanderson & Macera, 1999; 
Runge, Rehfeld & Resnicek, 2000; Visser, Pluijm, Stel, Bosscher & Deeg, 2002; Runge et al., 
2004).  
 
The test began on the verbal instruction to “go” and ended when the participant sat with their 
back against the back rest of the chair.  Participants were told their back must make contact 
with the back rest for all five chair stands.  Time taken was recorded with a stopwatch.  
Participants were told the procedure to complete the test and were given one familiarisation 
test at the first of three test occasions.  The timed test occurred 5 minutes after the 
familiarisation test to ensure recovery.  Participants were asked to complete the test as they 
felt comfortable.  One test was completed and used for reliability analyses at each test 
occasion separated by at least 48 hours.  
 
Functional Performance: The Timed-Up-and-Go Test 
The timed-up-and-go test (TUG test) was a modified version of the get-up-and-go test (GUG).  
The TUG test was reliable (inter-day ICC ≥ 0.970) and a valid quantifier of gait speed (r
2
 = 
0.74), and functional motor performance ability of older adults (Podsiadlo & Richardson, 
1991).  The TUG test involves a well recognised series of events used in active daily living 
(Isles, Low Choy, Steer & Nitz, 2004).  Presented by Podsiadlo and Richardson (1991) the 
TUG test eliminated observer variance systemic to the GUG test by examining the time taken 





For the TUG test, the participant was asked to sit in a standard height (46 cm) arm (63 cm) 
chair.  The participant was then asked to stand, walk three metres to a marker on the floor, 
turn, return, and sit on the chair (Brill et al., 1999; Dite & Temple, 2002; Cho, Scarpace & 
Alexander, 2004).  The test began on the verbal instruction to “go” and ended when the 
participant sat with their back against the back rest of the chair.  Participants were told their 
back must make contact with the back rest in order to complete the test.  
 
Time taken was recorded with a stopwatch.  Participants were told the procedure to complete 
the test and were given one familiarisation test at the first of three test occasions.  The timed 
test occurred 5 minutes after the familiarisation test to ensure recovery.  Participants were 
asked to complete the test as they felt comfortable.  Three tests were completed on each of the 
three test occasions with 60 seconds passive rest (sitting in the chair) interspersed among 
tests.  All three tests were used in the data analyses.  
 
Kinematic Variables of Gait  
The GAITRite
®
 Electronic Walkway 
The GAITRite mat was used for the capacity to collect a large number of kinematic datum per 
walking trial compared with the 5-chair test and the TUG test.  The GAITRite mat comprised 
of seven sensor pads embedded in a 14 foot portable roll up mat.  The data sensitive area of 
the mat (61 cm wide, by 360 cm long, by 0.6 cm high) allowed quantification of spatial and 
temporal kinematic variables of gait.  Each centimetre of walkway was embedded with 38 
sensors sampling at 80 Hz.  Data were transferred to a notebook computer with GAITRite 
software (Version 3.8).  The concurrent validity and reliability of the walkway had been 




& Besser, 1999; Cutlip, Mancinelli, Huber & DiPasquale, 2000; McDonough, Batavia, Chen, 
Kwon & Ziai, 2001; Nelson Zwick, Brody, Doran, Pulver, Rooz et al., 2002).  For the 
participants of this pilot test, data were collected for stride length, stride time, and stride 
velocity.  
 
Participants were instructed to walk at a self-selected comfortable speed along a straight, flat, 
and even walkway area containing the mat.  Body length was measured from the base of the 
foot (unshod) to the crown of the head while standing in the anatomical position.  During data 
collection, participants walked (shod) over the mat five times in a discontinuous process with 
an approach and departure distance equal to two body lengths (figure 3.7).  The procedure 
was reliable for step length, step time, and velocity among older woman (ICC range 0.860 to 
0.940; mean age = 68 years) (Paterson, Hill, Lythgo & Maschette, 2008).   
 
For reliability and subsequent use of this pilot test, stride length is quantified as the line of 
progression between two consecutive footprints of the same foot.  In figure 3.8, stride length 
was represented in metres by the length of the line of progression between points A and G.  
Stride time was the time taken in seconds between the first contacts of two consecutive 
footballs of the same foot (i.e., the time among points A and G).  Stride velocity was the ratio 
















Data sensitive area 3.60 m 
Figure 3.7. Walkway length showing data sensitive area and body length protocol. 
 
Figure 3.8. Spatial kinematic parameters of gait from the GAITRite
®
 Electronic Walkway. 
Source: CIR Systems Inc., GAITRite
®
 Electronic Walkway Technical Reference (WI-02-15).  
Stride length was the length in metres of the line of progression from points A and G.  
 






Descriptive statistics were computed to describe the participants and the severity of their 
COPD.  Reliability intra-class correlation coefficients; ICC (3, k) values were calculated to 
describe inter-day reliability of the dependent variables of exercise tolerance and functional 
performance.  The model suited a repeated measures ANOVA, where k denoted mean ratings, 
and ‘ratings’ were the test occasions (Portney & Watkins, 2000).  The repeated measures 
ANOVA was computed with the SPSS 19.0 for Windows spread sheet (SPSS Inc., Chicago, 
USA).  Normality was tested by: (1) Mauchly’s sphericity test; and (2) the data should not 
exceed ± 2 for skewness and kurtosis (Bluman, 1997; Macellari, Giacomozzi & Saggini, 
1999; Vincent, 1999; Portney & Watkins, 2000; Coakes, Steed & Dzidic, 2006).  
  
Each ICC (3, k) was calculated with equation 1 (Vincent, 1999; Portney & Watkins, 2000).  
For equation 1, ‘BMS’ was the between-subjects mean square from the repeated measures 
ANOVA and ‘EMS’ was the error mean square from the repeated measures ANOVA.  Intra-
class correlation coefficients were computed between values of 0.000 and 1.000.  An ICC 
value of 0.700 was ‘acceptable’, 0.800 was ‘good’, and, ≥ 0.900 was ‘excellent’ (George & 
Mallery, 2003). 
 
ICC (3, k) =      equation 1 
 
High ICC values can overestimate reliability because the results do not show within subject 
differences across test occasion (Menz, Latt, Tidenamm, Kwon & Lord, 2004).  Therefore, as 




variation (CV) were calculated to show variability within test occasions (Portney & Watkins, 
2000).  The SEM was calculated with equation 2 (Portney & Watkins, 2000) where ‘SD’ was 
the standard deviation of all data and calculated with equation 3 (Weir, 2005), and ‘SSTotal’ 
was the sum of squares total computed by the repeated measures ANOVA and ‘n’ was the 
total number of datum.   
 
SEM = SD       equation 2 
SD =        equation 3 
A 95% confidence interval (CI) of the SEM was calculated to describe the range of error for 
each dependent variable (Portney & Watkins, 2000) (equation 4).  The 95% CI was calculated 
for the grand mean ( ) of the three test occasions.  
 
95% CI =      equation 4  
 
The CV was calculated with equation 5 (Portney & Watkins, 2000).  For equation 5, ‘ ’ was 
the grand mean and SEM was calculated with equation 2. 
 








Table 3.7 shows the descriptive statistics of the participants in this reliability pilot.  Mean age 
of the four females and 12 males was 72 years.  Participant age ranged between 56 and 84 
years.  Mean body mass index (BMI) was 29.3 kg.m
2




Sample descriptors of participants with COPD 
Descriptor Mean SD 
Age (years) 72 7 
Stature (m) 1.7 0.1 
Mass (kg) 85.7 20.4 
BMI (kg.m
-2
) 29.3 6.1 
SBP (mmHg) 139 13 
DBP (mmHg) 75 10 
Resting HR (beats.min
-1
) 82 10 
Predicted maximum HR (beats.min
-1
) 148 7 
Note: N = 16 (4 females, 12 males).  SBP: systolic blood pressure. DBP: diastolic blood 
pressure. HR: heart rate. Resting HR: After sitting quietly in a chair for five minutes. 
Predicted maximum HR: 220 beats.min
-1
 – age. 
 
 
Spirometry testing results are shown in table 3.8.  According to GOLD (2007), 15 participants 
were affected by ‘moderate’ Stage II COPD.  Mean FEV1 was less than 80% predicted.  Mean 
FER was less than 70%.  One participant was affected with ‘severe’ Stage III COPD (FEV1 % 






Table 3.8  
Spirometry descriptors of the participants with COPD 
Descriptor  Pre Post 
 Mean SD 95% CI Mean SD 95% CI 
FEV1 (L BTPS) 1.5 0.5 ± 1.0 1.7 0.7 ± 1.4 
FEV1 % predicted 53.0 16.7 ± 32.7 58.5 19.0 ± 37.2 
FVC (L BTPS) 2.8 0.7 ± 1.3 3.0 0.8 ± 1.6 
FVC % predicted 78.5 13.3 ± 26.1 83.2 15.0 ± 29.4 
FER % 52.0 13.8 ± 27.0 52.3 10.8 ± 21.2 
PEF (L.sec
-1
) 3.8 1.4 ± 2.7 4.2 0.8 ± 1.6 
Note: Pre: before 0.3 mg Salbutamol inhalation.  Post: 15 minutes after 0.3 mg Salbutamol 
inhalation.  One participant was classified as severe Stage III COPD.  FEV1: forced expired 
volume of oxygen in the first second.  FVC: forced vital capacity of the lungs.  FER: forced 
expiratory ratio (FEV1.FVC
-1
).  PEF: peak expiratory flow.  L BTPS: Litres Body 
Temperature Pressure Saturated.  95% CI: confidence interval [ (SD)]  
 
 
Table 3.9 shows the descriptive statistics and the result of the ICC and CV calculations for the 
dependent variables of exercise tolerance and functional performance.  Data were collected 
across a test-retest-retest design interspersed with at least 48 hours.  Reliability of the 
dependent variables was at least ‘acceptable’ (ICC ≥ 0.700).  The maximum CV for exercise 
tolerance variables was 28.5% (i.e., Borg CR-10).  The maximum CV for functional 









Inter-class correlation reliability results of all dependent variables across three test occasions for people with COPD  






Skewness Kurtosis CV 
(%) 
SEM 
(± 95% CI)  
ICC 
 
Borg CR-10 1 16 2 0 1.69 1.48 28.5 2 (± 1.12) 0.706 
(VAS) 2 16 2 0 0.97 0.89    
 3 16 2 0 0.67 1.18    
Heart Rate 1 16 88 4 -0.12 -0.12 5.39 89 (± 9.40) 0.789 
(beats.min
-1
) 2 16 88 4 -0.27 0.25    
 3 16 90 2 0.24 1.43    
Saturation of  1 16 96 1 -0.66 -0.98 0.70 96 (± 1.31) 0.700 
haemoglobin  2 16 96 0 -0.13 -0.88    
(%) 3 16 95 1 -0.02 -0.07    










Table 3.9 (continued) 






Skewness Kurtosis CV 
(%) 
SEM 
(± 95% CI)  
ICC 
 
5-chair stands test  1 16 19.3 3.7 0.01 -1.56 1.27 3.67 (± 7.19) 0.881 
(sec) 2 16 19.3 4.1 0.09 -1.14    
 3 16 18.8 3.2 0.75 -0.34    
TUG test  1 46 11.8 2.1 0.18 -0.24 0.37 1.97 (± 3.86) 0.964 
(sec) 2 46 11.5 1.9 -0.13 -0.52    
 3 46 11.3 1.8 -0.05 -0.20    
Stride time  1 182 1.14 0.09 0.61 -0.39 0.03 0.10 (± 0.20) 0.928 
(sec) 2 182 1.13 0.10 0.86 0.18    
 3 182 1.13 0.11 0.92 0.30    
Stride length  1 182 1.13 0.16 0.54 -0.10 3.28 0.15 (± 0.29) 0.952 
(m) 2 182 1.14 0.14 0.25 -1.10    
 3 182 1.14 0.15 0.23 -0.93    
Stride velocity  1 182 0.99 0.15 0.35 -0.66 4.30 0.14 (± 0.27) 0.900 
(m.sec
-1
) 2 182 1.01 0.12 0.84 0.18    
 3 182 1.02 0.14 0.29 -0.42    
Note: The 5-chair test: 16 participants completed one trial on each test occasion, thus N = 48.  The TUG test: 15 participants completed three 
trials on each of three test occasions and 1 participant completed one trial on each test occasion, thus N = 138.  Stride time: at least 10 datum 
were recorded for each individual among the five trials.  Stride length: at least 10 datum were recorded for each individual among the five trials.  







Discussion and Summary 
This pilot test established the inter-day reliability of dependent variables fundamental to 
major study 1 and major study 2.  For the dependent variables of exercise tolerance (Borg CR-
10, heart rate, and saturation of haemoglobin), reliability was at least ‘acceptable’ (ICC ≥ 
0.700).  The range of ICC’s was good (0.881) to excellent (0.964) for functional performance 
dependent variables (5-char test, TUG test, stride time, stride length, and stride velocity). 
 
The Borg CR-10 VAS has been limited due to intra-individual variability across test 
occasions (Shen & Parsons, 1997).  The CV results of this pilot test (CV = 28.5%) similarly 
show a large intra-individual variability of the Borg CR-10 VAS.  Bearing in mind however, 
the acceptable reliability of the VAS (ICC = 0.706), the CV was considered to be satisfactory. 
 
For healthy young adults CV of resting HR was between 4 and 17% (Haddad, Laursen, 
Chollet, Ahmaidi & Buchheit, 2011).  In this pilot test CV of resting HR was similarly low at 
5.39% although quantified with a different device.  The similarity of HR and the acceptable 
reliability (ICC = 0.700) and CV (0.70%) of SpO2 in the current pilot test justifies the use of 
the CARESCOPE™ V100 Vital Sign Monitor to quantify the selected dependent variables of 
exercise tolerance of this research. 
 
The reliability data for the functional performance dependent variables of this research are 
supported by other studies of reliability of the 5-chair test (Guralnik, Ferrucci, Simonsick, 
Salive, & Wallace, 1995; Moreland et al., 2004) and the TUG test (Isles et al., 2004).  
Kinematic gait data are also supported by the ‘good’ to ‘excellent’ ICC’s reported by Paterson 




approach and departure distance was reliable for people with COPD for stride time, stride 
length, and stride velocity.   
 
For older adults, a comfortable self-selected walking pace with a 2 metre approach and 
departure distance was reliable for velocity and step length quantified with the GAITRite mat 
(ICC range 0.880 to 0.910) (Menz et al., 2004).  In this pilot test, a two body length approach 
and departure distance elicited similar ICC reliability.  
 
The CV values calculated in this pilot test were similar to Menz et al. (2004).  In that study, 
CV for velocity was 3.5% and 3.3% for step length of healthy older adults (mean age = 81 
years).  In this pilot test, CV of stride velocity was 4.30%, and 3.28% for stride length of 
people with COPD.  Although no limits of acceptability for CV were apparent in the 
literature, the CV for dependent variables of functional performance of people with COPD in 
this pilot test were low and similar to the CV results of other studies considered acceptable.  
The reliability data of this pilot test support the previous reports that the GAITRite
®
 
Electronic Walkway is reliable for quantifying kinematic variables of gait with older adults 










3.5 Sample Size Calculations 
Overview 
Whole-body vibration has never been used as an intervention in a community setting to 
improve or maintain exercise tolerance and functional performance of the lower limbs of 
people with COPD.  Therefore, sample size was estimated using data from a study of healthy 
community dwelling older adults (mean age = 72 years) who completed two sessions of WBV 
over a six week intervention (Furness & Maschette, 2009).  The dependent variables were the 
5-chair test and the TUG test.  The intensity of WBV was 0.6 g (weeks 1 and 2), 0.8 g (weeks 
3 and 4), and 1.3 g (weeks 5 and 6).  The WBV sessions consisted of five, one minute WBV 
bouts interspersed with one minute passive rest.  The data collection methods of this research 
for the 5-chair test and the TUG test were identical.  To allow sample size calculation, the 
primary dependent variables focussed on tests of functional performance: the 5-chair test and 




The raw data of Furness and Maschette (2009) are shown in table 3.10.  Descriptive statistics 
of that study are shown in table 3.11.  The value of kurtosis exceeded the assumption of 









Raw data of Furness & Maschette (2009) for healthy community dwelling older adults at 
baseline and after six weeks of WBV 
TUG Pre TUG Post CHAIR Pre CHAIR Post 
8.39 7.16 10.22 9.97 
6.58 6.25 18.61 11.55 
9.05 7.52 14.64 11.79 
9.28 6.95 20.40 16.48 
14.77 14.50 12.26 11.99 
10.19 9.41 24.61 18.73 
18.60 16.00 21.56 12.93 
13.55 9.80 15.79 12.93 
10.19 8.44 15.10 12.38 
9.61 8.44 18.44 16.40 
10.43 9.28 11.42 10.98 
11.44 9.16 15.12 12.93 
7.22 6.86 13.11 12.93 
8.84 8.44 13.48 11.32 
 
Table 3.11. 
Descriptive statistics of raw data of Furness & Maschette (2009) for healthy community 
dwelling older adults at baseline and after six weeks of WBV 
Variable TUG Pre TUG Post CHAIR Pre CHAIR Post 
Mean 10.44 9.11 16.05 13.11 
Standard Deviation 3.12 2.71 4.00 2.35 
Variance 9.72 7.37 15.98 5.54 
Kurtosis 2.34 2.78 -0.04 1.18 
Skewness 1.47 1.76 0.66 1.24 







Given the values of kurtosis violated the assumption of normality, reciprocal transformation 
(RT) was computed of the data (equation 1) (Portney & Watkins, 2000).  With equation 1, 
‘RT’ was the datum value of the reciprocal transformation computation and ‘x’ was the raw 
datum value.  Descriptive statistics of the transformed data are shown in table 3.12.  
RT =       equation 1 
 
Table 3.12. 
Descriptive statistics of raw data after reciprocal transformation 
Variable TUG Pre TUG Post CHAIR Pre CHAIR Post 
Mean 0.10 0.12 0.07 0.08 
Standard Deviation 0.03 0.03 0.02 0.01 
Variance 0.01 0.01 0.01 0.01 
Kurtosis 0.22 -0.39 -0.27 0.23 
Skewness -0.04 -0.59 0.35 -0.50 
Correlation coefficient 0.920 0.810 
 
 
The method of paired t-test (equation 2 and 3; Portney & Watkins, 2000, Table C.2 p, 720) 
was used to estimate sample size from the data of Furness and Maschette (2009).  With 
equation 2, d’ was based on paired score and ‘s’ was the common standard deviation.  After 
calculation of d’, the effect size index; d was calculated with equation 3, where ‘r’ was the 
correlation coefficient for the paired data.   
 
          equation 2 




Calculation of  the means of the pairs by equation 2 and the effect size index by equation 3 for 





Calculation of  the means of the pairs by equation 2 and the effect size index by equation 3 for 






Sample size needed for a one tailed paired t-test α 0.05 and n = 14 with power 0.90: 
The 5-chair test estimated n =   16 






3.6 Statistical Processes: Normality, Effect Size and Partial Eta Squared 
Normality 
All data were checked for normality according to an established standard (Bluman, 1997; 
Macellari, Giacomozzi & Saggini, 1999; Vincent, 1999; Portney & Watkins, 2000; Coakes, 
Steed & Dzidic, 2006).  The assumptions of normality comprised: (1) the distribution of the 
population data scores were normal, (2) the data should not exceed ± 2 for skewness and 
kurtosis, (3) the assumption of sphericity was met, and (4) Levene’s statistics for 
homogeneity of variance was not violated (Macellari, Giacomozzi & Saggini, 1999; Vincent, 
1999; Portney & Watkins, 2000; Coakes, Steed & Dzidic, 2006).  When the assumption of 




Effect size was calculated with equation 4, in which ‘SDPooled’ was the pooled standard 
deviation of the baseline and instantaneous WBV data (Vincent, 1999; Thalheimer & Cook; 
2001).  Specifically, effect size was calculated for paired t-tests of Study 1 (Chapter 4).  The 
effect size was expressed as Cohen’s d.  Effect size 0.2 was considered small, 0.5 moderate 
and > 0.8 large effect (Winer, Brown & Michels, 1991). 
 
d =        equation 4 
 




Partial Eta Squared 
Partial eta-squared (Partial η
2
) was computed to describe strength of association for repeated 
measures analysis of variance (RM-AVOVA) (Pallant, 2005).  Specifically, Partial η
2
 was 
calculated for dependent variables of Study 2 (Chapter 5).  Partial eta-squared of 0.01 was 
























A justification for the use of WBV for the management of stable COPD, specifically relating 
to exercise tolerance and functional performance was presented in Chapters 1 and 2.  The 
rationale was speculative, because the efficacy of WBV has not been established as a 
standalone mode of exercise.  Furthermore, safety of WBV has never been established for 
people with COPD.  Three studies however, two of which involve WBV and lung function of 
cystic fibrosis sufferers (Roth et al., 2008; Rietschel et al., 2008) and another on WBV and 
heart transplant recipients (Crevenna et al., 2003) supported the safe use of WBV.  
Specifically, experiences with WBV did not exacerbate each pathology.  
 
Position statements from respiratory bodies including the American Thoracic Society and the 
European Respiratory Society support the use of resistance training and aerobic conditioning.  
Generally, those modes of physical activity are regarded as safe and effective modes to 
improve exercise tolerance of people with COPD (Nici et al., 2006; GOLD, 2007).  As such, 
people with COPD are expected to respond safely to varied modes of peripheral muscle 
training, yet it remains unknown if people with COPD would respond safely to WBV.  
Furthermore, WBV may be an easier mode of exercise to perform for people with COPD than 
resistance training and aerobic conditioning because of low skill demand.  Whole-body 
vibration in a community setting is yet to be determined as an exercise mode well tolerated 




However, the safety of a single session of WBV in a community setting should first be 
established before long-term interventions can be introduced.  
 
4.2 Aim and Objectives 
The aim of this research is to describe effects of a single exercise session of WBV on selected 
psychological and physiological responses in people with COPD.  Specifically, the aim is to 
determine the safety of WBV by quantifying rating of perceived dyspnoea, heart rate, and 
saturation of haemoglobin for people with COPD during a WBV bout.  Physical activity, such 
as treadmill walking (Clark et al., 2000) and resistance training (Panton et al., 2004) routinely 
increase dyspnoea, even for healthy participants, yet those modes were considered necessary 
of pulmonary rehabilitation (GOLD, 2007).  Potentially less strenuous and less known, effects 
of WBV on COPD should be cautiously introduced.  Therefore, the objectives of major study 
1 were to: 
 Quantify and describe effects of a single session of WBV on rating of perceived 
dyspnoea, heart rate, and saturation of haemoglobin prior to and during a bout of 
WBV for people with COPD. 
 
Research Hypothesis 
The following research hypothesis was tested to describe effects a single session of WBV on 
selected psychological and physiological responses of exercise of people with COPD: 
HI: For people with COPD, a single session of WBV: (1) will increase rating of 







Participants were recruited via two independent methods: (1) advertising brochure and 
information sessions at COPD support group meetings (Appendix K), and (2) mail out to 
patients of the Monash Medical Centre, Department of Respiratory and Sleep Medicine, 
Monash Medical Centre, Southern Health (Appendix F).  After interest was attracted, each 
participant was provided with an information letter and consent form.  The Australian 
Catholic University Human Research Ethics Committee (Appendix L) and the Southern 
Health Human Research Ethics Committee A (Monash Medical Centre) (Appendix H) 
approved the procedures.  A convenience sample of 17 adults with COPD (mean age = 69 
years ± 8, mean stature = 1.7 metres ± 0.9, mean mass = 83.9 kilograms ± 19.2) provided 
informed voluntary consent and were included in the study.  The cohort was drawn from 
metropolitan Melbourne and the Mornington Peninsula, Victoria, Australia.  Data were 
collected in the home of each participant, April through May, 2011. 
 
Selection Criteria 
The selection criteria and selection protocol used in this research are more comprehensively 
described in Chapter 3 (pages 105 to 109).  Essentially participants were: (1) affected by 
COPD, and (2) community dwelling.  A third criterion specific for WBV was added to this 
research: (3) the potential participant satisfied WBV intervention inclusion guidelines and is 






To satisfy the third criterion, all participants had to report being free of self reported; vascular 
disease, reactive arthritis, vertigo, and risk of thromboembolism (Runge, Rehfeld & Resnicek, 
2000; Roelants, Delecluse & Verschueren, 2004; Bruyere, Wuidart, Di Palma, Gourlay, 
Ethgen, Richy et al., 2005).  A list of contraindications for WBV was tentatively suggested by 
Cardinale and Rittweger (2006).  Table 4.1 shows the potential problems associated with 
varying sub-optimal health conditions and WBV.  Notably, COPD is not a listed condition.  
Participants with any condition described in table 4.1 were not included in this research.  
 
Table 4.1 
Contraindications for WBV and people of sub-optimal health (Cardinale & Rittweger, 2006) 
Condition Potential Problem 
Diabetes with neuropathy and ulceration Lack of sensation or worsening 
ulcers 
Recent venous thrombosis Pulmonary embolism 
Recent fracture Instability/re-fracture 
Osteosynthesis in lower limbs 
containing metal implants 
Discomfort 
Spinal tumours or metastases Instability 
Acute vertebral disc herniation Instability 
Recent abdominal surgery Operative result may be 
compromised 
Pregnancy Unknown risk 
Hip or knee endoprosthesis or other 
metal implants 
Unknown risk 










Data were collected in the homes of the 17 participants.  The community setting was selected 
ahead of the University laboratory and the Monash Medical Centre because: (1) the home was 
more suited to the convenience of the participant, (2) space within the Monash Medical 
Centre was unavailable, (3) the instruments were transportable, and (4) the safety of WBV 
that could be potentially used in a community setting needed to be established.  
 
The independent variable was WBV.  A side alternating vibration platform (Amazing Super 
Health, Melbourne, AUS) was used in the homes of the participants.  For each vibration bout, 
the vibration platform frequency was set at 25 Hz with a peak-to-peak displacement at 2.0 
mm, peak acceleration was ~24.67 m.s
-2
, and the resulting gravitational force was ~2.52 g 
(cognisant of the findings of pilot test 1).  Validity of the vibration platform peak-to-peak 
displacement and frequency were established prior to commencement of the test procedure 
(pilot test 1, Appendix A).  Foot placement (second toe) was equidistant, 20 cm from axis of 
rotation.  The participant wore flat soled shoes.  Skidding was checked according to the 
recommended method of the International Society of Musculoskeletal and Neuronal 
Interactions (Rauch et al., 2010).  A piece of paper was placed under the foot during a 
vibration bout to ensure constant contact with the vibration platform (Rauch et al., 2010).  The 
method allows determination of the WBV parameters (i.e., vibration platform frequency, 
peak-to-peak displacement, and resultant gravitational force) (Rauch et al., 2010).  The 
participant stood with ~40º knee flexion.  Despite the position being checked with a 
goniometer, previous work by the student researcher showed knee flexion angle to vary (37º ± 
4º) independent of a request to maintain 40º knee flexion among healthy young adults (table 





The single session of WBV consisted of five, 60 secoond vibration bouts interspersed with 60 
seconds of passive rest.  Although the most effective protocol is yet to be established, the 
selected protocol had been used previously to establish efficacy of WBV interventions in 
healthy young adults (Cardinale & Lim, 2003; Cronin, Oliver & McNair, 2004) and non-
community dwelling old adults (i.e., nursing home residents, Bruyere, et al., 2005).  During 
rest, the participant remained on the vibration platform, but was encouraged to stand with a 
posture that mimicked the ‘anatomical position’ in accordance with the guidelines of the 
International Society for the Advancement of Kinanthropometry.  More specifically, the 
participant assumed a standing position with the feet close together, the arms to the side, and 
the head, eyes, and palms facing forwards.  
 
Data Collection and Instruments 
Anthropometric data (stature and mass) were collected at baseline.  Data of selected 
physiological responses to exercise were also collected at baseline (before the first WBV 
bout) and during the fifth and final WBV bout (after 30 seconds of the 60 second bout).  
Clinical spirometry tests were conducted no more than 12 months prior to inclusion in the 
study as part of usual care for the participant at the Monash Medical Centre.   
 
The Borg CR-10 VAS (Appendix J) was used to quantify the rating of perceived level of 
breathing limitation so that dyspnoea during WBV could be quantified.  Reliability of the 
VAS for dyspnoea was previously established (Mahler, 1992; Mahler, Mejia-Alfaro, Ward & 
Baird, 2001; Borg et al., 2010).  Population specific reliability of the VAS was acceptable 
(ICC ≥ 0.700, George & Mallery, 2003) mindful that the CV was almost one third of the 




single session of WBV, resting rating of perceived dyspnoea was collected after each 
participant had been sitting quietly in a chair for five minutes.   
 
Dependent variables were heart rate and saturation of haemoglobin (SpO2), both quantified 
with the CARESCOPE™ V100 Vital Sign Monitor (GE Health Care, Milwaukee, USA).  At 
baseline, those data were collected after each participant had been sitting quietly in a chair for 
five minutes.  Population specific reliability of the device is acceptable (ICC ≥ 0.700, George 
& Mallery, 2003) for heart rate and saturation of haemoglobin (Chapter 3, pilot test 3).  
 
Heart rate reserve (HRR) was calculated to allow comparison with other studies of physical 
activity.  Heart rate reserve was calculated with the Karvonen method (Karvonen, Kentala & 
Mustala, 1957) (equation 2).  Where ‘MRHPred’ was the predicted maximum heart rate 
calculated by 220 beats.min
-1
 – age in years, and ‘RHR’ was the resting heart rate quantified 
after each participant had been sitting quietly in a chair for five minutes. 
 
 HRR =     equation 2 
 
The percentage of heart rate reserve (HRR%) was calculated with the method of Colberg, 
Swain & Vinik (2003) (equation 3).  Where ‘Δ HR’ was the increment in heart rate from RHR 
during WBV. 
 




The HRR can describe the relative acute effects of physical activity (Cornelissen, Verheyden, 
Aubert & Fagard, 2010).  However, HRR% is calculated considering the HRR and is 
therefore relative to each individual even if the age in years is the same.  As such, a HRR 
value of 0% is the equivalent of rest and can allow comparison among individuals even if 
their resting heart rates differ.  
 
Statistical Procedures 
The Statistical Package for Social Scientists (SPSS Version 19.0, Chicago IL™) was used to 
compute descriptive statistics of participant anthropometric, spirometry and dependent 
variables.  Inferential statistics were computed to test the research hypothesis.  Parametric 
statistical methods were used to calculate inferential statistics.  Paired-sample t-tests were 
computed for Borg CR-10, heart rate and, saturation of haemoglobin.  The paired analyses 
were within baseline and during WBV.  Significance was accepted at p ≤ 0.05.  Effect size 
was calculated and expressed as Cohen’s d (Chapter 3, section 3.6).  
 
4.4 Results 
Participant anthropometric and selected descriptors are shown in table 4.2.  Descriptive and 
inferential statistics are shown to describe psychological and physiological effects of a single 
session of WBV on people with COPD.  Participant spirometry data are shown in table 4.3.  






Mean age of the four females and 13 males was 69 years, which is ‘older adulthood’ 
(Gallahue & Ozmun, 2006).  Mean body mass index (BMI) was 24.7, which is considered 
‘normal’ (WHO, 2012).  The oldest participant was 84 years.  The youngest participant was 
56 years (table 4.2).  
 
Table 4.2 
Anthropometric and descriptive statistics of the participants with COPD  
Descriptor Mean SD  
Age (years) 69 8  
Stature (m) 1.7 0.9  
Mass (kg) 83.9 19.2  
BMI (kg.m
-2
) 24.7 5.1  
Pack Years 53 48  
SBP (mmHg) 136 15  
DBP (mmHg) 73 11  
Resting HR (beats.min
-1
) 81 12  
Predicted maximum HR (beats.min
-1
) 148 7  
HRR (Karvonen) 67 14  
Note: N = 17 (four females, 13 males).  BMI: body mass index. 
 
Pack years: product of 
packets of cigarettes per day across years (i.e., one pack year = 365 packets of cigarettes).  
Pack years range was 10.5 to 140 pack years.  SBP: systolic blood pressure.  DBP: diastolic 
blood pressure.  HR: heart rate.  HRR: heart rate reserve with the Karvonen method.  
 
 
According to GOLD (2007), 14 participants were affected by moderate Stage II COPD (table 
4.3).  Mean FEV1 was less than 80% predicted.  Mean FER was less than 70%.  Three 







Table 4.3  
Spirometry descriptors of the participants with COPD prior to and after bronchodilator 
medication 
Descriptor  Pre Post  
 Mean SD 95% CI Mean SD 95% CI 
FEV1 (L BTPS) 1.4 0.5 ± 1.0 1.6 0.6 ± 1.2 
FEV1 % predicted 52.1 17.5 ± 34.3 58.2 19.4 ± 38.0 
FVC (L BTPS) 2.8 0.8 ± 1.6 3.1 0.8 ± 1.6 
FVC % predicted 80.3 16.1 ± 31.6 84.5 17.3 ± 33.9 
FER % 52.0 13.7 ± 26.9 52.7 11.8 ± 23.1 
PEF (L.sec
-1
) 3.8 1.4 ± 2.7 4.2 0.9 ± 1.8 
Note: Three participants were classified as severe Stage III COPD.  FEV1: forced expired 
volume of oxygen in the first second.  FVC: forced vital capacity of the lungs.  FER: forced 
expiratory ratio (FEV1.FVC
-1
).  PEF: peak expiratory flow.  L BTPS: Litres Body 
Temperature Pressure Saturated.  Pre: before 0.3 mg Salbutamol inhalation.  Post: 15 minutes 
after 0.3 mg Salbutamol inhalation.  95% CI: confidence interval [ (SD)]  
 
 
Selected psychological and physiological responses to a single session of WBV are shown in 
table 4.4.  There was a moderate effect of WBV on rating of perceived dyspnoea (t = 4.01, df 
= 16, p = 0.01).  With the Borg CR-10 VAS, rating of perceived dyspnoea increased from 
‘very slight’ to ‘slight’.  There was a large effect of WBV on heart rate (t = 10.8, df = 16, p = 
0.01, Cohen’s d = 0.91).  Resting HR was 55% of predicted maximum and 62% during WBV.  
Heart rate reserve was 16% (± 29%) during WBV; the range was 6 to 38%.  Saturation of 









Effects of WBV on rating of perceived dyspnoea, heart rate, and saturation of haemoglobin 
Dependent Variable Mean 
 
SD 95% Confidence 





Borg CR-10 baseline 1 2 0 2 1 0.01 0.55 
Borg CR-10 during WBV 2 2 1 3    
HR baseline (beats.min
-1
) 81 12 75 87 11 0.01 0.91 
HR during WBV (beats.min
-1
) 92 13 85 99    
SpO2  baseline (%)  97 2 96 97 -1 0.08 0.55 
SpO2  during WBV (%) 96 2 95 97    
HRR % 16 29      
Note: Effect size is Cohen’s d where 0.2 was considered small, 0.5 moderate and > 0.8 large 
effect (Winer, Brown & Michels, 1991).  SpO2: saturation of haemoglobin.  HR:  heart rate.  





In this first major study, the safety of WBV was explored via selected psychological and 
physiological responses to exercise.  Three major findings emerged to support the safeness of 
WBV for people with COPD: (1) WBV was associated with a minimal increase in rating of 
perceived dyspnoea from ‘very slight’ to ‘slight’ with moderate effect, (2) WBV was 
associated with an increased heart rate 7% higher than resting with large effect, and (3) WBV 
was associated with a minimal reduction of 1% in saturation of haemoglobin.   
 
Dyspnoea 
In this research, a single session of WBV was associated with an increase in dyspnoea from 1 
‘very slight’ at baseline to 2 ‘slight’ during the final WBV bout for people with COPD.  The 




Resistance training increased Borg CR-10 to a value of 3 ‘moderate’ after three sets of 10 to 
12 repetitions for people with moderate Stage II COPD (Panton et al., 2004).  Treadmill 
walking to subjective exhaustion caused dyspnoea to increases to 4 ‘somewhat severe’ on the 
Borg CR-10 scale for moderate Stage II COPD participants (Clark et al., 2000).  The six-
minute walk test also raised dyspnoea to the same value of ‘4’ (Breyer et al., 2010).  
Dyspnoea was perceived to be as high as a value of 7 ‘very severe’ during 70 to 80% peak 
limit of tolerance cycling among people with Stage III COPD (Oliveira et al., 2010).  The 
habitual sustainability of exercise that can cause dyspnoea to rise to levels perceived as 
‘severe’ and above could however, be questioned.  
 
At baseline, the participants of this research perceived ‘very slight’ dyspnoea.  In another 
study, people with moderate Stage II COPD perceived dyspnoea as ‘slight’ during a similar 
period of rest (Pickard, Yang & Lee, 2011).  Within the patients with moderate Stage II 
COPD, FEV1 was 65.5% predicted (± 9.1%), while in the current study FEV1 was 52.1% 
predicted (± 17.5%).  The broader distribution of the spirometry data about the mean in the 
current research vary because Stage II and Stage III participants were analysed collectively.  
Although COPD disease severity affects physical activity participation (Garcia-Aymerich et 
al., 2006), the clinical merit of ‘slight’ and ‘very slight’ dyspnoea could be negligible.   
 
In a recent study, people with severe Stage III COPD perceived resting dyspnoea as ‘slight’, 
increasing to ‘severe’ after three minutes of self determined ‘fast paced exercise’ (O’Driscoll, 
Neill, Pulakal & Turkington, 2011).  Despite a definition of ‘fast paced’, the exact protocol of 
exercise was lacking.  It seems that an increased level of perceived breathlessness among 




conditioning.  Furthermore dyspnoea classified as ‘severe’ can be expected during physical 
activity.  
 
Possible Mechanisms of Increased Dyspnoea with WBV  
The mechanism for increased dyspnoea can partly be attributed to oxygen demand of the task 
and supply of oxygen through the respiratory system (i.e., emphysematous change).  Given 
that many factors affect dyspnoea such as systemic inflammation, diet, oxygen supply at the 
cellular level, and diffusing capacity (Serres et al., 1998; Debigaré, Côté & Maltais, 2001; 
Augusti, et al., 2003; GOLD, 2007; Wüst & Degens, 2007), essentially, limitation of 
“exertional dyspnoea” during physical activity is primary for both pharmacological and non-
pharmacological interventions among people with COPD (Nishiyama, Taniguchi, Kondoh, 
Kimura, Kato, Ogawa, et al., 2007, p 834).  However, this research could only allow 
speculative comment about mechanisms of dyspnoea because none of the aforementioned 
variables were quantified.    
 
Heart Rate and Saturation of Haemoglobin 
COPD 
In this research, heart rate increased from 81 beats.min
-1
 at baseline to 92 beats.min
-1
 during a 
single session of WBV.  Observation of increased heart rate is supported by other research 
using exercise modes of various intensities in people with COPD.  For people with moderate 
Stage II COPD, combined resistance training and aerobic conditioning increased heart rate to 
125 beats.min
-1
 (Panton et al., 2004).  For people with severe Stage III COPD, heart rate 
increased from 86 to 99 beats.min
-1
 after self determined ‘fast paced exercise’ (O’Driscoll et 
al., 2011) and to 115 beats.min
-1




on the Borg CR-10 scale to ‘severe’ (Martin & Davenport, 2011).  It may be that the increase 
in heart rates observed in this research can be attributed to an ‘exercise’ effect of WBV that is 
commonly associated with resistance training and aerobic conditioning. 
 
Concurrently, saturation of haemoglobin significantly reduced to 90% during perceived 
‘severe’ aerobic conditioning, yet those data were considered safe and standard for exercise 
training for people with COPD (Martin & Davenport, 2011).  Other physical activity modes 
have reduced saturation of haemoglobin to 89% for people with COPD (Oliveira et al., 2010; 
O’Driscoll et al., 2011).  Results from this research show saturation of haemoglobin was not 
significantly reduced (∆ mean 1%, p = 0.08).  Saturation of haemoglobin was reduced from 
97 to 96% during WBV however, the clinical significance may be negligible despite the 
moderate effect size.  Given the negative correlation of diffusing capacity and saturation of 
haemoglobin (West, 2008), the slight reduction of SpO2 was expected.  Contemporary safety 
recommendations are that exercise should be terminated if saturation of haemoglobin reduces 
to ≤ 85% (Poulain et al., 2003; Jenkins, Hill & Cecins, 2010).  The effect of WBV on 
saturation on haemoglobin in this study remained below the threshold of safe exercise. 
 
WBV 
For participants in this research %HRR was 16% during WBV.  The result was similar to a 
study of heart transplant recipients, in whom %HRR during WBV was 14% (Crevenna et al., 
2003).  Interestingly, for community dwelling older adults, HRR during synchronous WBV 
increased to as much as 62% (Bogaerts, Delecluse, Claessens, Troosters, Boonen & 




vibration platform that may have concurrently affected the results.  The participants with 
COPD in this research maintained a static isometric squat. 
 
The gravitational force of the vibration platform in this research was ~2.52 g.  For non-
community dwelling older adults, heart rate increased to 135 beats.min
-1
 when the 
gravitational force was 9.5 g (Bruyere et al., 2005).  Exposure to WBV at 8 g in healthy adults 
elicited a %HRR to 8% (Jacobs & Burns, 2009).  It may be that irrespective of gravitational 
force and health status, WBV elicited physical stress on the body that stimulated responses 
synonymous with exercise.  Muscular contraction about the lower limbs quantified by EMG, 
for example, significantly increased during WBV (Bosco, Cardinale & Tsarpela, 1999; 
Rittweger, Mutschelknauss & Felsenberg, 2003; Di Giminiani et al., 2009).  As such, 
increased muscular activity during WBV increased oxygen uptake and heart rate (Rittweger, 
Beller & Felsenberg, 2000). 
 
Nevertheless, it is suspected that high gravitational forces caused by WBV could damage 
fragile bones (Kiiski et al., 2008).  Subsequently, the appropriateness of prescribed doses of 
WBV should be at the forefront of exercise intervention planning for people with COPD.  
Perhaps due to long term medication (e.g., corticosteroids), limited mobility, or other 
physiological or lifestyle related factors, people with moderate Stage II COPD are known to 
have lower bone mineral density than healthy matched controls (Dam, Harrison, Fink, 
Ramsdell & Barrett-Connor, 2011; Duckers, Evans, Fraser, Stone, Bolton & Shale, 2011).  
Bone fragility therefore becomes an important consideration with WBV for people with 





Rating of perceived dyspnoea may also increase during exercise due to uncontrolled 
psychological factors.  As such, the Borg CR-10 VAS has been limited when participants 
have used the scale with an inconsistent procedure (Shen & Parsons, 1997).  That is, mean 
ratings were confounded with dyspnoea and intra-individual variability.  Recently though, the 
Borg CR-10 VAS was strongly correlated to leg fatigue during exercise for healthy young 
adults (Borg et al., 2010).  It was noted that during moderate to strong intensity exercise, for 
people with COPD, symptom limited dyspnoea may be the major cause of discomfort rather 
than leg fatigue (Borg et al., 2010).  For participants in this research however, the intensity of 
exercise was low, which was associated with a minimal increase in rating of perceived 
dyspnoea during WBV.  
 
This research associated WBV to increase dyspnoea.  Although to a lesser extent than other 
modes of exercise (Breyer et al., 2010; Oliveira et al., 2010), a single session of WBV in this 
research may have increased oxygen uptake for people with COPD.  This may be because an 
increase in oxygen demand is expected during WBV with a static stance posture (Rittweger, 
Schiessl & Felsenberg, 2001).  Specifically, static stance WBV increased oxygen uptake 








 in healthy adults (Rittweger, Schiessl & 
Felsenberg, 2001).  That was equivalent to a rise in energy expenditure of 1.5 MET 
(metabolic equivalents) to 2.9 MET.  Recently 2.9 MET is the upper threshold of low 
intensity physical activity for older adults (Borjesson, Urhausen, Kouidi, Dugmore, Sharma, 
Halle et al., 2011).  The long-term effect of WBV on oxygen uptake for healthy older adults 






The aforementioned studies (Rittweger, Schiessl & Felsenberg, 2001; Bogaerts et al., 2009) 
show an immediate effect of WBV on selected physiological responses to exercise, and a 
long-term effect of WBV on the cardiovascular system.  The gravitational force of those two 
studies was not less than 2.9 g.  The gravitational force of WBV in this research was ~2.5 g.  
Quantification of oxygen uptake was not possible because data were collected in a community 
setting in this research.  However, the rise in dyspnoea may be attributed to greater oxygen 
demand associated with WBV even though the gravitational force was lower than had been 
used for other interventions.  The notion of increased energy demands with low intensity 
WBV (i.e., ~2.5 g) is supported by the observed increase of heart rate of people with COPD.  
Given the results of this research, it is possible that a cardiovascular stimulus may be elicited 
by exposure to low intensity WBV.  
 
Limitations and Considerations 
This research was limited because current medication (other than bronchodilators and 
corticosteroids) and history of medication were neither recorded nor controlled.  Rather, the 
priority was given to recruitment of participants whose COPD is stable.  Specifically, 
participants were ‘well’ medicated in order to avoid potential exacerbations, and may have 
influenced the effects of WBV.  However, being ‘well’ medicated during WBV has been 
observed in a population living in sub-optimal health (Crevenna et al., 2003).  Similarly, it is 
likely that people managing their COPD in the community would medicate responsibly to 






External validity was considered carefully before the conduct of this research.  Given this 
research targeted a population living in sub-optimal health, the validity of everyday 
pharmacologic management would be sacrificed if participants were to be deprived normal 
pharmacologic care.  Normal daily practices in COPD management had to be well 
represented, as well as the strong ethical decision of not interfering with usual care. 
Furthermore, considering the mantra ‘first do no harm’, WBV for people with COPD needed 
to be cautiously introduced.   
 
The effect of sitting and standing postures on heart rate should be considered.  Heart rate is 
shown to increase as much as 22 beats.min
-1
 once an individual stood (MacWilliams, 1933; 
Rittweger, Beller & Felsenberg, 2000; Martinmäki, Häkkinen, Mikkola & Rusko, 2008) and 
can be broadly explained by changes in blood pressure and other autonomic nervous system 
mechanisms.  A similar change in heart rate was quantified in this research.  It may be that the 
task of standing on the vibration platform increased heart rate rather than WBV.  Perhaps 
there was a concurrent effect of standing and WBV on heart rate.  This research was limited 
because only resting sitting heart rate data were collected and then compared with standing 
heart rate data during WBV.  Further study is needed to describe the independent effects of 
standing and WBV on heart rate to understand effects of WBV for people with COPD.  
However, a placebo design could also be used to describe the effect of WBV on standing 
heart rate to address the limitation. 
 
Body mass index of participants in this research was ‘normal’.  Considering the global trend 
of obesity as estimated by BMI, subsequent studies of WBV and people with COPD may 
draw participants classified as ‘overweight’ and ‘obese’.  Recently, people with and without a 




distance (Bautista, Ehsan, Normandin, Zuwallack & Lahiri, 2011), although relative to body 
mass, measures of respiration (respiratory rate, EO2, RER) were the same.  Similarly aerobic 
conditioning (80% limit of tolerance) of ‘normal’, ‘overweight’ and ‘obese’ people with 
COPD elicited different effects on performance, though relative to body mass, magnitude of 
performance improvement was the same (Sava, Laviolette, Bernard, Breton, Bourbeau & 
Maltais, 2010).  Regardless of BMI, people with COPD respond safely to exercise 
interventions, with exacerbations of the disease rarely elicited (GOLD, 2007; McKenzie, 
Abramson, Crockett, Glasgow, Jenkins, McDonald et al., 2007; Grove, 2010).  While 
cognisant of co-morbidities and contraindicators of COPD, future studies involving WBV 
should be considered to beneficially affect exercise tolerance, avoid exacerbations of the 
disease, and possibly, improve functional performance of the lower limbs.  
 
4.6 Summary 
This was the first study to quantify and describe effects of a single exercise session of WBV 
on selected psychological and physiological responses to exercise for people with COPD with 
the aim to quantify safety of WBV.  The specific aim was to quantify several markers of 
safety surrounding the use of WBV.  For the participants of this research, considering the 
nature of COPD and the known contraindications of the disease, a single session of WBV was 
associated with markers of psychological and physiological safety.  Negligible changes in 
dyspnoea, saturation of haemoglobin, and heart rate during the single session of WBV were 
expected and support the use of WBV as a safe mode of exercise for people with COPD.   
Furthermore, changes of the markers of safety compared with resting results did not exceed 





Given the data were collected in the home of each participant with COPD, this research is 
unique.  Whole-body vibration can be safely completed in the home of the individual with 
moderate, but likely negligible effect on dyspnoea (table 4.5).  Modes of exercise that can 
beneficially affect, or at least maintain exercise tolerance, avoid exacerbations, and improve 
functional performance of the lower limbs of people with COPD is salient.  Further study of 
community based WBV and effects on exercise tolerance and functional performance of the 
lower limbs of people with COPD should be conducted to establish efficacy, because results 
of this research support the use of WBV as a safe mode of exercise for people with COPD.  
 
Table 4.5 
Summary of research hypothesis and decision after inferential statistical analyses 
Research Hypothesis Accept Reject Data Interpretation 
WBV will increase Borg CR-10   Increased from 




people with COPD 
 
WBV will increase HR   Increased 7%  Within safe responses 
reported of other 
exercise modes for 
people with COPD 
 
WBV will reduce SpO2   Reduced 1% Negligible clinical 
significance for 









CHAPTER  5. MAJOR STUDY 2: EFFICACY OF WBV ON EXERCISE 
TOLERANCE AND FUNCTIONAL PERFORAMCE OF THE LOWER 
LIMBS OF PEOPLE WITH COPD 
 
5.1 Introduction 
Following on from the safe WBV protocol for people with COPD identified with major study 
1 (Chapter 4), a second study (major study 2) was conducted.  The general aim of this 
research was to advance knowledge of effects of WBV on exercise tolerance and functional 
performance of the lower limbs of people with COPD in a community setting.  Achieving the 
general aim of this research would determine efficacy of a WBV intervention to: (1) effect 
exercise tolerance while avoiding exacerbations of COPD that add to physical inactivity, and, 
(2) improve performance of ADLs of people with COPD.  This research is registered with the 
Australian New Zealand Clinical Trials Registry, ANZCTR12612000508875:  
http://www.ANZCTR.org.au/ACTRN12612000508875.aspx 
 
To meet the general aim, participants were allocated to: (1) a six week WBV intervention, and 
then (2) a six week PLACEBO intervention.  A two-week wash out interval interspersed the 
WBV and PLACEBO interventions.  Given the nature of COPD, and exacerbations expected 
of it, this research was designed as a community based efficacy trial and was not conducted as 
a randomised controlled trial.  For each intervention, data were collected at baseline and 
subsequent fortnights over the 14 week intervention period (i.e., pre-test, mid-test, and post-
test).  The methods described in Chapter 3 were used for major study 2 (i.e., selection criteria, 
selection criteria protocol, instruments, and data collection).  Although this research was not 




reporting of randomised controlled trails) is generated to describe enrolment, intervention 
allocation, and analysis (Moher, Schultz, Altman & the CONSORT Group, 2001) (figure 5.1).   
 
The multiple challenges of participant recruitment are presented in Appendix M.  Specifically, 
substantial effort was taken over a 24 month period to recruit participants for the 14 week 
community based efficacy trial through modes including: (1) hospital outpatient clinics, (2) 
private practice respiratory specialists, (3) community support networks, and (4) public 
information sessions.  As such, being enrolled at a university without direct clinical links was 
problematic and time inefficient, but not insurmountable once a link was established with the 
Monash Medical Centre.  Despite the multiple challenges presented in Appendix M, results of 
this research were robust because: (1) the sample sizes of the primary dependent variables 
were met with calculations based about an almost identical WBV intervention (i.e., Furness & 
Maschette, 2009), (2) the participants acted as their own control group because of the cross-
over design of this research, and (3) the number of datum to dependent variable for each 






























Figure 5.1. Flow of participation in the study based on the CONSORT flow chart for 
reporting randomised controlled trails. 
Analysed for WBV (n = 16) 
 Excluded from analysis (n = 0) 
Analysed for PLACEBO (n = 11) 
 Excluded from analysis (n = 0) 
 
Assessed for eligibility (n = 16) 
 
Allocated to six week PLACEBO intervention (n = 11)  
(m = 8, f = 3) 
 Received allocated intervention (n = 11) 
 
Excluded (n = 4) 
 Not meeting inclusion criteria (n = 1) 
 Declined to participate (n =1) 




Allocated to six week WBV intervention (n =16) (m = 12, f = 4) 
 Received allocated intervention (n = 16) 
Enrolment  Monash Medical Centre, Department of Respiratory and Sleep 
Medicine COPD data base (n = 600) 
 
 Moderate Stage II COPD in metropolitan Melbourne and 
the Mornington Peninsula (n = 50) 
 Responded to mail out (n = 20) 
Allocation 
Wash-out (2 weeks), then cross-over from WBV to PLACEBO 
 Lost to follow up (n = 2) 
 Discontinued involvement (n = 3) 
o Relocation (n = 1) 
o Illness of spouse (n = 1) 





Research Hypotheses (from Chapter 2) 
The following research hypotheses were tested to determine efficacy of WBV on exercise 
tolerance and functional performance of the lower limbs of people with COPD: 
 
Exercise Tolerance 
HI: For people with COPD, a six week WBV intervention; two sessions per week of 
five 60 second bouts interspersed with 60 seconds passive rest will: (1) acutely 
increase dyspnoea during a WBV bout, (2) not elicit a long-term change of dyspnoea 
quantified with the Borg CR-10 visual analogue scale, (3) acutely increase heart rate 
and reduce saturation of haemoglobin during a WBV bout, and, (4) not elicit a long-
term change of heart rate and saturation of haemoglobin. 
HI: For people with COPD, there will be a difference among a six week WBV 
intervention and a six week PLACEBO intervention (two sessions per week of five 60 
second bouts interspersed with 60 seconds passive rest) for dyspnoea, heart rate and 
saturation of haemoglobin. 
Functional Performance 
HI: For people with COPD, a six week WBV intervention; two sessions per week of 
five 60 second bouts interspersed with 60 seconds passive rest will improve: (1) 
performance of the timed-up-and-go test, (2) performance of the 5-chair stands test, 
and, (3) stride time, stride length and stride velocity quantified with a portable 
electronic walkway. 
HI: For people with COPD, a six week WBV intervention will improve functional 









Participants were recruited from the Department of Respiratory and Sleep Medicine, Monash 
Medical Centre.  The Department patient database was accessed by the Clinical Trials 
Manager.  The Clinical Trials Coordinator sent an information letter to potential participants 
whom were then invited to record their interest in the study by contacting the student 
researcher (Appendix F).  Medical consent was complicit within the approval of this research 
by the Department Head (Professor Philip Bardin).  The Australian Catholic University 
Human Research Ethics Committee (Appendix G) and the Southern Health Human Research 
Ethics Committee A (Monash Medical Centre) (Appendix H) approved the procedures.  A 
convenient sample of 16 community dwelling adults with COPD provided voluntary informed 
consent to participate (mean ± SD age = 72 ± 7 years, stature = 1.7 ± 0.1 metres, body mass = 




Data were collected in the 16 participants’ homes.  The community setting was selected ahead 
of the University laboratory and the Monash Medical Centre because: (1) the home was more 
suited to the convenience of the participant, (2) space within the Monash Medical Centre was 




COPD had been established after major study 1, and (5) a home-based protocol would 
maximise compliance. 
  
To describe effects of the test procedure on day to day variation of dyspnoea a one-way 
ANOVA was computed for PLACEBO intervention data.  It was important to know that 
changes in dyspnoea may be associated with WBV rather than the demand of completing the 
test procedure.  Data were collected with the Borg CR-10 VAS in Week 9 immediately after: 
(1) the 5-chair test but prior to the first PLACEBO bout, (2) the gait trials but prior to the first 
PLACEBO bout, and, (3) during a PLACEBO bout.  There was no effect of the test procedure 
on dyspnoea (F(2,30) = 0.62, p = 0.55).   
 
Independent and Dependent Variables 
The independent variables were ‘intervention’ with two levels: (1) WBV and, (2) PLACEBO 
and ‘test occasion’ with three levels: (1) pre-test, (2) mid-test, and (3) post-test.  The 
dependent variables were selected variables of: (1) exercise tolerance (rating of perceived 
dyspnoea, heart rate, and saturation of haemoglobin), and (2) functional performance (TUG 
test, 5-chair test, stride length, stride time, and stride velocity). 
 
The Borg CR-10 VAS (Appendix J) was used to quantify the perceived level of breathing 
limitation.  Heart rate, saturation of haemoglobin and blood pressure were quantified with the 
CARESCOPE™ V100 Vital Sign Monitor (GE Health Care, Milwaukee, USA).  Reliability 
of the test procedures was no less than ‘acceptable’ (ICC ≥ 0.700, Chapter 3) for the three 




Selected dependent variables of functional performance (i.e., TUG test, and 5-chair test) were 
quantified with a stop-watch.  Kinematic variables of gait: stride length, stride time, and stride 
velocity were quantified with the GAITRite® Electronic Walkway (CIR Systems Inc, 
Peekskill, USA).  Reliability of the test procedures was no less than ‘good’ (ICC ≥ 0.881, 
Chapter 3) for the five dependent variables. 
  
Data of all dependent variables were collected to quantify at least one of three different data 
classifications: (1) long-term, (2) instantaneous, and (3) acute (table 5.2).  Long-term data 
were collected at least 48 hours after a WBV bout (Cochrane, Legg & Hooker, 2004; Furness 
& Maschette, 2009).  Instantaneous data were collected during the final WBV bout (after 30 
seconds of the 60 second bout).  Acute data were collected within two minutes of a completed 
WBV bout (Cardinale & Lim, 2003; Humphries et al., 2004).   
 
Data were collected with the same procedure for each occasion (table 5.1).  For long-term 
data, exercise tolerance data were collected first, followed by functional performance data.  
The procedures were designed to ensure that the most physically exertive test was completed 
last (i.e., the 5-chair test).  Data collection of the PLACEBO intervention was identical to the 










Data collection procedure showing long-term, instantaneous, and acute variables for the WBV 
intervention and washout period 
Occasion Session Variable Data 




































































Note: Gait: stride length, stride time, and stride velocity. SpO2: saturation of haemoglobin.  








The WBV intervention consisted of 12 WBV sessions over a consecutive six week period.  
The participants completed two vibration sessions per week interspersed with at least 48 
hours.  The session frequency was determined using past work by the student researcher of 
healthy community dwelling older adults as a guide (Furness & Maschette, 2009; Furness, 
Maschette, Lorenzen, Naughton & Williams, 2010).  The results show no main effect among 
two and three vibration sessions per week, though both session frequencies were significantly 
more effective than one session per week to improve functional performance of the lower 
limbs over a six week WBV intervention (Furness & Maschette, 2009). 
 
In this research, a WBV session consisted of five, 60 second vibration bouts interspersed with 
60 seconds of passive rest.  Evidence suggests the test procedure was safe for people with 
COPD (Chapter 4).  The design of the intervention is shown in table 5.2.   
 
Table 5.2 





































Note: pre-test: data collected before the first WBV or PLACEBO bout and immediately after 
the final bout.  mid-test: data collected before the seventh session of the WBV or PLACEBO 
intervention and immediately after the final bout of the sixth session.  post-test: data collected 
immediately after the final bout of the twelfth session of the WBV or PLACEBO intervention 








The vibration platform and skidding method used in major study 1 was also used for the 
WBV intervention of major study 2 (Chapter 4, pages 133 to 134).  A prototype vibration 
platform was developed to deliver the PLACEBO intervention (Appendix N).  For each 
PLACEBO vibration bout, the selected vibration platform frequency was 25 Hz and peak-to-
peak displacement was ~0.0 mm, peak acceleration was ~0.00 m.s
-2
, gravitational force was 
~0.0 g (cognisant that the Earth’s gravitational force is constant 1.0 g).  Foot placement 
(second toe) was equidistant, 20 cm from the axis of rotation.  The participants wore flat soled 
shoes.  When the vibration platform was operational, the participants could hear the motor 
running and may have felt vibration.  Participants were told the PLACEBO intervention was 
an “ultra-low frequency” vibration intervention that is “very different” to the WBV 
intervention.   
 
Participants were told to stand with a bent knee posture that could be maintained for the 
duration of each WBV and PLACEBO bout.  The procedure was based on evidence that 
transmission of WBV about the knee of healthy young adults was not different for 20, 40 and 
60° knee flexion (Chapter 3, section 3.3).  Knee flexion was checked manually with a 
goniometer after 30 seconds of every bout with the procedure described in Chapter 3 (section 
3.3).  During WBV, the participants stood with the knees flexed to 53º (SD ± 10º).  During 








Data of dependent variables of exercise tolerance and functional performance: rating of 
perceived dyspnoea, heart rate, saturation of haemoglobin, TUG test, and 5-chair test were 
recorded with pen and paper, then transposed to a SPSS for Windows spread sheet (SPSS 
Version 19.0, Chicago IL™).  Functional performance gait data were imported to SPSS from 
the GAITRite software package.  After calculation, with 0.90 power, sample size was 
estimated to be n < 10 for the TUG test and n = 16 for the 5-chair test (Chapter 3, section 3.5).        
 
Descriptive Statistics 
Descriptive statistics were calculated for all participants.  All data were checked for normal 
distribution with methods previously described (Bluman, 1997; Macellari, Giacomozzi & 
Saggini, 1999; Vincent, 1999; Portney & Watkins, 2000; Coakes, Steed & Dzidic, 2006).  The 
assumptions of normality are described in Chapter 3 (section 3.6).  
 
Inferential Statistics 
To test the research hypotheses of major study 2, parametric statistical methods were used to 
calculate inferential statistics.  Repeated measures analysis of variance (RM-ANOVA) with 
repeated contrasts (WBV - Week 1 to Week 3; Week 3 to Week 6; PLACEBO - Week 9 to 
Week 11, Week 11 to Week 14) were computed for the dependent variables (rating of 
perceived dyspnoea, heart rate, saturation of haemoglobin, TUG test, 5-chair test, and gait 
variables).  Despite a washout period, the RM-ANOVA was more appropriate than several 
one-way ANOVAs or a multivariate ANOVA because data were collected of the same 
participants across the WBV and PLACEBO interventions (personal correspondence with 




difference post-hoc comparisons were computed for WBV intervention and PLACEBO 
intervention to compare long-term with acute data.   
 
5.3 Results 
Participants’ anthropometric and selected descriptors are shown in tables 5.4 and 5.5. 
Descriptive and inferential statistics to test the research hypotheses are shown to describe 
efficacy of WBV on exercise tolerance and functional performance of the lower limbs of 
people with COPD in tables 5.6 through 5.9.  Raw data are shown in Appendix O. 
 
Descriptive Statistics of Participants 
Of the four females and 12 males recruited to this research, the youngest person was 56 years 
and the oldest 83 years.  Mean BMI was 29.3 kg.m
-2
, which is within the ’normal’ range 
(WHO, 2012).  The range of age in years was 56 to 84 years (table 5.3). 
 
The method of Miller et al. (2005), described in Chapter 3 (section 3.4) was used for 
spirometry testing.  According to GOLD (2007), the participants were affected by ‘moderate’ 
Stage II COPD.  Mean FEV1 was less than 80% predicted.  Mean FER was less than 70%.  
No participants were using supplemented oxygen therapy as part of usual care.  One 








Anthropometric and descriptive statistics of the participants with COPD at baseline 
Descriptor Mean SD 
Age (years) 72 7 
Stature (m) 1.71 0.1 
Mass (kg) 85.7 20.4 
BMI (kg.m
-2
) 29.3 6.1 
Pack Years 52 45 
SBP (mmHg) 139 13 
DBP (mmHg) 75 10 
Resting HR (beats.min
-1
) 82 10 
Predicted maximum HR (beats.min
-1
) 148 7 
HRR (Karvonen) 67 11 
Note: N = 16 (4 females, 12 males).  BMI: body mass index. 
 
Pack Years: product of packets 
of cigarettes per day across years (i.e., one pack year = 365 packets of cigarettes).  Pack years 
range was 10.5 to 140 pack years.  SBP: systolic blood pressure.  DBP: diastolic blood 
pressure.  HR: heart rate.  HRR: heart rate reserve with the Karvonen method.  
 
 
Table 5.4  
Spirometry descriptors of the participants with COPD (one participant was classified as 
severe Stage III COPD) 
Descriptor  Pre Post 
 Mean SD 95% CI Mean SD 95% CI 
FEV1 (L BTPS) 1.5 0.5 ± 1.0 1.7 0.7 ± 1.4 
FEV1 % predicted 53.0 16.7 ± 32.7 58.5 19.0 ± 37.2 
FVC (L BTPS) 2.8 0.7 ± 1.3 3.0 0.8 ± 1.6 
FVC % predicted 78.5 13.3 ± 26.1 83.2 15.0 ± 29.4 
FER % 52.0 13.8 ± 27.0 52.3 10.8 ± 21.2 
PEF (L.sec
-1
) 3.8 1.4 ± 2.7 4.2 0.8 ± 1.6 
FEV1: forced expired volume of oxygen in the first second.  FVC: forced vital capacity of the 
lungs.  FER: forced expiratory ratio (FEV1.FVC
-1
).  PEF: peak expiratory flow.  L BTPS: 
Litres Body Temperature Pressure Saturated.  Pre: before 0.3 mg Salbutamol inhalation.  Post: 






Effects of WBV and PLACEBO Interventions on Exercise Tolerance of People with 
COPD 
Effects of the independent variable ‘test occasion’ were computed with repeated measures 
ANOVA with repeated contrasts of long-term and instantaneous results of each intervention 
on exercise tolerance.  Test occasion and intervention results are shown in table 5.5.  Data 
were collected to show a potential ‘training’ and/or ‘placebo’ effect of WBV.  The long-term 
data were collected at rest across each intervention.  The instantaneous data were collected 
during a WBV or PLACEBO bout.  Effects of the independent variable ‘test occasion’ on 
exercise tolerance (long-term data compared with instantaneous data) are shown in figures 
5.2, 5.3 and 5.4.  
 
There were no long-term, or instantaneous effects of WBV on rating of perceived dyspnoea 
and heart rate (p > 0.05) (table 5.5).  Dyspnoea was as high as ‘severe’, while the maximum 
heart rate was 115 beats.min
-1
.  However, repeated contrasts showed an interaction within 
Week 3 and Week 6 for instantaneous dyspnoea (F(1,15) = 4.63, p = 0.05, partial eta square = 
0.24, power 0.52).  A significant long-term effect of WBV was found on saturation of 
haemoglobin (F(2,30) = 8.33, p = 0.01).  The effect occurred within Week 3 and Week 6 in 
which saturation of haemoglobin reduced from 96 to 95% (p = 0.02, partial eta square = 0.31, 
power 0.69).  There was no instantaneous effect of WBV on saturation of haemoglobin 









Long-term and instantaneous effects of WBV and PLACEBO interventions on rating of 
perceived dyspnoea, heart rate, and saturation of haemoglobin of people with COPD 
Long- Term Intervention Dependent Variable Week 1 Week 3 Week 6 
 WBV Borg CR-10 1 ± 1 2 ± 1 1 ± 1 
  HR (beats.min
-1
) 82 ± 10 86 ± 11 83 ± 11 
  SpO2 (%) 97 ± 2 96 ± 2 95 ± 2* 
   Week 9 Week 11 Week 14 
 PLACEBO Borg CR-10 2 ± 1 2 ± 1 2 ± 1 
  HR (beats.min
-1
) 81 ± 13 83 ± 10 83 ± 11 
  SpO2 (%) 95 ± 2 96 ± 2 94 ± 2
‡
 
Instantaneous Week 1 Week 3 Week 6 
 WBV Borg CR-10 2 ± 2 1 ± 1 2 ± 1* 
  HR (beats.min
-1
) 92 ± 10 94 ± 12 95 ± 9 
  HRR 67 ± 11 63 ± 13 66 ± 13 
  HRR% 16 ± 6 14 ± 8 18 ± 7 
  SpO2 (%) 96 ± 2 96 ± 2 96 ± 1 
   Week 9 Week 11 Week 14 
 PLACEBO Borg CR-10 2 ± 2 2 ± 1 2 ± 1 
  HR (beats.min
-1
) 88 ± 13 88 ± 13 90 ± 8 
  HRR 64 ± 16 64 ± 15 66 ± 16 
  HRR% 7 ± 9 7 ± 10 11 ± 7 
  SpO2 (%) 96 ± 2 96 ± 1 95 ± 2 
Note: Data are mean ± SD.  * significant difference within Week 3 to Week 6 (p ≤ 0.05).  
‡ 
significant difference Week 11 to Week 14 (p ≤ 0.05).  SpO2: saturation of haemoglobin.  HR: 
heart rate.  HRR: heart rate reserve with Karvonen method.  HRR%: percentage of heart rate 
reserve.   
 
 
There were no long-term, or instantaneous effects of PLACEBO on dyspnoea and heart rate 
(p > 0.05) (table 5.6).  There was a significant long-term effect of PLACEBO on saturation of 
haemoglobin (F(2,20) = 6.02, p = 0.01).  The effect occurred within Week 11 and Week 14 in 
which saturation of haemoglobin reduced from 96 to 94% (p = 0.01, partial eta square = 0.52, 
power 0.84).  There was no instantaneous effect of PLACEBO on saturation of haemoglobin 




There was no mean difference of long-term compared with instantaneous dyspnoea (F(7,100) 
= 1.59, p = 0.15) and saturation of haemoglobin (F(7,100) = 1.20, p = 0.31) across the 14 
week efficacy trial.  Neither the WBV intervention nor the PLACEBO intervention caused an 
immediate rise in dyspnoea (figure 5.2) or reduction in saturation of haemoglobin (figure 5.3).   
 
 
Figure 5.2. Instantaneous effects WBV (blue) and PLACEBO (red) interventions on rating of 
perceived dyspnoea of people with COPD. Columns are mean data.  Error bars are one 


























Figure 5.3. Instantaneous effects WBV (blue) and PLACEBO (red) interventions on 
saturation of haemoglobin of people with COPD.  Columns are mean data.  Error bars are one 
standard deviation shown in the ‘positive’ direction. 
 
 
A main effect for heart rate occurred among the long-term and instantaneous data (F(7,100) = 
3.67, p = 0.01) (figure 5.4).  The WBV intervention immediately increased heart rate at Week 
1 (p = 0.01) and Week 6 (p = 0.01) compared with instantaneous data.  The PLACEBO 
intervention did not increase heart rate.  During the WBV intervention, heart rate mean 
difference was 10 beats.min
-1
 at Week 1, and 12 beats.min
-1
 at Week 6.  Mean difference was 
7 beats.min
-1

















Figure 5.4. Instantaneous effects WBV (blue) and PLACEBO (red) interventions on heart rate 
of people with COPD. Columns are mean data.  Error bars are one standard deviation shown 




































Effects of WBV and PLACEBO Interventions on Functional Performance of the Lower 
Limbs of People with COPD 
Effects of the independent variable ‘test occasion’ were computed with repeated measures 
ANOVA with repeated contrasts of long-term and acute results of each intervention on 
functional performance.  Test occasion and intervention results are shown in tables 5.6 
through 5.8.  Data were collected to show a potential ‘training’ and/or ‘placebo’ effect of 
WBV.  The long-term data were collected at rest across the two interventions.  The acute data 
were collected within two minutes of a completed WBV or PLACEBO session.  Effects of the 
independent variable ‘intervention’ on functional performance variables were analysed with a 
one-way ANOVA and least significant difference post-hoc comparisons were used to describe 
differences.  Intervention results are shown in figures 5.5 though 5.9.  
 
Long-term Effects on the TUG Test and 5-Chair Test  
There was a main effect of WBV on the TUG test (F(2,94) = 47.52, p = 0.01) and the 5-chair 
test (F(1.41,21.11) = 20.75, p = 0.01) (table 5.6).  Performance of the TUG test improved after 
the first six WBV sessions (Week 1 and Week 3 repeated contrast; p = 0.01, partial eta square 
= 0.28, power = 0.99), and second six WBV sessions (Week 3 and Week 6 repeated contrast; 
p = 0.01, partial eta square = 0.41, power = 1.00).  Performance of the 5-chair test also 
improved after the first six WBV sessions (Week 1 and Week 3 repeated contrast; p = 0.01, 
partial eta square = 0.50, power = 0.95), and second six WBV sessions (Week 3 and Week 6 






There was no effect of PLACEBO on performance of the TUG test (F(2,64) = 1.11, p = 0.34) 
and the 5-chair test (F(1.29,12.88) = 0.15, p = 0.76) (table 5.6).  The mean difference within 
the intervention was not more than ± 0.2 sec for both tests.  Overall, TUG test time reduced 
by 1.5 seconds and 5-chair stands test time reduced by 3.4 seconds after the six week WBV 
intervention.  Improvement of functional performance measured with simulated ADLs after 
WBV was maintained over the washout period and across the PLACEBO intervention.  
 
Table 5.6 
Long-term effects of WBV and PLACEBO interventions on functional performance of the 
lower limbs of people with COPD: Simulated ADLs 
Occasion TUG (sec) CHAIR (sec) 
 Mean SD 95% CI  Mean SD 95% CI  
* WBV      Week 1 11.3 1.9 ± 3.7  18.5 3.4 ± 6.7  
                  Week 3
+
 10.7 1.7 ± 3.3  16.4 2.7 ± 5.3  
                  Week 6
+
 9.8 1.9 ± 3.7  15.1 2.4 ± 4.7  
PLACEBO Week 9 10.8 2.2 ± 4.3  16.1 2.4 ± 4.7  
                  Week 11 10.7 2.0 ± 3.9  16.3 3.5 ± 6.8  
                  Week 14 10.6 1.7 ± 3.3  16.3 2.8 ± 5.5  
Note: n WBV = 16, n PLACEBO = 11.  * significant main effect after repeated measures 
ANOVA computation (p ≤ 0.05).  
+ 
significant difference after repeated contrast.  95% CI: 
confidence interval [ (SD)]. 
 
 
Figure 5.5 shows effects of both the WBV and PLACEBO interventions on TUG test time. 
Post-hoc comparisons revealed a reduction in performance after the six week WBV 
intervention (Week 6 and Week 9; mean increase in time = 1.0 seconds, p = 0.02).  
Performance of the 5-chair test was not different across the same time interval (Week 6 and 






Figure 5.5. Effects of the washout period on functional performance of the TUG test.  Week 6 
results were long-term, Week 9 results were prior to the first PLACEBO session.  Error bars 
are one standard deviation.  * indicates p ≤ 0.05 among Week 6 and Week 9 results. 
 
 
Figure 5.6. Effects of the washout period on functional performance of the 5-chair test.  Week 
6 results were long-term, Week 9 results were prior to the first PLACEBO session.  Error bars 












































Long-term Effects on Kinematics of Gait 
There was a main effect of WBV on stride length (F(1.48,244.07) = 50.21, p = 0.01) (table 
5.7).  Stride length was longer within Week 1 and Week 3 results (p = 0.01, partial eta square 
= 0.24, power = 1.00), and Week 3 and Week 6 results (p = 0.01, partial eta square = 0.36, 
power = 1.00).  There was no effect of PLACEBO on stride length (F(1.79,141.76) = 1.46, p 
= 0.24).  
 
There was a main effect of WBV on stride time (F(1.63,269.58) = 8.20, p = 0.01) (table 5.7).  
Stride time was faster within Week 1 and Week 3 results (p = 0.01, partial eta square = 0.14, 
power = 1.00), and Week 3 and Week 6 results (p = 0.01, partial eta square = 0.03, power = 
0.70).  There was no main effect of PLACEBO on stride time (F(1.78,140.41) = 2.32, p = 
0.11) although stride time was 0.1 sec faster within Week 9 and Week 11 results (p = 0.02, 
partial eta square = 0.07, power = 0.65). 
 
There was a main effect of WBV on stride velocity (F(1.35,223.37) = 323.17, p = 0.01) (table 
5.7).  Stride velocity increased within Week 1 and Week 3 results (p = 0.01, partial eta square 
= 0.72, power = 1.00), and Week 3 and Week 6 results (p = 0.01, partial eta square = 0.72, 








Long-term effects of WBV and PLACEBO interventions on kinematic variables of gait of 
people with COPD 








  Mean SD 95% 
CI 
Mean SD 95% 
CI 
Mean SD 95% 
CI 
WBV * Week 1 1.14 0.16 ±0.31 1.11 0.13 ±0.25 1.04 0.15 ±0.29 
 Week 3 
‡
 1.19 0.17 ±0.33 1.09 
‡
 0.12 ±0.24 1.10 
‡
 0.15 ±0.29 
 Week 6 
+
 1.27 0.11 ±0.22 1.10 
+
 0.06 ±0.12 1.16 
+
 0.11 ±0.22 
PLACEBO Week 9 1.22 0.11 ±0.22 1.03 0.10 ±0.20 1.19 0.15 ±0.29 
 Week 11
#
 1.20 0.13 ±0.25 1.02 
#
 0.09 ±0.18 1.18 0.15 ±0.29 
 Week 14 1.22 0.10 ±0.20 1.02 0.11 ±0.22 1.20 0.16 ±0.31 
Note: WBV n = 166 datum per test occasion, per variable.  PLACECO n = 80 datum per test 
occasion, per variable.  * significant main effect after repeated measures ANOVA (p ≤ 0.05).  
‡
 significant interaction Week 1 to Week 3 (p ≤ 0.05).  
+
 significant interaction Week 3 to 
Week 6 (p ≤ 0.05).  
#
 significant interaction Week 9 to Week 11 (p ≤ 0.05).  95% CI: 
confidence interval [ (SD)]. 
 
 
Acute Effects on Kinematics of Gait 
There was a main effect of WBV on stride length (F(1.45,248.97) = 143.34, p = 0.01) (table 
5.8).  Stride length was longer within Week 1 and Week 3 results (p = 0.01, partial eta square 
= 0.25, power = 1.00), and Week 3 and Week 6 results (p = 0.01, partial eta square = 0.34, 
power = 1.00).  There was a main effect of PLACEBO on stride length (F(2,150) = 4.48, p = 
0.01).  Stride length was shorter within Week 9 and Week 11 results (p = 0.01, partial eta 
square = 0.10, power = 0.83), and longer within Week 11 and Week 14 results (p = 0.03, 






There was a main effect of WBV on stride time (F(1.60,275.30) = 7.72, p = 0.01) (table 5.8).  
Stride time was faster within Week 1 and Week 3 results (p = 0.01, partial eta square = 0.14, 
power = 1.00).  There was a main effect of PLACEBO on stride time (F(1.75,148.11) = 4.66, 
p = 0.02).  Mean difference was a 0.20 sec reduction in time within the test occasions even 
though there were no differences in the contrast analyses (i.e., p > 0.05). 
 
There was a main effect of WBV on stride velocity (F(1.86,319.23) = 159.73, p = 0.01) (table 
5.8). Stride velocity increased within Week 1 and Week 3 results (p = 0.01, partial eta square 
= 0.29, power = 1.00), and Week 3 and Week 6 results (p = 0.01, partial eta square = 0.36, 
power = 1.00).  There was no effect of PLACEBO and test occasions for stride velocity 
(F(1.78,133.67) = 1.84, p = 0.17). 
 
Table 5.8 
Acute effects of WBV and PLACEBO interventions on kinematic variables of gait of people 
with COPD 








  Mean SD 95% 
CI 
Mean SD 95% 
CI 
Mean SD 95% 
CI 
WBV * Week 1 1.12 0.17 ±0.33 1.10 0.12 ±0.24 1.03 0.16 ±0.31 




 0.17 ±0.33 1.07
‡
 0.11 ±0.22 1.09
‡
 0.15 ±0.29 




 0.12 ±0.24 1.08 0.06 ±0.12 1.18
+
 0.13 ±0.25 
PLACEBO * Week 9 1.24 0.13 ±0.25 1.04 0.10 ±0.20 1.17 0.14 ±0.27 




 0.15 ±0.29 1.03 0.10 ±0.20 1.18 0.18 ±0.35 




 0.13 ±0.25 1.02 0.11 ±0.22 1.20 0.17 ±0.33 
Note: WBV n = 173 datum per test occasion, per variable. PLACECO n = 80 datum per test 
occasion, per variable. * significant main effect after repeated measures ANOVA (p ≤ 0.05).  
‡
 significant interaction Week 1 to Week 3 (p ≤ 0.05). 
+
 significant interaction Week 3 to 
Week 6 (p ≤ 0.05). 
#
 significant interaction Week 9 to Week 11 (p ≤ 0.05). 
$ 
significant 





There were main effects for long-term compared with acute stride length (F(11,1808) = 15.40, 
p = 0.01), stride time (F(11,1808) = 9.13, p = 0.01), and stride velocity (F(11,1808) = 30.92, p 
= 0.01) across all test occasions of the 14 week efficacy trial.  However, interaction among 
each test occasion of the 14 week efficacy trial was of specific interest rather than interaction 
across all weeks.  As such, there were no interactions among all test occasions (i.e., long-term 
compared with acute results for: Weeks 1, 3, 6, 9, 12, and 14 p > 0.05) for stride length 
(figure 5.7) and stride velocity (figure 5.9).  An interaction occurred among Week 6 stride 
times (p = 0.04) (figure 5.8).  As such, stride time was faster after the WBV session in Week 
6.  After the WASHOUT period, long-term and acute gait performance was unaffected (p > 
0.05). 
 
Figure 5.7. Effects WBV and PLACEBO interventions on stride length of people with COPD. 
Results were both long-term (blue) and acute (red).  Results are mean stride length.  Error 




























Figure 5.8. Effects WBV and PLACEBO interventions on stride time of people with COPD. 
Results were both long-term (blue) and acute (red).  Results are mean stride time.  Error bars 
































Figure 5.9. Effects WBV and PLACEBO interventions on stride velocity of people with 
COPD. Results were both long-term (blue) and acute (red).  Results are mean stride velocity.  





In this second major study, efficacy of a WBV intervention on exercise tolerance and 
functional performance of the lower limbs was explored by conducting a non-randomised 
placebo crossover trial of people with COPD.  Selected dependent variables specific to 
exercise tolerance (rating of perceived breathlessness, heart rate and, saturation of 
haemoglobin) and functional performance (simulated ADLs and walking gait) were quantified 
over a 14 week research period.  Prior to this 14 week research, pilot studies for validity and 



























safety of WBV for people with COPD was conducted.  After the acute safety of WBV as a 
mode of exercise for people with COPD was confirmed, four major findings of this research 
emerged to support efficacy of WBV: (1) the WBV intervention failed to negatively affect 
exercise tolerance, (2) the WBV intervention did not cause exacerbations of COPD that can 
limit participation in physical activity modes, (3) the WBV intervention improved functional 
performance of the lower limbs, (4) the effects of WBV on functional performance of the 
lower limbs were at least maintained eight weeks after the WBV intervention, and (5) the 
effects of a WBV intervention on exercise tolerance and functional performance of the lower 
limbs were not susceptible to a placebo effect.   
 
Exercise Tolerance 
In this research there were no long-term or instantaneous effects of WBV on exercise 
tolerance.  Exercise tolerance was maintained over the duration of this research.  The 
dependent variables of exercise tolerance quantified in the current research can be viewed in 
two perspectives: (1) exercise tolerance can describe the potential ‘fitness training’ effect of 
WBV to improve aerobic performance commonly associated with ‘exercise’, and (2) exercise 
tolerance can describe exacerbations of COPD over the duration of a WBV intervention.  In 
the first perspective, there was no ‘fitness training’ effect of a six week WBV vibration 
intervention on: (1) rating of perceived dyspnoea, (2) heart rate, and (3) saturation of 
haemoglobin.  Although significant poorer results of saturation of haemoglobin (table 5.6: 
Week 3 to 6 WBV: 1% reduction, Week 11 to 14 PLACEBO: 2% reduction) and rating of 
perceived dyspnoea were found (table 5.6: Week 3 to 6 WBV: ‘very slight’ to ‘slight’), a lack 
of clinical importance persists because the results of exercise tolerance were: (1) expected 
after major study 1, and (2) considered safe after comparison with another sample of people 




perspective, the results of this research are similar to other beneficial peripheral muscle 
training interventions among people with COPD. 
 
Fitness – Long-Term Compared with Instantaneous Results 
The negligible changes in exercise tolerance in this research do not follow the trend of 
published literature for improvement in exercise tolerance (i.e., fitness training) among people 
with COPD after various methods of aerobic conditioning, and for healthy older adults after 
WBV.  The mechanisms of improvement in exercise tolerance for humans (after WBV or 
indeed any mode of exercise training of COPD patients) can be demonstrated by increased 
oxygen uptake and VO2peak (Rittweger, Schiessl & Felsenberg, 2001), increased peripheral 
blood flow (Kerschan-Schindl, et al., 2001), hypertrophy of skeletal muscle of the lower 
limbs, and improved oxidative capacity within skeletal muscle fibres (Maltais, LeBlanc, 
Whitton, Simard, Marquis, Belanger et al., 2000; Haykowski, McGavock, Vonder Muhll, 
Koller, Mandic, Welsh et al., 2005).   
 
The aforementioned variables of exercise tolerance were not quantified due to field-based 
testing.  Such quantification is suited to a controlled laboratory setting rather than a 
community setting.  Although WBV increased blood flow about the lower limbs (Kerschan-
Schindl et al., 2001; Yamada, Kusaka, Miyamoto, Tanaka, Morita, Tanaka, et al., 2005; 
Lohman III, Petrofsky, Maloney-Hinds, Betts-Schwab & Thorpe, 2007; Lythgo et al., 2009), 
it is plausible that enhanced oxygen transport and uptake at the skeletal muscle could occur 
during WBV.  Although for participants of this research, the WBV sessions increased heart 
rate, there was no fitness training effect because resting heart rate did not change.  Given the 




output after fitness training (the product of stroke volume and heart rate), WBV may have 
increased oxygen uptake for people with COPD.  However, the effect was not shown with 
instantaneous rating of perceived dyspnoea and saturation of haemoglobin results or resting 
heart rate results.  
 
Efficacy of WBV to improve fitness of healthy older adults was recently established over a 12 
month period (Bogaerts et al., 2009).  During WBV, participants performed dynamic 
movement that allowed an increase of HRR to as much as 85%, which was within the aerobic 
fitness training zone (ACSM, 2005).  The HRR of participants in the current research was 
18% (± 7%), where 40% was the minimum threshold for aerobic conditioning improvement 
(ACSM, 2005).  The negligible changes in exercise tolerance shown in the results in this 
research therefore, may be explained by an absence of a suitable ‘stimulus’ to enhance fitness.   
 
Eliciting a suitable stimulus during exercise interventions for people with COPD can be 
compromised due to a reduced ability to deliver oxygen to peripheral skeletal muscle because 
of gas exchange inefficiency, flow limitation, and concurrent activation of large muscle 
groups (Troosters, Casaburi, Gosselink, & Decramer, 2005).  Given that people with COPD 
present a reduced anaerobic threshold (Maltais, LeBlanc, Simard, Jobin, Bérubé, Bruneau et 
al, 1996) and an increased muscular fatigability represented by a trend towards Type II 
muscle fibre distribution (Gosker et al., 2000; Gosker, van Mameren, van Dijk, Engelen, van 
der Vusse, Wouters et al., 2002; Allaire, Maltais, Doyon, Noel, LeBlanc, Carrier et al., 2004), 
whole body exercises common with aerobic conditioning and resistance training increase 
ventilatory demand (Troosters et al., 2005).  The net benefit of increased ventilatory stress can 
be modified reparatory techniques (Gigliotti, Coli, Bianchi, Romagnoli, Lanini, Binazzi et al., 




Casaburi, 2003), however compliance to intervention protocols remains problematic 
(Troosters et al., 2005).  The results of this research show that ventilatory demand was not 
beyond normal daily variation for people with COPD (i.e., perceived breathlessness) and 
despite the absence of improvement in ‘fitness’ of the participants in this research, WBV did 
not reduce exercise tolerance of people with COPD.     
 
The ongoing challenge of peripheral muscle training therefore, remains to design exercise 
interventions that stimulate the cardiovascular and musculoskeletal systems to allow 
physiological adaptations in skeletal muscle to improve exercise tolerance by avoiding 
exacerbations and reducing skeletal muscle dysfunction (Troosters et al., 2005).  Skeletal 
muscle dysfunction is synonymous with the dyspnoea spiral, and can also be quantified by 
poor aerobic performance due to reduced muscular strength, endurance, and oxidative 
capacity (Maltais et al., 2000).  However, the exact mechanisms of skeletal muscle 
dysfunction among people with COPD remain individualised and largely unknown (Troosters 
et al., 2005).  Results of this research do not support efficacy of WBV to improve the generic 
notion of exercise tolerance (i.e., fitness training) among people with COPD.  The possibility 
of simultaneously addressing fitness and musculoskeletal dysfunction in patients with COPD 
(as evidenced by improvements when healthy older adults added resistance training exercises 
to WBV) remains a challenge for the future.  
 
Exacerbations – Long-Term Compared with Instantaneous Results 
Results of this research suggest that WBV can be a mode of exercise for people with COPD 
that will not exacerbate the core limitations of the disease because a meaningful change in 




of this research compare favourably to other investigations of resistance training and aerobic 
conditioning of people with COPD.  After 12 weeks of both training modes, Borg CR-10 
values were not different within and among resistance training and aerobic conditioning for 
people with COPD (Skumlien et al., 2008).  However, during performance of the six-minute 
walk test, perceived dyspnoea increased to a value of ‘6’ (Skumlien et al., 2008).  
Concurrently, saturation of haemoglobin reduced from 95 to 87% (Skumlien et al., 2008) and 
has reduced to similar values across other exercise investigations of people with COPD 
(Poulain et al., 2003; O’Driscoll et al., 2011).   
 
The use of WBV for people with COPD can be supported with quantification of saturation of 
haemoglobin to allow speculative description of hypoxemia.  A method to define hypoxemia 
was to observe a > 4% drop in saturation of haemoglobin to resting levels (Poulain et al., 
2003).  Others have defined ‘severe’ hypoxemia at 90% saturation of haemoglobin (Stoller, 
Panos, Krachman, Doherty, Make & the Long-term Oxygen Treatment Trial Research Group, 
2010; Liu, Chisholm, Ngeow, John, Shaw, Ma et al., 2011).  Although not to the same values, 
the results of this research further support use of WBV as a mode of physical activity for 
people with COPD.  Results of major study 1 supported the safety of a single session of 
WBV.  Results of this research support the efficacy of a long-term WBV intervention to avoid 
exacerbations of COPD.    
 
As a mode of exercise, WBV reduced muscle oxygenation (Yamada et al., 2005) and 
increased cortisol and circulating levels of insulin-like growth factor I (Cardinale, Soiza, 
Leiper, Gibson & Primrose, 2007) of healthy participants, while for people with mild to 
moderate COPD, long-term physical activity was shown to improve oxygen saturation 




or physical exertion associated with WBV may be transferred to people with COPD so that if 
the lower limbs are shown to increase metabolic activity, physiological responses, such as 
increased breathlessness or reduced saturation of haemoglobin may be expected during WBV.  
For participants of this research however, there was an absence meaningful change of 
dyspnoea and saturation of haemoglobin across the WBV intervention.  As such, if metabolic 
activity of people with COPD increased due to WBV, the change was not represented with the 
Borg CR-10 VAS and SpO2.  Metabolic activity however, was shown to increase due to 
results of heart rate in the current research.  During the 14 week research, heart rate increased 
more during WBV (p ≤ 0.05, mean heart rate increase ≥ 10 beats.min
-1
) than during PLACBO 
(p > 0.05, mean heart rate increase = 7 beats.min
-1
).  Others have reported similar increases in 
heart rate during WBV for sub-optimal health (Crevenna et al., 2003) and healthy older adults 
(Bogaerts et al., 2009).   
 
A consideration from major study 1 was further study to describe the independent effects of 
standing and WBV on heart rate.  The current results indicated WBV increased metabolic 
activity, as demonstrated by heart rate, of people with COPD whereas PLACEBO did not.  As 
such, the limitation of Chapter 4, that heart rate was quantified in a sitting position and 
compared to an anatomical position, can also be discounted.  For humans, regardless of health 
status, exercise increases heart rate.  This research has shown that a WBV bout increases heart 
rate for people with COPD.  Those results were previously unknown for people with COPD.  
As such, and given the known and broad physiological responses of the human body to 
exercise, WBV may be viewed as an effective mode of exercise to increase metabolic activity 






Conversely, the WBV intervention of this research did not increase HRR as had been shown 
in a previous WBV intervention of healthy older adults (Bogaerts et al., 2009).  However, 
because COPD is a progressive disease, with the progression to poor exercise tolerance, 
improvements in HRR or other physiological responses to exercise should be secondary to 
maintenance of current levels.  Whole-body vibration was a well tolerated exercise 
intervention for people with COPD highlighted by the absence of exacerbations of COPD.  
Fluctuations (i.e., standard deviation) of results of this research can be partly explained by 
normal day-to-day variation and should be expected concurrently with WBV effects and 
people with COPD rather than caused by WBV.    
 
The exercise tolerance results of this research show that participants had more trouble 
completing the 5-chair test than the WBV and PLACEBO interventions.  There was no main 
effect of the test protocol on Borg CR-10 VAS results (page 163), yet, rating of perceived 
breathlessness was as high 6 (between ‘severe’ and ‘very severe’) immediately after the 5-
chair test.  Given the test mimics ADLs, as a mode of exercise, WBV could be added to the 
‘normal’ daily routine of people with moderate Stage II COPD without causing dyspnoea 
commonly associated with other modes of physical activity common place among pulmonary 









Functional Performance of the Lower Limbs  
Simulated ADLs 
The results of this research show the beneficial effect of WBV on functional performance of 
people with COPD.  The results are supported by other WBV interventions of older adults and 
aerobic and resistance training interventions of people with COPD.  The improvements in 
performance of the TUG test (13%) and 5-chair test (18%) after WBV for people with COPD 
in this research were greater than the respective 6% and 12% improvements reported after a 
two month WBV intervention of healthy older adults (Rees, Murphy & Watsford, 2007).  
Given the community dwelling sub-optimal health status of participants in this research, it is 
logical that the potential for improvement in performance of ADLs in people with COPD after 
WBV would be larger than healthy older adults when considering data of non-community 
dwelling older adults who’s TUG test time improved 48% after six weeks of WBV (i.e., 
Bruyere et al., 2005).   
 
A three week resistance training combined with WBV intervention reduced time taken to 
complete the 5-chair test by 4.0 sec (± 4.8 sec) (Gloeckl et al., 2012).  Results of this research 
show a 3.4 sec (± 2.8 sec) reduction of performance of the 5-chair test after a six week 
standalone WBV intervention (table 5.6).  The results of combined resistance training and 
WBV however, should be cautiously appraised because the standard deviation is larger than 
the mean and reliability of the test procedure is not reported.  Reliability of the 5-chair test 






For people with COPD, chair stands in 60 seconds and stair climbing have improved after 
resistance training and aerobic conditioning (Kongsgaard et al., 2004; Alexander, Phillips & 
Wagner, 2008; Arnardóttir et al., 2011).  Compared with resistance training, WBV is not as 
effective for people with COPD because improvement of TUG test performance was 67% 
after 12 weeks of resistance training (Panton et al., 2004) compared with 13% in this research.  
A resistance training intervention in this population however, would require facilities not 
usually available in the home, and specialised supervision.  As such the efficacy of 




Participants in this research walked with longer strides, in a faster time after the WBV 
intervention.  Similarly, eight weeks of combined resistance training and WBV in healthy 
older adults lengthened step length from 61 cm to 65 cm (7%) (Kawanabe, Kawashima, 
Sashimoto, Takedu, Sato & Iwamoto, 2007).  Stride length of participants in this research was 
13 cm longer (11%), which is similar to the ≥ 14 cm improvement of healthy older adults 
after resistance training interventions (Persch, Uginowitsch, Pereira & Rodacki, 2009; 
Fahlman et al., 2011).  Similar effects were reported for gait velocity after resistance training 
and aerobic conditioning for people with COPD.  Specifically, velocity increased 13%, from 
0.89 m.sec
-1
 to 1.01 m.sec
-1
 (Alexander, Phillips & Wagner, 2008).  The 12% increase of 
stride velocity for people with COPD in this research is similar to previous results in the range 
of 14 to 30% (Berry et al., 1999; Kongsgaard et al., 2004; Panton et al., 2004) for people with 
COPD.  For healthy older adults, a 12% improvement in gait velocity after resistance training 




compared with this research, WBV may also be an attractive strategy to improve gait for 
people with COPD. 
 
Possible Mechanisms of Improvement of Functional Performance  
The possible mechanisms for improvement in functional performance during and after WBV 
were reviewed in Chapter 2.  Specifically, improvement has been postulated to be linked to 
stimulation of various mechanisms including the stretch reflex (Norlund & Thorstensson, 
2007), the endocrine system (Rehn et al., 2007), and other components of the autonomic 
nervous system (Kerschan-Schindl et al., 2001; Torvinen et al., 2002; Lythgo et al., 2009; 
Mileva, Botwell & Kossev, 2009).  Such mechanisms could be attributed to increased 
perceived exertion and blood lactate during WBV (Rittweger, Mutschelknauss & Felsenberg, 
2003), and a similar explanation may be made for the increase in heart rate of participants 
with COPD in this research during WBV.  
  
Given the known physiological benefits of aerobic conditioning and resistance training on 
people with COPD (e.g., skeletal muscle hypertrophy and increased oxidative capacity), it 
may be appropriate to view possible mechanisms of improvement in functional performance 
of people with COPD after this research with a similar perspective.  However, given the 
predominance of Type II muscle fibre activity during exercise for people with COPD leading 
to increase anaerobic fatigue (Allaire et al., 2004), it may be possible that improvement of 
functional performance of people with COPD after WBV could be partly attributed to training 
of Type II skeletal muscle fibres rather than for example, an increase of oxidative capacity at 





Given that Type II muscle fibres are predominantly anaerobic and the simulated ADLs of this 
research were largely based about anaerobic energy supply (i.e., the phosphogen system and 
anaerobic glycolysis), improvement in performance may be due to an increase in anaerobic 
power, or an anaerobic training effect of WBV.  This point may be supported by linking the 
exercise tolerance results of this research showing that the WBV ‘stimulus’ was too low to 
allow improvement in aerobic fitness, and the improvements in performance of ADLs after 
WBV reported by others (e.g., Bruyere et al., 2005; Rees, Murphy & Watsford, 2007).  Given 
the known leg fatigue exhibited by people with COPD due to high-intensity exercise designed 
to improve anaerobic performance, and persistence of poor exercise compliance associated 
with symptom limited participation (Troosters et al., 2005; Kortianou, Nasis, Spetsioti, 
Daskalakis & Vogiatzis, 2010), WBV may be a more attractive mode of anaerobic exercise 
for people with COPD when comparing results across interventions.       
 
If then, WBV has the capacity to improve anaerobic power of the skeletal muscles of the 
lower limbs of people with COPD, a purely physiological perspective may only partly explain 
the possible mechanisms leading to improvement in functional performance of the lower 
limbs.  The gait of participants in this research for example, may have been enhanced due to 
increased motoneuron excitability observable with the H-reflex at the triceps surae.  Given 
that WBV effected the H-reflex (Armstrong et al., 2008), the known role of the H-reflex in 
motoneuron excitability (Hamada et al., 2000; Palmieri, Hoffman & Ingersoll, 2002; 
Hoffman, Palmieri & Ingersoll, 2003), and the role of the triceps surae during gait, 
motoneuron enhancement may have occurred during WBV for people with COPD.  It may be 
that WBV elicited either strength and power improvement, or improvement in motor unit 





Improvement in functional performance of the lower limbs may also be partly attributed to the 
stretch reflex.  After WBV to exhaustion of healthy adults, patella tendon reflex amplitudes 
were similar to, and sometimes exceeded baseline compared with a reduction in amplitudes 
among a control group (Rittweger, Mutschelknauss & Felsenberg, 2003).  The results 
occurred independent of similar declines in motor performance in both groups (Rittweger, 
Mutschelknauss & Felsenberg, 2003).  The authors attributed the results most likely to an 
enhanced central motor excitability resulting in patella tendon reflex activation (i.e., the 
stretch reflex).  Given that resistance training interventions initially improve motoneuron 
performance before structural morphology occurs (Sale, 1988), it may be that the current 
WBV intervention improved neural activity to allow strength and power improvement of the 
lower limbs of people with COPD.  Regardless of the neural mechanisms, functional 
performance of simulated ADLs of people with COPD was positively affected by the current 
WBV intervention.  Specifically, functional measures of muscular strength and muscular 
power were improved after a six week WBV intervention.  Essentially, participants were able 
to rise from a chair and perform other simulated daily activities with assumed synergies of 
greater muscular strength and muscular power.  
 
It was beyond the scope of this research to quantify cellular components of muscle, fibre Type 
distribution, or more direct metabolic responses, yet long-term improvement of field tests 
designed to indirectly quantify muscular strength and muscular power were comparable to 
other modes of training such as resistance training and aerobic conditioning among people 
with COPD and healthy older adults.  However, invasive laboratory procedures required for 
more mechanistic explanations are unlikely to be obtained from populations in sub-optimal 





Maintenance of Functional Performance of the Lower Limbs and a Placebo Effect 
Results of this research show the maintenance of functional performance following a WBV 
intervention for people with COPD (i.e., figures 5.5 to 5.9).  The trend of simulated ADLs 
results was an improvement in performance after WBV and then maintenance of the improved 
performance during the PLACEBO intervention.  It may be that the participants reached a 
‘ceiling’ that limited further improvement during the PLACEBO intervention and therefore, a 
placebo effect may have been systemic to the WBV intervention.  However, performance of 
the TUG test was worse (p ≤ 0.05) after the two week washout period, and did not improve 
over the duration of the PLACEBO intervention.  It may also be that: (1) simply standing on 
the placebo vibration platform with the knees flexed was enough stimulus to maintain the 
improvement, or (2) participants were more physically active after the WBV intervention 
despite the requirement not to begin any new mode of physical activity during the 14 week 
research period.   
 
The kinematic gait results of this research show that compared with a PLACEBO 
intervention, WBV improved functional performance.  Although there were differences 
among PLACEBO and WBV results, the differences were not meaningful (i.e., p > 0.05).  
After WBV for example, stride length was 1.27 m compared with 1.22 m after PLACEBO, 
while stride velocity was 1.16 m.sec
-1
 compared with 1.20 m.sec
-1
 (table 5.9).  The observed 
improvement in stride velocity of the PLACEBO results may be explained by the difference 
in stride time among the interventions, because stride velocity is the product of stride time and 






Although to test for a placebo effect during WBV is not common among the WBV literature 
base, the evidence of a placebo effect is equivocal.  The effect has been discounted when, for 
example, measuring TUG test performance of people with multiple sclerosis (Schuhfried 
Mittermaier, Jovanovic, Pieber, & Paternostro-Sluga, 2005).  Equivocation arises because 
WBV was often added to resistance training or some other mode of training and compared 
with a placebo condition with the same mode of training (e.g., Artero, Espada-Fuentes, 
Argüelles-Cienfuegos, Román, Gómez-López, & Gutiérrez, 2012).  Furthermore, highlighted 
by inconsistent WBV protocols (e.g., frequency and peak-to-peak displacement) a clear 
consensus of WBV and a potential placebo effect has not been confirmed.  Results of this 
research show that at Week 14, eight weeks after the WBV intervention was completed, 
functional performance was better compared with baseline data, though the meaningful 
improvement occurred across the WBV intervention and not across the PLACEBO 
intervention. 
 
Compliance and Drop-Out 
All participants successfully completed all WBV and PLACEBO sessions however, the 
number of participants reduced over the 14 week duration of this research (figure 5.1).  The 
drop-out of participants was due to circumstances beyond the demands of the research during 
the washout period.  As the importance of compliance to pulmonary rehabilitation had been 
documented and problematic (e.g., Troosters et al., 2005) it was meaningful that participants 
complied 100% of the WBV intervention. As a mode of physical activity to maintain exercise 
tolerance, avoid exacerbations of COPD, and improve functional performance of the lower 





Compared with other outpatient based interventions, the compliance and drop-out rate in this 
research was unique.  The drop-out rate of three month resistance training research projects 
ranged from 20% to 38% (Suzuki, Kim, Yoshida & Ishizaki, 2004; Means, Rodell & 
O’Sullivan, 2005).  Compliance, in some instances among healthy adults was at best 79% 
(Brill et al., 1999) and as low as 75% (Suzuki et al., 2004) for resistance training 
interventions.  Symptom limitation was a major reason for poor compliance among people 
with COPD during pulmonary rehabilitation (Troosters et al., 2005).  Given that only 10% of 
older American adults regularly engage in resistance training (Seguin & Nelson, 2003), and 
only 48% of older Australians are physically active (ABS 4156.0.55.001, 2011), the 
requirement of exercise that does not exacerbate people living with sub-optimal health is 
salient.  The results of the home-based WBV intervention used in this research of people with 
COPD confirm the ease and convenience of WBV highlighted by high compliance and an 
absence of drop-out during the WBV intervention. 
 
Anecdotal Responses and Future Directions 
Anecdotal responses, though biased and poorly controlled, can lead to additional research 
questions and outline the need for a placebo condition in WBV research.  The following 
occurred during the WBV and PLACEBO interventions: 
 Two participants lost body mass.  One participant lost 10 kg over six weeks (~8% 
body mass) and was sure that was due to WBV becausee it was the only difference in 
his life.  His weight did not change over the PLACEBO intervention.  One female lost 
2 kg (~2% body mass) after six weeks of WBV.  She was adamant that she had tried 
“everything” over time and that WBV was the cause. 
  One participant was sure the PLACEBO intervention was better then the WBV 




 Most participants, at the beginning of the study, felt leg fatigue due to the demand of 
standing on the vibration platform with the isometric squat.  That fatigue was 
negligible after 14 weeks.  Several participants also felt the need to rest for up to 60 
minutes after a session, regardless of intervention. 
 
Transmission of WBV about the knee and other landmarks of the body for people with COPD 
remains unknown.  Metabolic activity such as oxygen uptake and responses of the 
musculoskeletal system to WBV such as EMG activity, and circulating blood lactate, cortisol 
and creatine kinase also remains unknown for people with COPD.  More invasive 
experimental protocols however, are more suited to a controlled laboratory environment 
rather than a community setting used in this research.  The combined effect of a pulmonary 
rehabilitation program and a WBV intervention requires further investigation because the 
results of this research support the contention that WBV may be a “promising new exercise 
mode” for people with COPD (Gloeckl et al., 2012, p 76). 
 
Whole-body vibration intensity (i.e., g force) to elicit improvement of a component of 
exercise tolerance such as aerobic fitness should be investigated for people with COPD.  The 
gravitational force of the WBV during this research (~2.52 g) did not provide a suitable 
stimulus to enhance aerobic fitness.  Despite the need for aerobic fitness and the safe use of 
low (i.e., Furness & Maschette, 2009: 1.26 g) and high (i.e., Cardinale & Lim, 2003: 50.33 g) 
WBV intensity, as a mode of exercise, WBV should be prescribed mindful that older adults 







This was the first study to quantify and describe effects of a WBV intervention on exercise 
tolerance and functional performance of the lower limbs of people with COPD in a 
community setting.  Furthermore, a potential placebo effect of WBV was quantified with a 
PLACEBO intervention.  Both the WBV and PLACEBO interventions occurred in the home 
of each participant, which maximised participant compliance to each intervention.  Results of 
this research confirmed efficacy of WBV to improve functional performance of the lower 
limbs of people with COPD.  Exercise tolerance was not negatively effected by WBV, nor did 
the intervention exacerbate the stable COPD of the participants.   
 
Changes in the dependent variables of exercise tolerance were negligible or clinically 
meaningless across the duration of the WBV intervention (table 5.9).  Improvement in 
performance of simulated ADLs and walking gait occurred associated with large effect sizes 
across the duration of the WBV intervention.  The improvement in functional performance 
was at least maintained over the PLACEBO intervention.  Interpretation of the results may 
suggest that if a WBV intervention is susceptible to a placebo effect, it was not evident after 











Summary of research hypotheses and decision after inferential statistical analyses 
Research Hypothesis Accept Reject Data Interpretation 
EXERCISE TOLERANCE     
WBV will instantaneously 
increase dyspnoea 





impact for people 
with COPD 
WBV will not change long-term 
dyspnoea, heart rate or SpO2  
  Reduction of 
SpO2 from 
96 to 95% 
Negligible clinical 
impact for people 
with COPD 
WBV will instantaneously 
increase heart rate 
  Significant 
increase 
WBV is a mode of 
exercise to increase 
metabolic activity 
WBV will instantaneously reduce 
SpO2 
  No 
difference 
WBV did not elicit 
hypoxemia 
WBV will be different to 
PLACEBO 
  No 
difference  
WBV has no effect 
on exercise 
tolerance, but does 




    
WBV will improve performance 
of the TUG test 
  13% 
improvement 
WBV improved 
strength and power 
WBV will improve performance 
of the 5-chair test 
  18% 
improvement 
WBV improved 
strength and power 
WBV will improve selected 
kinematic variables of gait 
  Significant 
improvement 
WBV improved 
strength and power 
WBV will be different to 
PLACEBO 











As components of pulmonary rehabilitation, efficacy of resistance training and aerobic 
conditioning has been confirmed (GOLD, 2011).  Results of this research support efficacy of 
WBV to improve functional performance of the lower limbs of people with stable COPD in a 
community setting, while avoiding exacerbations of the disease that can limit compliance to 




CHAPTER 6. CONCLUSION 
 
This was the first research to advance knowledge of effects of WBV on exercise tolerance and 
functional performance of the lower limbs of people with COPD in a community setting.  
Safety and efficacy of a WBV intervention to maintain exercise tolerance and avoid 
exacerbations of COPD that add to physical inactivity, and improve performance of ADLs of 
people with COPD was determined. 
 
The specific aims of this research were met by: (1) establishing validity of a WBV platform, 
(2) determining safety of a single session of WBV for people with COPD by quantifying 
rating of perceived dyspnoea and selected acute physiological responses to exercise, (3) 
establishing reliability of the test procedure of major study 2, and (4) determining efficacy of 
a six week WBV intervention on rating of perceived dyspnoea, selected physiological 
responses to exercise, and functional performance of the lower limbs of people with COPD 
compared with a six week PLACEBO intervention.  All of the aims were met with exception 
of the aim to describe transmission of WBV about the knee of people with COPD in a 
community setting.  This aim was not met mainly because the robustness of the laboratory 
could not be replicated with the limited resources of the community setting available at the 
time of data collection and the overall arduousness of the test protocol for people with COPD. 
Nevertheless, the results from this research determine sufficient evidence of efficacy to 
proceed to higher levels of evidence in both rehabilitative and disease management programs 
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NOTE: peak-to-peak displacement can be calculated from the equations of gravity 














Not shown in the conference abstract, reflective ball markers were placed on the end of the 
vibration platform to determine peak-to-peak displacement with VICON.  As such peak-to-
peak displacement at the end on the vibration platform was ~ 3.00 mm.   
 
 
Using the frequency (Hz) and amplitude (mm) of a vibration 
platform, it is possible to quantify WBV at the surface of the 
platform.  Equation 1 shows the calculation of gravity (g) which is 
was reported within WBV literature along with frequency and 
amplitude (Rittweger, Schiessl & Felsenberg, 2001). 
 
    equation 1 
 
Where A is the amplitude (m), f is the frequency (Hz), 2πf
2
 is the 
maximum acceleration of the platform and 9.81 is the acceleration of 
gravity.  If peak-to-peak displacement was 1.0 mm and frequency 









































































































A Collaboration of: 
SOUTHERN HEALTH - MONASH MEDICAL CENTRE 
Respiratory & Sleep Medicine Department 
 
AUSTRALIAN CATHOLIC UNIVERSITY 
Faculty of Health Sciences, School of Exercise Science 




In conjunction with the Australian Catholic University (ACU) we are conducting 
a free to participate research project into the benefits of whole body vibration 
as a very gentle exercise program for you. 
This would mean a researcher from ACU coming to your home twice a week 
with a vibration platform, at times and days convenient to you. Each home visit 
will occupy about 15 minutes of your day. You will be asked to stand on that 
platform for five lots of one minute exercise with one minute rest in between 
(a total of about 9 minutes). There are two different types of platforms. You 
will stand on one of these over the first six weeks, have a two week break, and 
the stand on the second platform for another 6 weeks.  
The idea of the project is to increase your exercise capacity without making you 
breathless, therefore improving your ability to complete typical everyday 
activities like walking about and getting out of a chair. Your total involvement is 
14 weeks.  
For more information please contact: 
Name: Trent Furness    Name: Nicole Bate   
School of Exercise Science   Dept Respiratory Medicine 
Australian Catholic University   Monash Medical Centre 
Ph: 9953-3041     OR     0432-299-956  Ph: 9594-2279 






















The Mini-Mental State Exam (MMSE) 
 
Participant___________________________________ Examiner __________________________ Date____________ 
Maximum Score 
Orientation 
5 ( ) What is the (year) (season) (date) (day) (month)? 
5 ( ) Where are we (state) (country) (town) (hospital) (floor)? 
Registration 
3 ( ) Name 3 objects: 1 second to say each. Then ask the patient 
all 3 after you have said them. Give 1 point for each correct answer. 
Then repeat them until he/she learns all 3. Count trials and record. 
Trials ___________ 
Attention and Calculation 
5 ( ) Serial 7’s. 1 point for each correct answer. Stop after 5 answers. 
Alternatively spell “world” backward. 
Recall 
3 ( ) Ask for the 3 objects repeated above. Give 1 point for each correct answer. 
Language 
2 ( ) Name a pencil and watch. 
1 ( ) Repeat the following “No ifs, ands, or buts” 
3 ( ) Follow a 3-stage command: 
“Take a paper in your hand, fold it in half, and put it on the floor.” 
1 ( ) Read and obey the following: CLOSE YOUR EYES 
1 ( ) Write a sentence. 
1 ( ) Copy the design shown. 
 
 




















































































Successful and Unsuccessful Modes of Participant Recruitment for the 14 Week Intervention 
Unsuccessful participant recruitment options 
 
Successful participant recruitment options 
General Practitioners at four community 
medical centres based about the Mornington 
Peninsula. 
 
COPD suppose group; Rosebud Better 
Breathers  
St Vincent’s Hospital, Melbourne. 
Department of  (Restoring Health Program) 
 
Monash Medical Centre, Department of 
Sleep and Respiratory Medicine, Southern 
Health 
Frankston Hospital. Department of  
 
 
Respiratory Specialists at 2 private practices 
in Frankston 
 




COPD suppose group; Hawthorn Huffers. 
And a few more 
 
 
















Picture 1. View of PLACEBO vibration platform. 
 
 
Specifications of the prototype vibrating platform: 
 Baldor Electrical Co USA 
o Industrial Motor Direct Current 
o 1750 RPM 
o 29.16 Hz 
o 180 V 
o 2.5 Amps 
o Cam wheel/lever arm set for 0.0 mm perk-to-peak displacement 









Dimensions of the prototype vibrating platform: 
 Lateral View 
o 55 cm long by 26 cm high 
o Total height (including handle) 130 cm  
 From Above 
o 55 cm by 55 cm (78 cm diagonal) 
 
 
Calibration of frequency for the prototype vibrating platform was performed with the same 






















Figure 1. Raw data of the TUG test. 
 
 






y = -0.0084x + 11.207 













Across Six Week WBV Intervention 
TUG 
y = -0.066x + 18.251 

































y = 0.0289x + 113.02 













Across Six Week WBV Intervention 
STRIDE LENGTH 
y = -4E-05x + 1.109 






















Figure 5. Raw data of long-term stride velocity.  
 
 








y = 0.0287x + 102.65 





















Across Six Week WBV Intervention 
STRIDE VELOCITY 
y = 0.0289x + 113.02 



















Figure 7. Raw data of acute stride time.  
 
 







y = -7E-05x + 1.0984 
















Across Six Week WBV Intervention 
STRIDE TIME 
y = 0.0384x + 100.69 





























Figure 9. Raw data of the TUG test. 
 
 






y = 0.0051x + 10.447 














Six Week PLACEBO Intervention  
TUG 
y = 0.0449x + 15.442 






























y = -0.018x + 123.71 


















Across Six Week PLACEBO Intervention 
STRIDE LENGTH 
y = 0.0003x + 0.989 

























Figure 14. Raw data of acute stride length.  
 
y = -0.0528x + 125.73 






















Across Six Week PLACEBO Intervention 
STRIDE VELOCITY 
y = -0.0302x + 126.01 



































y = 0.0003x + 0.9937 















Across Six Week PLACEBO Intervention 
STRIDE TIME 
y = -0.0622x + 127.19 























Across Six Week PLACEBO Intervention 
STRIDE VELOCITY 
